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ABSTRACT 
Prion infections cause inexorable, progressive neurological dysfunction and neurodegeneration. 
Expression of the cellular prion protein PrPC is required for toxicity, suggesting the existence of 
deleterious PrPC-dependent signaling cascades. Because Group-I metabotropic glutamate receptors 
(mGluR1 and mGluR5) can form complexes with the cellular prion protein (PrPC), we investigated the 
impact of mGluR1 and mGluR5 inhibition on prion toxicity ex vivo and in vivo. We found that 
pharmacological inhibition of mGluR1 and mGluR5 antagonized dose-dependently the neurotoxicity 
triggered by prion infection and by exposure to prion-mimetic anti-PrPC antibodies in organotypic brain 
slices. Prion-mimetic antibodies increased mGluR5 cell surface expression and clustering around 
dendritic spines mimicking a mechanism of toxicity documented for Aβ oligomers, whereas prion-
protective antibodies prevented mGluR5 clustering. Oral treatment with the mGluR5 inhibitor, MPEP, 
delayed the onset of motor deficits and prolonged survival of prion-infected mice. Although Group-I 
mGluR inhibition was not curative, these results suggest that it may alleviate the neurological 
dysfunctions induced by prion diseases. 
ABSTRAKT 
Prionen-Infektionen verursachen unaufhaltsame, progressive neurologische Dysfunktionen und 
Neurodegeneration. Die Expression des zellulären Prionproteins PrPC ist für die Toxizität 
unabdingbar, was auf schädliche PrPC abhängige Signalwege hindeutet. Weil Gruppe-I metabotropen 
Glutamatrezeptoren (mGluR1 und mGluR5) Komplexen mit den zellulären Prionproteinen (PrPC) 
bilden können, wurde der Einfluss von mGluR1 und mGluR5-Hemmung auf die Prion Toxizität ex vivo 
und in vivo untersucht. Gefunden wurde, dass, wenn mGluR1 und mGluR5 pharmakologisch und 
dosisabhängig gehemmt wurde, die Neurotoxizität, die durch Prionen-Infektion antagonisiert wurde.  
Des Weiteren werden wurde  die Neurotoxizität von prionenmimetischen anti-PrPC Antikörper in 
Hirnschnitten, ebenfalls  antagonisiert. Der prionmimetische Antikörper erhöhte dabei die mGluR5 
Zellober-flächenexpression sowie die Clusterbildung um die dendritischen Dornen. Dieser imitiert 
einen Mechanismus der Toxizität, der bereits für Aß-Oligomere bestätigt ist. Indes verhindert der 
prion-schützende Antikörper mGluR5 die Clusterbildung. Die orale Behandlung mit dem mGluR5-
Inhibitor, MPEP, verzögert den Beginn der motorischen Defizite und verlängert das Überleben von 
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prioninfizierten Mäusen. Obwohl die Behandlung mit dem Gruppe-1 mGluR Hemmer nicht kurativ war, 
legen diese Ergebnisse nichtsdestotrotz nahe, dass diese Behandlung neurologische 
Funktionsstörungen von prionen-induzierten Erkrankungen lindern kann. 
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SUMMARY 
 
Prion infections cause fatal, progressive neurological dysfunction and neurodegeneration. Expression 
of the cellular prion protein PrPC is required for toxicity, suggesting the existence of deleterious PrPC-
dependent signaling cascades. But how can PrPC, an extracellular GPI-linked protein, initiate toxicity? 
Most likely this process requires interactions with transmembrane constituents, and indeed PrPC was 
shown to interact with membrane proteins that initiate intracellular signaling cascades. Among these 
proteins are group I metabotropic glutamate receptors (mGluR1 and mGluR5). 
We first attempted to characterize the interaction domain of PrPC and group I metabotropic glutamate 
receptors on PrPC by utilizing an array of amino-proximal deletion mutants of the cellular prion protein 
(PrPC). The interaction domain for mGluR1 and mGluR5 on PrPC seems to span amino acid residues 
51 to 90 and 32 to 134, respectively. Control experiments in which we probed for selected group II 
and III mGluRs in PrPC immunoprecipitates further confirm the specificity of the interaction.  We next 
investigated the impact of mGluR1 and mGluR5 inhibition on prion toxicity ex vivo and in vivo. We 
found that pharmacological inhibition of mGluR1 and mGluR5, as well as mGluR5 genetic ablation, 
antagonized dose-dependently the neurotoxicity triggered by prion infection and by exposure to prion-
mimetic anti-PrPC antibodies in organotypic brain slices.  
We further assessed the effect of toxic (POM1) versus protective (POM2) anti PrPC antibodies on the 
cell surface expression of mGluR5 using biotinylation of organotypic slice cultures with a cell 
impermeable reagent. At 2hr, scPOM1 treatment induced an increase in surface mGluR5 as well as 
surface PrPC, indicating fixation of the PrPC and mGluR5 in stable, immobile complexes on the 
membrane. In contrast, blocking of scPOM1 with scPOM2 or parallel treatment with MPEP rescued 
the surface mGluR5s clustering.  
In primary hippocampal cultures, treatment with prion-mimetic antibodies (POM1) induced PrPC and 
mGluR5 redistribution in dendritic spines and accumulation in spine heads; mimicking a mechanism of 
toxicity documented for Aβ oligomers. The observed clustering of mGluR5s in dendritic spines was 
prevented by protective anti PrPC antibodies (POM2). In contrast, the cluster size of NMDA and 
AMPA receptors was not modified by addition of anti-PrP antibodies. In prion-infected mice, oral 
treatment with the mGluR5 inhibitor MPEP delayed the onset of motor deficits, reduced the vacuole 
size and the extent of astrogliosis and prolonged survival.  Although genetic ablation of mGluR5 
The Role of Group I Metabotropic Glutamate Receptors in Prion Induced Toxicity PhD Dissertation 
 
 
12  Despoina G. Goniotaki – October, 2016  
  
rescued POM1- or RML6-induced neuronal death in organotypic brain slices, it did not exert a similar 
statistically significant disease modifying effect in vivo. 
We conclude that formation of POM1/PrPSc-PrPC-mGluR5 complexes on the neuronal membrane 
mobilizes mGluR5 to alter the normal neuronal activity; resulting in toxicity. Although Group-I mGluR 
inhibition was not curative, these results suggest that it may have the potential to alleviate – at least 
temporarily – the neurological dysfunctions induced by prion diseases. 
 
 
Keywords: group I metabotropic glutamate receptors (mGluRs), mGluR1, mGluR5, prion diseases, 
PrPC, organotypic slice cultures, prion mouse models, prion mimetic antibodies (POMs), MPEP, 
Grm5ko, rotarod, mouse primary neurons. 
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ERs: estrogen receptors  
ER: endoplasmic reticulum 
ERK: extracellular regulated kinases  
fCJD: familial CJD 
FFI: fatal familial insomnia  
FMRP: fragile-X mental retardation protein  
FSE: feline spongiform encephalopathy  
FXS: Fragile X syndrome 
HR: hydrophobic core  
GABA: gamma-aminobutyric acid  
GDL: globular domain ligand 
GDP: guanosine 5/- diphosphate  
GFAP: glial fibrillary acidic protein  
GTP: guanosine 5/-triphosphate 
Glu: Glutamate  
GluR: glutamate receptor  
GPCRs: G-protein coupled receptors  
GPI: glycosylphosphatidylinositol  
GSS: Gerstmann-Straüssler-Scheinker  
HD: heptahelical domain  
HD: Huntington’s disease 
HOCS: Hippocampal organotypic cultures slices  
HSPG: heparan-sulphate proteoglycan  
iCJD: iatrogenic CJD 
iGluR: ionotropic glutamate receptor 
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IP3: inositol 1,4,5-trisphosphate  
IP3Rs: inositol triphosphate receptors  
KAR: kainate receptor 
KBPs: kainate binding proteins  
LBD: ligand-binding domain  
Ln γ1: laminin γ chain  
LTD: long-term depression  
LTP: long-term potentiation  
MAPK: mitogen-activated protein kinases  
MPEP: 2-Methyl-6-(phenylethynyl)pyridine  
MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine  
MTEP: 3-((2-Methyl-4-thiazolyl)ethynyl)pyridine  
mGluR: metabotropic glutamate receptor 
NCAM: neural cell adhesion molecule  
NMDA: N-methyl-D-aspartate  
NMDARs: NMDA receptors  
VGCCs: N-type voltage-gated Ca2+ channels  
OGD: oxygen/glucose deprivation 
OR: octapeptide repeat  
ORF: open reading frame 
PALM: Photoactivated Localization Microscopy  
PCD: programmed cell death  
PD: Parkinson’s disease  
PFA: paraformaldehyde  
PI: phosphoinositide  
PI3K: phosphatidylinositol-4,5-biphosphate 3-kinase  
PIKE: PI3K enhancer  
PK: proteinase K 
PKA: protein kinase A  
PKC: protein kinase C  
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PLC-β1: phospholipase C-β1  
PLC1: 4,5-bisphosphate phosphodiesterase 1  
PM: plasma membrane  
PNS: peripheral nervous system 
PrPC: normal cellular prion protein 
PrPSc: scrapie prion  
PRNP: prion protein gene  
PSDs: post-synaptic densities  
PSD95: postsynaptic density protein 95 
PVDF: Polyvinylidene difluoride 
rPrP: recombinant prion protein  
ROS: reactive oxygen species  
sCJD: sporadic CJD  
Scrg1: scrapie regulated gene 1  
SERCA: sarco/endoplasmic reticulum calcium ATPase  
SOD: superoxide dismutase  
SP: signal peptide  
Stip 1: stress-inducible protein 1  
TMD: transmembrane domain  
TME: transmissible mink encephalopathy  
TSEs: transmissible spongiform encephalopathies  
UPR: unfolded protein response  
UV: ultraviolet  
vCJD: variant CJD 
VFT: venus fly trap domain  
Vn: vitronectin  
VTA: ventral tegmental area 
XBP-1: X-box-binding protein-1    
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1.1 Common Features of Neurodegenerative Diseases  
Neurodegenerative diseases are a phenotypically heterogenous group of diseases that have unique 
characteristics. Diseases including prion diseases, Alzheimer’s disease (AD), Parkinson’s disease 
(PD) and Huntington’s disease (HD) target different subsets of neurons and thus exhibit a range of 
pathological and molecular features. For example, prion diseases can initially target neurons of 
various brain areas, cortex, cerebellum and/or thalamus (Farlow et al., 1989; Reder et al., 1995). The 
specific anatomical region of the brain that is targeted is dependent on several factors including the 
etiology and the prion strain. However, the exact mechanism for such variation remains unknown 
(Mallucci and Collinge, 2005).  The latter accentuates the phenotypic and pathologic heterogeneity of 
these diseases. As a result, depending on the affected brain region, initial symptoms can vary from 
dementia, ataxia and psychological problems or insomnia. In turn, cholinergic neurons of the cerebral 
cortex and hippocampus are targeted in AD and lead to progressive dementia (Babic, 1999). 
Dopaminergic neurons of the substantia nigra are targeted in PD and cause aberrant function in 
movement (Sulzer and Surmeier, 2013), while GABAergic medium-sized spiny neurons of the 
striatum are targeted in HD which leads to the development of dementia, motor and psychiatric 
problems (Graveland et al., 1985).  Although these neurodegenerative diseases affect different 
regions of the brain, they are all caused by the misfolding of specific cellular proteins that results in 
the formation of intracellular and/or extracellular aggregates as disease progresses (Figure 1.1). 
Remarkably, the earliest pathological alteration observed in all of these diseases [reviewed in (Martin, 
1999)] is disruption of synapses followed by spine loss and dendrite retraction. It can therefore be 
speculated that a similar molecular mechanism is responsible for driving neurodegeneration 
downstream of protein misfolding in all these diseases. Consequently, identifying cellular processes 
involved in neurodegeneration in one of these diseases may prove helpful for understanding 
degeneration in others. 
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Figure 1.1. Common features of major neurodegenerative diseases. The degeneration process 
starts with the misfolding of the normal form of protein. Misfolded isoforms accumulate and aggregate 
intracellularly and/or extracellularly. As a consequence, neuronal death is observed, proceeded by 
synaptic dysfunction and dendritic loss. 
 
The neuronal cell loss observed in neurodegenerative disorders is generally restricted to cell bodies 
and dendrites of glutamatergic neurons. For example, in AD, the highest damage is observed to 
neurons in layers III and IV of the neocortex. Damage is also observed to glutamatergically-innervated 
cortical and hippocampal neurons (Albin and Greenamyre, 1992). Axons, terminal buttons, glia, 
endothelial and ependymal cells are relatively spared (Choi, 1992). The observed pathological 
phenotypes are attributed to toxic glutamatergic signaling, due to continuous stimulation of the 
glutamate receptors. Detailed information about the different types of glutamate receptors, as well as 
their roles in physiology and pathology, will be presented in the following paragraphs. 
 
1.2. Glutamate and Glutamate receptors 
Glutamate (Glu) is the primary excitatory neurotransmitter in the central nervous system (CNS) 
participating in a wide range of neural functions such as learning and memory, long-term potentiation 
and synaptic plasticity (Fairman and Amara, 1999).  The observation that increased amounts of Glu 
can trigger excitotoxicity and neuronal death established the research interest on the role of Glu in 
neurodegeneration. Extensive study of Glu signaling mechanisms has promoted the development of 
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treatments for Glu-related neurodegeneration.  
Glutamate exerts its effects through the activation of several glutamate receptor (GluR) subtypes. 
GluRs are divided into two families: ionotropic (iGluR) and metabotropic (mGluR) depending on the 
mechanism of postsynaptic current generation (Conn and Pin, 1997; Julio-Pieper et al., 2011; 
Traynelis et al., 2010). The ionotropic receptor family comprises of N-methyl-D-aspartate (NMDA), a-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainate receptor subtypes; so 
named by the pharmacological agonist that selectively binds to each subtype. Researchers have also 
identified another subgroup in vertebrates (the orphan delta receptors, δ1 and δ2) and another 
subfamily, the kainate binding proteins (KBPs), in non–mammalian vertebrates. Although each 
receptor subtype serves a distinct function, they all share a common voltage-gated ion channel 
function and serve as the main mediators of fast excitatory synaptic transmission (Mayer, 2006). The 
metabotropic glutamate receptor (mGluR) family on the other hand, comprises of three subfamilies: 
group I, group II and group III; subdivided based on sequence homology, pharmacology and second 
messenger association. They are all G-protein coupled receptors (GPCRs) consisting of a seven 
transmembrane domain structure. Upon Glu binding, they initiate signaling cascades, modulate or fine 
tune synaptic activity (Conn and Pin, 1997). Advancing our understanding of the specific roles of 
iGluRs and mGluRs could significantly benefit the development of novel treatment strategies for a 
variety of neurologic disorders.  
 
1.2.1. Ionotropic Glutamate Receptors (iGluRs) 
The glutamate-receptor ion channels (iGluRs), namely NMDA, AMPA and kainate, are typically 
classified by the synthetic agonists that mimic the effects of L-Glu and are the primary mediators of 
excitatory synaptic transmission in the CNS (Collingridge and Lester, 1989). 
IGluRs are integral membrane proteins consisting of four large subunits (> 900 residues), which form 
the central ion channel pore. Each of the four subunits that form the channel shares a common 
structure of four well-conserved domains: a. the extracellular amino-terminal domain (ATD), b. the 
ligand-binding domain (LBD), c. the transmembrane domain (TMD) and d. the intracellular carboxy-
terminal domain (CTD). The CTM region is unique to iGluRs and is involved, via protein interactions, 
in synaptic anchoring, trafficking and receptor-mediated signaling (Chen et al., 1999). 
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Upon Glu or agonist binding to the LBD a conformation shift occurs which changes the angle of the 
TMD regions. The latter induces opening of a pore in the membrane where influx of sodium, 
potassium and/or calcium takes place.  
 
 
Figure 1.2. Structure and activation mechanism of iGluRs 
iGluRs share the same basic structure comprising of four well-conserved domains: a. the extracellular 
amino-terminal domain (ATD), b. the ligand-binding domain (LBD), c. the four transmembrane 
domains (TMDs; numbered 1-4)  and d. the intracellular carboxy-terminal domain (CTD). The 
schematic on the left illustrates the native resting conformation of iGluRs. Although only two subunits 
are depicted, the entire molecule naturally consists of four subunits arranged in such a way as to 
create a channel through the plasma membrane. Upon glutamate binding (schematic on the right), a 
conformational change in TDM region I occurs triggering the opening of the channel and allowing the 
influx of Ca2+ into the cell by diffusion [modified by (Willard and Koochekpour, 2013)].  
 
If a sufficient amount of iGluRs is simultaneously stimulated, high concentrations of cation influx will 
trigger an action potential – the fastest type of excitatory synaptic transmission throughout the central 
and peripheral nervous systems (CNS, PNS) and the retina. The signal is received by the target cell 
and induces the activation of excitatory amino acid transporters (EAATs; also known as glutamate 
transporters). EAATs are mainly expressed on postsynaptic and supporting glial cells. They serve to 
empty the synaptic cleft of Glu, to effectively turn off the signal and to reset the system for generation 
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and propagation of new action potentials (Traynelis et al., 2010). Sustained stimulation and 
overactivation of iGluRs allows high levels of calcium ions to enter the cell and initiates a pathological 
process, known as excitotoxicity. Even though physiological increases in intracellular Ca2+ levels are 
salient to normal cell functioning, the excessive influx of Ca2+ in addition to any Ca2+ release from 
intracellular compartments can overwhelm Ca2+-regulatory mechanisms, induce aberrant over-
activation of proteases and caspases as well as the production of reactive oxygen species (ROS) and 
lead to cell death (Dong et al., 2009).  
An AMPA receptor was the first iGluR to be identified by expression cloning (Hollmann et al., 1989). 
The same method also resulted in identification of the first NMDA receptor subunit and the first 
metabotropic glutamate receptor (mGluR) (Nakanishi and Masu, 1994). Sequence information on the 
cloned receptors prompted the identification of the various members of the iGluR family.  To date, 18 
genes belonging to the iGluR family have been identified in mammals. Of the eighteen subunits, 7 
belong to the NMDA subtype (NR1 or GluN1, NR2 or GluN2 (A-D), NR3 or GluN3 (A-B)), 4 to the 
AMPA (GluR1-4/GluRA-D) subtype and 5 to the kainate (GluR5-7, KA1-2) subtype. The remaining 
two, δ1 and δ2, share high sequence similarity with the other iGluR subunits and are called orphan 
receptors because there is no evidence that they form functional glutamate-gated receptors 
(Hollmann and Heinemann, 1994; Hollmann et al., 1993).  
Each iGluR subtype has a unique role. NMDA receptors (NMDARs) are glutamate-gated ion channels 
that monitor changes in membrane potential and presence of glutamate in the synaptic cleft 
(Collingridge and Bliss, 1995).  They are located not only at synapses but also at extrasynaptic sites 
(Clark et al., 1997). As a result, they play key roles in synapse development, consolidation and 
plasticity, as well as in learning and memory. NMDARs exist in different forms, defined by the different 
combinations of subunits that can assemble into a functional reporter; they form a tetramer consisting 
of at least one GluN1 and combinations of GluN2 and GluN3 subunits. The so-called classical 
NMDARs contain two GluN1 and two GluN2 subunits, are highly permeable to Ca2+ and accumulate 
at post-synaptic densities (PSDs). Owing to their permeability to calcium, they relay not only 
physiological signals to neurons, but also trigger intracellular signalling cascades that can ultimately 
lead to cell death. Thus, they are also involved in excitatory amino acid (EAA)-mediated neuronal 
toxicity (Hynd et al., 2004). 
NMDA receptors are found in most CNS neurons (Petralia et al., 1994a; Petralia et al., 1994b) and 
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mediate Ca2+-influx in response to coincident agonist binding (Seeburg, 1993). Two agonists bind to 
activate them: glutamate (L-Glu), which binds to the S1 and S2 regions of the GluN2 subunit and 
glycine which binds to the S1 and S2 regions of the GluN1 subunit. Activation of these receptors also 
requires synchronous post-synaptic depolarization. The latter facilitates extrusion of Mg2+ ions, which 
normally block the ion pore at resting membrane potentials, and thus allow Ca2+ influx (Paoletti et al., 
2013). NMDARs can identify coincident presynaptic and postsynaptic activity, connect it to Ca2+-
activated signalling pathways and induce permanent synaptic changes, such as changes in 
“functional” [long-term potentiation (LTP) or long-term depression (LTD)] or “structural” plasticity 
(synapse enlargement and stabilization) (Malenka and Nicoll, 1999; Matsuzaki et al., 2004). 
Potentiation of NMDA channels happens dose-dependently and is characterized by increase in peak 
channel open probability and peak channel current duration (Araneda et al., 1993). 
AMPA receptors (AMPARs) are believed to be the most common type of neurotransmitter receptor in 
the CNS. They are tetrameric, cation-permeable ionotropic glutamate receptors, expressed 
throughout the brain (Beneyto and Meador-Woodruff, 2004). They are assembled as two identical 
heterodimers, formed by combinations of the GluR1-4 subunits. They reside at extrasynaptic sites of 
the soma or the dendrites and travel to dendritic spines via lateral diffusion (Traynelis et al., 2010). 
GluA1/2 is the predominant AMPAR subtype in hippocampal pyramidal neurons, followed by GluA2/3 
(Lu et al., 2009). Upon Glu binding, the pore opens and allows the influx of Na+ ions (along with K+ 
efflux) to depolarize the postsynaptic compartment.  However, depending on the subunit composition 
and the RNA editing, AMPARs also permit Ca2+-influx, which has important consequences for 
receptor trafficking and synaptic plasticity (Henley et al., 2011; Kessels and Malinow, 2009). AMPARs 
primarily vary in their intracellular C-terminal domains. These domains contain regulatory elements 
that interact with scaffold proteins and signalling molecules and are subjected to multiple post-
translational modifications. Therefore, they are crucial for the regulation of the receptors’ functions, 
such as channel gating, trafficking and stabilization at synapses (Shepherd and Huganirl, 2007). Due 
to the rapid nature of both AMPAR desensitization and resensitization kinetics, AMPARs are 
considered to be the primary mediators of fast excitatory synaptic transmission in the mammalian 
brain, through sodium and potassium conductance, with nominal permeability to calcium (Gouaux, 
2004). The trafficking of AMPARs into and out of synapses is highly dynamic and regulates activity-
dependent changes in synaptic transmission. It is controlled by subunit specific AMPAR-interacting 
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proteins as well as by various post-translational modifications that occur on their C-terminal domains. 
Practically, increased AMPAR activity at synapses results in the long-term potentiation (LTP) of 
synaptic strength, whereas removal of synaptic AMPARs leads to long-term depression (LTD) 
(Shepherd and Huganirl, 2007).  
Kainate receptors (KARs), on the other hand, are tetrameric assemblies of subunits that share 
structural similarities with the subunits of the other iGluRs. The resultant receptors contain 
combinations of low-affinity GluK1-3 (formerly named GluR5-7) and high-affinity GluK4 and GluK5 
(formerly KA-1 and KA-2) subunits (Ayalon and Stern-Bach, 2001). Similar to both NMDA and AMPA 
receptors, KARs are widely distributed throughout the brain. Unlike other receptors, studies of KARs 
proved out to be complicated, due to the lack of specific compounds to activate or block them. For 
example, kainite (the principal KAR agonist) can also activate AMPARs. Moreover, the prototypic 
AMPAR agonist, AMPA, can also activate KARs. Contrary to NMDARs and AMPARs, the activation of 
postsynaptic KARs produces small amplitude excitatory post-synaptic currents (EPSCs), with slow 
activation and de-activation kinetics (Castillo et al., 1997). The slow kinetics of EPSPKAR is a distinct 
feature that separates KARs and highlights their role in integrating exclusive information transfer 
(Pinheiro et al., 2013).  Also, while NMDARs and AMPARs are found at the PSDs of most 
glutamatergic brain synapses, KARs are only found in certain central synapses (Lerma and Marques, 
2013). Therefore, based on their electrophysiological and distribution profile it has been suggested 
that KARs, rather than being direct mediators of synaptic plasticity, they play a modulatory role. KARs 
are also reported to contribute to the development of early neuronal connectivity by driving the 
formation and guidance of the early synaptic contacts and tracks (Goda and Davis, 2003; Lanore et 
al., 2012). The disparate actions of kainate receptors as well as their unique functions are supported 
by the variety shown in their subcellular localization and the interaction with multiple proteins, some of 
which are shown to be true ancillary proteins. 
Although glutamate signaling is of utmost importance for synaptic plasticity and transmission 
throughout the CNS, continuous application of L-Glu could result in the death of post-synaptic 
neurons. Also, application of glutamate agonists could induce neurotoxicity. Based on the later 
observations, the term “excitotoxicity”, the pathological process by which neurons are either damaged 
or killed as a result of excessive stimulation by EAAs, was coined (Olney, 1989; Olney et al., 1990; 
Rothman and Olney, 1995). Excitotoxicity induces entering of excessive amounts of Ca2+ at the post-
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synaptic neuron. The latter triggers the activation of many nucleolytic and proteolytic pathways 
(Zundorf and Reiser, 2011). As a result, with continuous L-Glu stimulation and concomitant Ca2+-
influx, the neuron undergoes cellular degeneration. This includes cellular DNA, RNA and protein 
degradation along with disassembling of the cell membrane and the cytoskeleton (Olney et al., 1986; 
Whetsell and Shapira, 1993).  
Excitotoxicity is considered a major contributing factor to a multitude of neurodegenerative disorders, 
such as traumatic brain injury (Luo et al., 2011), amyotropic lateral sclerosis (ALS) (Grosskreutz et al., 
2010), multiple sclerosis (Frigo et al., 2012), epilepsy (Czuczwar, 2000) and chronic 
neurodegenerative disorders like AD (Woods and Padmanabhan, 2012), PD (Surmeier et al., 2010) 
and HD (Raymond et al., 2011).  
For many years, iGluRs were thought to be the sole regulators of glutamatergic signaling and the 
culprits of excitotoxicity-mediated neuronal death.  Recent research, however, has also implicated 
glutamate receptors coupled to second messenger systems via GTP-binding proteins, denoted 
metabotropic glutamate receptors (mGluRs) (Conn and Pin, 1997). 
1.2.2. Metabotropic Glutamate Receptors (mGluRs) 
Metabotropic Glutamate receptors (mGluRs) are members of the G-protein-coupled receptor (GPCR) 
superfamily, the largest receptor gene family in the human genome. The GPCR family contains 
several subfamilies. The classical neurotransmitter GPCRs, known as rhodopsin-like GPCRs, belong 
to subfamily A.  They are structurally common, containing an extracellular N-terminal domain, seven 
transmembrane-spanning domains, and an intracellular C-terminal domain. In contrast to family A 
receptors, mGluRs as well as gamma-aminobutyric acid B (GABAB) receptors, calcium-sensing 
receptors, pheromone receptors, and taste receptors belong to class C GPCRs. These receptors 
differ from the family A receptors in the presence of a large extracellular N-terminal domain that 
contains the endogenous ligand-binding site (Conn and Pin, 1997). GPCRs are membrane-bound 
proteins activated by multiple extracellular ligands, such as light, peptides, and neurotransmitters, and 
transduce intracellular signals via interactions with G proteins. Ligand binding triggers a 
conformational change of the GPCRs, which further activates a receptor-bound G protein. Each G-
protein is composed of a heterotrimeric complex of α, β, and γ subunits. In their inactive state, G 
proteins bind guanosine 5/- diphosphate (GDP). However, activation of the G protein induces the 
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exchange of GDP for guanosine 5/-triphosphate (GTP), causing the α-subunit dissociation from the 
βγ-subunit. Activated G protein subunits subsequently change the function of various effector 
molecules (such as enzymes, ion channels, and transcription factors) and induce changes in 
intracellular signalling. Inactivation of the G protein occurs when the bound GTP is hydrolyzed to 
GDP, resulting in reassembly of the heterotrimer (Niswender and Conn, 2010). Two independent 
groups cloned the first mGluR cDNA (mGluR1a) by using the same functional expression assay 
(Houamed et al., 1991; Masu et al., 1991). MGluR1 amino acid sequence revealed that this receptor 
shared no sequence homology with any other GPCR, suggesting that it could be a member of a new 
receptor gene family. The search for mGluR-related cDNA resulted in the isolation of seven more 
genes (known as mGluR1-8), many with several splice variants, which are differentially expressed 
throughout the CNS (Conn and Pin, 1997). These receptors are subclassified into three groups based 
on sequence homology, ligand selectivity and G-protein coupling. Group I consists of mGluR1 and 5, 
Group II includes mGluR2 and 3, and group III includes mGluR4, 6, 7 and 8.  
 
Figure 1.3. Relationship between the three mGluR subgroups 
The phenogramshows the relationship between the three mGluR subgroups (Group I, II and III) as 
well as the individual receptors within each group. Branch length indicates the amino acid identity 
between the protein sequences [modified by (Willard and Koochekpour, 2013)].  
 
Activation of group I mGluRs results in coupling to heterotrimeric Gq/G11 proteins (Conn and Pin, 
1997). Gq activation promotes phospholipase C-β1 (PLC-β1) stimulation, which triggers the hydrolysis 
of phosphoinositide (PI). The latter results in the formation of 1,2-diacylglycerol (DAG), an activator of 
protein kinase C (PKC), and inositol 1,4,5-trisphosphate (IP3), which initiates calcium release from 
intracellular stores. Conversely, group II and group III mGluRs, couple primarily to Gi/o proteins, which 
inhibit adenylate cyclase (AC) and indirectly adjust ion channel activity  (Table (Conn and Pin, 1997; 
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Niswender and Conn, 2010).  
 
Table 1.1. Key features of mGluRs (Niswender and Conn, 2010) 
 
1.3.  Group I mGluRs: structure and signalling 
Group I share the same basic mGluR structure; they consist of: a. a large bi-lobed extracellular N-
terminal domain (known as amino-terminal domain (ATD)) - also referred to as the venus fly trap 
domain (VFT), due to its unique shape, b. the cysteine-rich domain (CRD) that is critical for 
dimerization and activation of the receptors, c. the classic seven alpha-helical transmembrane 
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domains (TMD) and d. an intracellular carboxy-terminal domain (CTD) (Seebahn et al., 2013). 
 
 
 
Figure 1.4. Structure and activation mechanism of mGluRs 
mGluRs share the same basic structure comprising of four well-conserved domains: a. the amino 
terminal domain (ATD) at the N-terminus (N) is followed by the cysteine rich domain (CRD), the seven 
transmembrane domains (TMD; numbered) and the C-terminal domain (CTD). At the native resting 
conformation of mGluRs (schematic on the left side), cysteine residues aid the receptor dimerization, 
as indicated by the formation of the S-S bond. Upon, Glu binding (schematic on the right), a 
conformational change at the ATD region, involving the CRD region – stars indicate the disulfide 
bridges created by Glu binding- induces activation of the receptor-bound G-proteins. 
Note: i1,i2, etc. indicate intracellular loops between transmembrane regions, while e1, e2, etc. indicate 
extracellular loops. The stars (*) at the right schematic indicate cysteine residues that are important in 
transmitting activation information to the docked G-protein complex [modified by (Willard and 
Koochekpour, 2013)] 
 
Their particularly large N-terminal domain allows for extracellular ligand recognition and protein 
interactions. Ligand binding occurs at the neighboring VFD region. Induction and propagation of 
signals via the VFD regions partly depends on the presence of a disulfide bridge between the ninth 
cysteine residue of the CRD region and the cysteine on lobe 2 of the VRD region (Jingami et al., 
2003; Muto et al., 2007; Rondard et al., 2006). Upon ligand binding, a conformational change occurs 
that is relayed to the heptahelical domain (HD) of the intracellular C-terminus (Liu et al., 2006). The 
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VFD has also been known to bind auxiliary ligands such as divalent cations, which both activate and 
intensify receptor activity (Francesconi and Duvoisin, 2004; Kubo et al., 1998). Depending on the 
presence of an agonist or an antagonist, VDF can exist in three conformational states: a. the open-
open conformation (an inactive state induced by antagonist treatment), b. the open-closed 
conformation and c. the closed-closed conformation (both induced by ligand or agonist binding).  
Upon stable ligand (glutamate) binding on both monomers, the two lobes of each VFD come together 
and form a cleft; acquiring a closed-closed state conformation (Tsuchiya et al., 2002) (Kunishima et 
al., 2000).  
 
 
 
Figure 1.5. Activity-dependent states of mGluR5 dimers 
A schematic representation of the mGluR5 dimeric structures in different activity-dependent states. 
The mGluR5 dimers contain two extracellular domains called the Venus flytrap domains (VFDs), 
which bind glutamate and other orthosteric ligands. The open-open state (left) is the inactive 
conformation of the receptor and can be stabilized by treatment with antagonists. Either one or two 
VFDs can then bind glutamate, resulting in the closed-open (middle) or the closed-closed (right) active 
receptor conformations [modified by (Niswender and Conn, 2010)].  
The dimerization hypothesis is further supported by functional studies showing that group I mGluRs 
behave as constitutive, covalently linked homodimers (Jingami et al., 2003; Kunishima et al., 2000). It 
has been reported that group I mGluRs will perform at maximum activity only when both dimer 
subunits are occupied (Kammermeier and Yun, 2005). The significance of receptor dimerization 
however is still unknown. The main function of the intracellular C-terminal domain is to modulate G-
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protein coupling. It also takes part in protein-protein interactions and is the major site of post-
translational modifications, such as regulatory phosphorylation and alternative splicing (Niswender 
and Conn, 2010). Activation of the C-terminal region of the mGluR induces the stimulation of the 
coupled Gq/11- protein. GDP is then exchanged for GTP causing α-subunit dissociation from the ßγ- 
subunit, which induced PLC and various downstream effector molecules’ activation (Pin et al., 2003). 
In addition to well-established coupling to Gq-type G-proteins, group I mGluRs can also couple to 
Gi/o, Gs and G-protein independent pathways (Hermans and Challiss, 2001) so as to activate 
alternative downstream effector molecules including adenylate cyclase (AC), tyrosine kinases, and 
mitogen-activated protein kinases (MAPK) (Balazs et al., 1997; Boxall, 2000). 
 
1.4.  Group I mGluRs: expression patterns and distribution  
Group I mGluRs are differentially expressed throughout the mammalian central CNS and PNS in a 
diverse array of neuronal subpopulations (Pin et al., 2003). Both receptor subtypes are highly 
expressed at the postsynaptic densities (PSDs) of excitatory glutamatergic synapses. Nonetheless, 
there is also evidence for presynaptic localization of group I mGluRs as well as of presynaptic-
targeted actions via endogenous retrograde signalling (Maejima et al., 2001; Niswender and Conn, 
2010). In early developmental stages high expression of both mGlu1 and 5 receptors has been 
reported in multiple brain areas, including the cortex, hippocampus and cerebellum (Catania et al., 
1994; Lopez-Bendito et al., 2002; Romano et al., 1996a). In adult brain, mGluR1 is most abundant in 
the Purkinje neurons of the cerebellum (Shigemoto et al., 1992), while mGluR5 is most abundant in 
the strata oriens and radiatum of the hippocampus (Lopez-Bendito et al., 2002; Lujan et al., 1996). 
The hippocampus is a region of differential group I mGluR expression; mGluR1 predominates in CA3, 
while mGluR5 in CA1 pyramidal cells (Fotuhi et al., 1994). Within the hippocampus, mGluR1 is mainly 
localized in cell bodies whereas mGluR5 in the dendritic regions. Apart from the hippocampus 
mGluR5 is also highly expressed in the cerebral cortex, subiculum, olfactory bulb, nucleus 
accumbens, lateral septal nucleus and in the medium spiny projection neurons of the striatum (Fotuhi 
et al., 1994; Luscher and Huber, 2010; Romano et al., 1996a). mGluR1 is additionally expressed in 
the mitral cells of the olfactory bulb, the lateral septum, the pallidum, and in the thalamus (Luscher 
and Huber, 2010). Both group I mGluRs are also expressed in the PNS in peripheral sensory 
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unmyelinated afferent terminals (Bhave et al., 2001). At the subcellular level, mGluR1 and 5 are 
localized in the extrasynaptic regions of dendritic spines, where they are anchored to NMDARs via 
scaffolding proteins, such as Homer, Shank, and postsynaptic density protein 95 (PSD95) (Baude et 
al., 1993; Lujan et al., 1996; Tu et al., 1999). Their localization profile supports their role as mediators 
of synaptic strength, by modulating the activity and distribution of ionotropic and GABA(A) receptors 
(Xiao et al., 2006). The knowledge about the distinct expression profiles of mGluR1 and mGluR5 and 
their roles in modulating glutamate and GABA(A) neurotransmission can provide a basis for 
identifying the physiological and pathological factors that can contribute to changes in group I 
mGluR’s activity, expression and interaction profile and thus for understanding and treating many 
CNS diseases.  
1.5.  Group I mGluRs: roles in Physiology and Pathology  
 In the nervous system, Glu is the primary fast excitatory neurotransmitter participating in a wide 
range of neural functions such as learning and memory, long-term potentiation and synaptic plasticity 
(Fairman and Amara, 1999; Meldrum, 2000). Although glutamatergic signalling is considered fast, 
mGluRs are classified as slow-acting, neuromodulators (Pin et al., 2003). Group I mGluRs, due to 
their diverse expression profile and their role in modulating signalling pathways (Coutinho and 
Knopfel, 2002), have been linked to modulation of multiple processes, such as neuronal development, 
synaptic plasticity (Le Duigou and Kullmann, 2011) and induction of reactive astrocytes (Ferraguti et 
al., 2008). The principal function of group I mGluRs is the modulation of excitatory neuronal signalling, 
mainly by inhibition of potassium conductance and activation of selective cationic transmissions 
(Guerineau et al., 1994). However, mGluR1/5 can also induce inhibitory hyperpolarizing responses 
(Crepel et al., 1994). For example, mGluR1 generates inhibitory hyperpolarizing signals in midbrain 
dopamine neurons (Valenti et al., 2002). Moreover, pharmacological inhibition studies have shown 
that regulation of CA1 pyramidal cell excitability is executed by mGluR1, while mGluR5 generates the 
slow after hyperpolarization potential (Mannaioni et al., 2001). This illustrates that, in spite of high 
sequence homology between mGluR1 and mGluR5 (Abe et al., 1992), each receptor subtype exerts 
specific physiological effects even at the same neuronal population (Valenti et al., 2002).  
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Neurodevelopmental processes are considerably influenced by aberrant group I mGluR signaling. 
This notion is finely demonstrated in the rodent barrel cortex. In Grm5-/-
 
mice, despite fractional 
segregation of thalamic afferents, the barrel cortex fails to develop, most probably due to lack of 
mGluR5-stimulated PLC-β1 signalling, which is important in the early development of the region 
(Hannan et al., 2001). Additional studies have highlighted a role of mGluR1 in the regression of 
climbing fibers from cerebellar Purkinje neurons. In normal development, innervations of Purkinje 
neurons cease so that most climbing fibers regress and only one strong excitatory input remains. The 
climbing fibers of transgenic mice expressing reduced levels of mGluR1 fail to regress (Aiba et al., 
1994; Levenes et al., 1997; Sachs et al., 2007). Another distinctive feature of mGluR1-/- mice is ataxia, 
a common hallmark of many neurological disorders (Conti et al., 2006; Sachs et al., 2007). 
Additionally, ataxia, a common hallmark of many neurological disorders, has been linked to mutants in 
the mGluR1 locus (Sachs et al., 2007). A role of group I mGluRs in neuronal differentiation was 
additionally demonstrated. PrPC and laminin γ chain (PrPC-Ln γ1) were identified as group I mGluR 
interaction partners (Graner et al., 2000). Beraldo and colleagues showed that upon formation of the 
group I mGluRs -PrPC -Ln γ1 complex, group I mGluRs are activated and transduce signals for 
neuritogenesis (Beraldo et al., 2011).  
Furthermore, group I mGluRs are key regulators of synaptic plasticity. Both receptor subtypes have 
been associated with hippocampal long-term potentiation (LTP), long-term depression (LTD), spatial 
learning and memory formation (Balschun et al., 1999; Salinska and Stafiej, 2003). In agreement with 
these observations, Grm1-/-
 
mice lack induction of hippocampal LTP (Lapointe et al., 2004), whereas 
antagonism of both mGluR1 and mGluR5 is required to fully suppress cortico-striatal LTP (Gubellini et 
al., 2003).  
The localization of group I mGluRs significantly influences their role in pathology. Both mGlu1 and 5 
receptors reside in the extrasynaptic region of the dendritic spines, interacting with the NMDARs 
through a group of scaffolding proteins, such as Homer, Shank and PSD95 (Tu et al., 1999). Group I 
mGluRs promote the activation of NMDARs by either relieving the Mg2+-ion blockage of the NMDA 
channel or by other mechanisms (Attucci et al., 2001; Doherty et al., 1997; Mannaioni et al., 2001; 
Pisani et al., 2001). Thus, it was expected that the activation of mGlu1/5 receptors induces neuronal 
damage by the activating NMDA receptor. However, activation of mGluR1/5 receptors by addition of 
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(S)-3,5-Dihydroxyphenylglycine (DHPG) was reported to either amplify or reduce excitotoxic neuronal 
death, depending on the neurodegeneration models used (Bruno et al., 2001; Nicoletti et al., 2011). 
The idea that group I mGluRs either promote or attenuate neuronal damage depending on their 
functional state was supported by multiple in vitro and in vivo studies. For example, in mixed primary 
cortical cultures DHPG amplifies NMDA toxicity when applied only once (either before or during the 
NMDA pulse). However, it turns neuroprotective when applied for the second time after a brief pre-
exposure, due to an activity-dependent switch in group I mGluR activity triggered by hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PtdIns-4,5-P) and a subsequent inhibition of voltage-sensitive 
Ca2+ channels (Herrero et al., 1998; Sistiaga and Sanchez-Prieto, 1998). Another study showed that 
mGluR1a could both stimulate intracellular Ca2+ release and activate phosphatidylinositol-4,5-
biphosphate 3-kinase (PI3K) signalling only when the C-terminal region (main interaction domain) of 
the receptor is intact. This favours the toxic activation of NMDARs and a sustained Ca2+-influx, which 
induce a calpain-mediated cleavage of the C-terminus of mGluR1a. The latter prevents activation of 
the PI3K pathway and instead promotes stimulation of the PtdIns-4,5-P hydrolysis, which results in 
the production of a neurotoxic signal and ultimately in neuronal cell death (Xu et al., 2007). 
Conversely, prevention of calpain-mediated truncation of the C-terminus of mGluR1a protects 
hippocampal slices against oxygen/glucose deprivation (OGD). It also protects neonatal rats from 
hypoxia/ischemia-induced neuronal damage (Zhou et al., 2009). In cultured cerebellar granule cells, 
mGluR1 promotes cell survival in the presence of glutamate, but causes apoptotic death in the 
absence of bound ligand (Pshenichkin et al., 2008), due to an interaction of the mGluR1a C-terminal 
domain with intracellular targets that regulate the activation of pro- and anti- apoptotic signals 
(Pshenichkin et al., 2011). On the other hand, mGluR1a-mediated neuroprotection involves a G-
protein independent pathway, driven by β-arrestin1 dependent activation of the mitogen-activated 
protein kinase (MAPK) pathway (Emery et al., 2010; Pshenichkin et al., 2011). Pharmacological 
studies further suggest the existence of a “ligand bias”. Glutamate binding can induce both 
neuroprotective and neurotoxic signals, whereas quisqualate (an mGluR1 orthosteric agonist) can 
only stimulate PtdIns-4,5-P hydrolysis and neurotoxicity.  Interestingly, mGluR1 antagonists can block 
PtdIns-4,5-P hydrolysis, but not the pro-survival signals triggered by glutamate. The mechanism of 
action is still elusive (Emery et al., 2011).   
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Contrary to receptor agonists, mGlu1 and mGlu5 receptor antagonists or negative allosteric 
modulators (NAMs) are repeatedly neuroprotective, independently of the context and the nature of the 
toxic insult. Both in vitro and in vivo studies have shown that selective mGlu1 receptor antagonists are 
neuroprotective by enhancing GABA release (Battaglia et al., 2001; Cozzi et al., 2002). Group I 
mGluRs have also been studied in mechanisms of ischemic tolerance. In organotypic hippocampal 
slices, treatment with mGluR1, but not mGluR5, antagonists abrogated a non-lethal 10min pre-
exposure to OGD, a paradigm of “ischemic preconditioning”. A subsequent lethal exposure to OGD, a 
paradigm of pharmacological preconditioning, was rescued by pre-exposure to DHPG (Werner et al., 
2007). Conversely, when hippocampal slices were subjected to a protocol of “ischemic post-
conditioning”, in which a brief (3 min) period of OGD was delivered 5 min after a lethal episode of 
OGD, neuroprotection was suppressed by both mGluR1 and mGluR5 antagonists, due to stimulation 
of the phosphatidylinositide 3-kinase/ Protein kinase B/ Glycogen synthase kinase (3PI3K/Akt/GSK3β 
pathway) (Scartabelli et al., 2008). A recent study shows that mGluR1/5 and also highly expressed on 
oligodendrocytes during development and their modulation is protective in a rodent model of 
periventricular leukomalacia (Jantzie et al., 2010). 
mGluR5 has been critically linked to a wide spectrum of disorders including neurodegenerative 
disorders,  fragile X and autism spectrum disorder (Caraci et al., 2012; Krueger and Bear, 2011).  
Intracellular mGluR5 has been shown to induce an increase of dendritic Ca2+, with amplitude that 
differs from activation of the cell surface variant (Purgert et al., 2014). Intracellular mGluR5 was 
additionally shown to mediate protein-synthesis-dependent LTD, whereas cell-surface mGluR5 
mediated both LTD and LTP (Purgert et al., 2014). Increases in the levels of mGlu5 and β-arrestin 
immunoreactivity have been reported in the putamen of PD patients as well as in the frontal cortex, 
hippocampus and putamen of patients with Lewy Body Dementia (Price et al., 2010). Levels of mGlu5 
receptors were also increased in α-synuclein transgenic mice (Price et al., 2010). In parkinsonian 
disease models in mice and monkeys (animals were challenged with 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) compound), systemic treatment with mGluR5 inhibitor [2-Methyl-6-
(phenylethynyl)pyridine (MPEP) and 3-((2-Methyl-4-thiazolyl)ethynyl)pyridine (MTEP), respectively) 
protected nigro-striatal neurons against degeneration (Battaglia et al., 2004; Masilamoni et al., 2011). 
Moreover, in a 6-hydroxydopamine model of PD, pharmacological inhibition or genetic deletion of 
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mGluR5 attenuated motor deficits and prevented the loss of nigrostriatal neurons (Armentero et al., 
2006; Black et al., 2010).  
In Fragile X syndrome (FXS), aberrant signaling via group 1 metabotropic glutamate receptors 
(mGluRs) is suggested to trigger the observed pathophysiology. The first connection between the 
fragile-X mental retardation protein (FMRP) and mGluR pathways was described by Weiler et al., who 
observed that DHPG-mediated activation of group I mGluRs stimulated protein synthesis (including 
the expression of FMRP) in synaptoneurosomes (Weiler et al., 1997). Studies in Fmr1 knockout (KO) 
mouse models demonstrated that the absence of FMRP leads to increased protein synthesis and 
altered synaptic plasticity, including enhanced long-term depression (LTD) (Huber et al., 2002). These 
observations set the basis for the formulation of the mGluR theory. The latter states that the absence 
of FMRP in FXS induces excessive glutamatergic signaling via mGluR5 (Bear, 2005). In the absence 
of FMRP, increased local mRNA translation as well as a high rate of AMPAR internalization, and then 
degradation occurs at the synapse and gradually weakens it. Increased internalization of AMPARs 
influences the maturation of dendritic spines, resulting in an increased number of immature dendritic 
spines and thus intellectual disability (Portera-Cailliau, 2012). 
In Alzheimer’s disease (AD), PrPC and mGluR5 were considered to directly contribute to disease 
manifestation and toxicity of Amyloid β (Aβ) aggregates. Aβ oligomers can bind to PrPC at the cell 
surface (Lauren et al., 2009) and form complexes that contain mGluR5 (Haas et al., 2014). In a 
mouse model of Aβ deposition, cognitive decline and synaptic alterations were rescued by mGluR5 
inhibition (Um et al., 2013). Furthermore, PrPC-mGluR5 coupling is involved in Aβ-mediated inhibition 
of LTP and Aβ-facilitated LTD in vivo (Hu et al., 2014), and genetic ablation of mGluR5 reverses 
disease-related memory deficits in a murine model of AD (APPswe/PS1∆E9) (Hamilton A. et al., 
2014). In another study, exposure of cortical APPswe/PS1∆E9 neuronal cultures to Aβ oligomers 
upregulated mGluR1 and PrPC α-cleavage, whereas activation of group-I mGluRs increased PrPC 
shedding from the membrane (Ostapchenko et al., 2013). In primary hippocampal neurons, 
membrane-bound Aβ oligomers induce toxicity by promoting clustering of mGluR5 in synapses, 
resulting in elevated intracellular calcium and synaptic failure (Renner et al., 2010). All these studies 
speak in favor of an involvement of group-I mGluRs in the pathogenesis of AD. On the other hand, 
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others have reported that neither PrPC ablation nor overexpression had any effect on neurotoxicity in 
AD models (Balducci et al., 2010; Calella et al., 2010; Cisse et al., 2011; Kessels et al., 2010). As a 
possible explanation for these discrepancies, it has been suggested that only a defined oligomeric 
fraction of Aβ (Kostylev et al., 2015) interacts with mGluR5 (Haas et al., 2016). These findings are 
particularly interesting because mGluR5 inhibitors are under clinical development for the treatment of 
PD, AD and FXS.  
The role of mGluR5 in neurodegeneration/neuroprotection-related mechanism should also be 
examined in the context of glia-neuron crosstalk. Cultured astrocytes express mGlu5 receptors and its 
expression is increased with culturing conditions promoting a reactive-like phenotype in astrocytes. 
Conversely, thrombin treatment, which reverses the reactive-like phenotype of cultured astrocytes, 
reduces the mGluR5 expression (Balazs et al., 1997; Miller et al., 1995; Miller et al., 1996). 
Pharmacological inhibition of mGluR5 reduces excitotoxic death of cultured spinal motor neurons 
grown in cultures enriched of reactive astrocytes (D'Antoni et al., 2011) and delays the onset of motor 
symptoms in transgenic mice expressing a mutated form of human superoxide dismutase (SOD) 
(Rossi et al., 2008); models of ALS.  
To conclude, group I mGluRs possess a variety of physiological functions owing to their distribution, 
localization, structural variants and protein- interaction partners. However, finr tuning of the receptor 
activity is required so as not to exert their neurotoxic function.  
1.6. Group I mGluRs: Interaction partners  
Group I mGluRs are mainly located at the PSD, a specialized region of the post-synapses that 
concentrates and organizes multiple signalling molecules and thus serves as a signalling apparatus. 
Their localization and their interactions with neighboring molecules frequently specify their functions.  
The most well-established interaction partners are members of the Homer family adaptor proteins 
(Shiraishi et al., 2004). Homer proteins are postsynaptic scaffolding proteins that interact with the C-
terminal region of mGluR1a and mGluR5a/b through their PDZ domains and couple the latter with 
intracellular inositol triphosphate receptors (IP3Rs). They are an integral component of the 
postsynaptic mGluR signalling complex (Duncan et al., 2005; Xiao et al., 1998). Long forms of Homer, 
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harbor a distinct dimerization domain that allows them to function both as scaffolds for multiprotein 
complex formation at PSDs and as mediators of mGluR signalling. Long homer protein dimerization 
assists recruitment of PI3K enhancer (PIKE) to mGluR5. PIKE is a small GTPase molecule, which 
binds PI3K to trigger its endogenous lipid kinase activity (Rong et al., 2003). For example, the 
interaction of mGluR1-Homer is necessary for mGluR1-LTD and reversal of cocaine-induced plasticity 
in vivo in the ventral tegmental area (VTA) (Mameli et al., 2009), whereas disruption of this interaction 
in hippocampal slices antagonizes mGluR-LTD (Ronesi and Huber, 2008).  In contrast, short forms of 
Homer, such as Homer1a, lack the dimerization domain and behave as dominant negatives (Xiao et 
al., 1998). 
Multiple studies have shown that mGlu1 receptors interact with membrane estrogen receptors (ERs) 
in hypothalamic neurons. This interaction is integral for the regulation of the estrous cycle 
(Mermelstein, 2009; Micevych and Mermelstein, 2008). In cortical neurons, the same interaction 
occurs. In these cultures, the protective effect of 17-β-estradiol treatment against β-amyloid is 
prevented by addition of mGluR1 inhibitors. Also, the protective effect of DHPG application is 
prevented by the pharmacological inhibition of ER  (Spampinato et al., 2012). However, the 
mechanism of interaction still remains unknown. 
NMDARs are also known functional interaction partners of group I mGluRs. Homer proteins facilitate 
the physical association of group I mGluRs with the NR2 subunit of the NMDARs. Homer proteins act 
as scaffolds and recruit PSD95 and Shank to the complex to stimulate group I mGluRs (Tu et al., 
1999). The latter promote the activation of NMDARs by either relieving the Mg2+-ion blockage of the 
NMDA channel or by other mechanisms (Attucci et al., 2001; Doherty et al., 1997; Mannaioni et al., 
2001; Pisani et al., 2001). Pharmacological agonists of either mGluR1 or mGluR5 also enhance 
NMDA receptor function (Collett and Collingridge, 2004; Pisani et al., 2001). For example, exposure to 
DHPG potentiated NMDA toxicity in cultured cortical cells (Bruno et al., 1995). Sustained activation of 
group I mGluRs promotes the toxic stimulation of NMDARs and a sustained Ca2+-influx, which induce 
a calpain-mediated cleavage of the C-terminus of mGluR1a. The latter prevents activation of the PI3K 
pathway and instead promotes stimulation of the PtdIns-4,5-P hydrolysis, which further supports the 
production of a neurotoxic signal and ultimately causes neuronal cell death (Xu et al., 2007). 
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In line with this, Jin and colleagues have showed that the interaction of calcium/calmodulin-dependent 
protein kinase type II alpha chain (CamKIIα), NMDAR GluN2B subunit and mGluR5 at the synapse, 
regulates excitatory synaptic transmission. The binding of CaMKIIa to the proximal C-terminal region 
of mGluR5 is Ca2+-sensitive. Ca2+ activates calmodulin (CaM) and CaMKIIa and thus induces the 
dissociation of CamKIIa from mGluR5 in vitro and in striatal neurons. Also, treatment with an mGluR5 
agonist triggers the activation of CaMKIIa and its subsequent binding to the GluN2B subunit of the 
NMDAR. This enables CaMKIIa to phosphorylate GluN2B at position S1303 and activate NMDARs. 
To sum up, Jin and colleagues described a model of functional interaction between mGlu5 and NMDA 
receptors via the mGluR5- and Ca2+- regulated CamKIIa activation (Jin et al., 2013). 
Another interactor of mGluR5 is Calmodulin (CaM). CaM binding actively regulates the cell surface 
expression of mGluR5.  In rat hippocampal neurons, CaM was shown to compete with E3 ligase 
seven in absentia homolog (Siah-1A) to regulate the trafficking of mGluR5 in a phosphorylation-
dependent manner. More specifically, phosphorylation of mGluR5 at position S901 by protein kinase 
C (PKC) displaces CaM and favors Siah-1A binding. Siah-1A binding decreases the surface 
expression and increases endosomal trafficking and lysosomal degradation of mGluR5 (Ko et al., 
2012).  
A balanced trafficking of the mGluRs is essential so as to ensure attenuation, preclude 
overstimulation and cell damage and maintain a healthy cellular milieu (Lipton, 2007). A known 
regulator of mGluR localization and activity, through phosphorylation and subsequent desensitization, 
is the G-protein-coupled receptor kinase 2 (GRK2). GRK2 is primarily regulated by inflammation in 
several cell types (Dale et al., 2000). Inflammation-induced neuronal sensitization triggers GRK2 
down-regulation and over-activation of group I mGluRs. The latter promotes continuous calcium 
mobilization from intracellular stores; mimicking the sensitizing effect of inflammation on excitotoxic 
neurodegeneration. The same effect was observed upon genetic deletion of GRK2 gene (Degos et 
al., 2013). Thus, GRK2 at the molecular level links sensitizing inflammation with group I mGluR 
activation and excitotoxicity; highlighting group I mGluRs as potential therapeutic targets. 
The Role of Group I Metabotropic Glutamate Receptors in Prion Induced Toxicity PhD Dissertation 
 
 
50  Despoina G. Goniotaki – October, 2016  
  
1.7. Group I mGluRs and PrPC 
The normal cellular prion protein (PrPC) has also recently emerged as an interaction partner of group I 
mGluRs. PrPC together with laminin γ chain (Ln γ1) were identified as group I mGluR interaction 
partners (Graner et al., 2000). Beraldo and colleagues showed that the formation of the group I 
mGluRs -PrPC -Ln γ1 complex, stimulates group I mGluRs to transduce signals for neuritogenesis 
(Beraldo et al., 2011). However, PrPC-group I mGluR interaction can also contribute to neuronal 
toxicity and pathology.  
 In AD, binding of Aβ oligomers to PrPC induces its interation with mGluR5 (Lauren et al., 2009). The 
Aβ-PrPC-mGluR5 complex fomation, (Haas et al., 2014) activates mGluR5s, which act as the effectors 
of the Aβ-toxicity.  In a mouse model of Aβ deposition, cognitive decline and synaptic alterations were 
rescued by mGluR5 inhibition (Um et al., 2013). Furthermore, PrPC-mGluR5 coupling has been shown 
to be involved in Aβ-mediated inhibition of LTP and Aβ-facilitated LTD in vivo (Hu et al., 2014), and 
genetic ablation of mGluR5 reversed disease-related memory deficits in a murine model of AD 
(APPswe/PS1∆E9) (Hamilton A. et al., 2014). In another study, exposure of cortical APPswe/PS1∆E9 
neuronal cultures to Aβ oligomers upregulated mGluR1 and PrPC α-cleavage, whereas activation of 
group-I mGluRs increased PrPC shedding from the membrane (Ostapchenko et al., 2013). In primary 
hippocampal neurons, membrane-bound Aβ oligomers induced toxicity by promoting clustering of 
mGluR5 in synapses, resulting in elevated intracellular calcium and synaptic failure (Renner et al., 
2010). All these studies speak in favor of a role of group-I mGluRs in the pathogenesis of AD. A role 
of PrPC-mGluR1 interaction has additionally been suggested in prion diseases. Impairment of the 
mGluR1/1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase 1 (PLC1)/protein kinase C (PKC) 
signaling pathway has been observed in a murine model of BSE; abnormal mGluR1 signaling 
correlated with PrPSc deposition, histological changes, and clinical scores (Rodriguez et al., 2006).  
Another study proposed that PrPC functioned as a receptor to mediate the deleterious effects of Aβ 
oligomers. This interaction did not require the infectious PrPSc conformation. This proposition was 
further supported by the binding of Aβ-oligomers to a neurodegeneration-linked domain of PrPC as 
well as by the isolation of PrPC as an Aβ-oligomer interaction partner in an unbiased, genome-wide 
screen (Lauren et al., 2009). PrPC has also been shown to interact with the 2D subunit of NMDARs 
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and to modulate its function (Khosravani et al., 2008; Senatore et al., 2012); suggesting a potential 
role of PrPC as a regulator of glutamatergic signalling, by fine-tuning mGluR5-NMDA interaction. 
Detailed information about PrPC and its role in physiology and in prion diseases will be presented in 
the following paragraphs. 
1.8. Introduction to Prion Diseases 
Prion diseases, also known as transmissible spongiform encephalopathies (TSEs), are a group of 
rare, progressive, neurodegenerative disorders of sporadic genetic or infectious origin that are 
invariably fatal. They affect human and a wide variety of animals. TSEs include scrapie, bovine 
spongiform encephalopathy (BSE), disease in humans (Aguzzi and Calella, 2009; Collinge, 2001). 
Although quite rare in the human population, industrial (i.e. cattle) and wild-life (i.e. deer and elk) 
animal populations have been affected by prion diseases at a much larger scale. Indeed, it was prion-
infected cattle in the 1990s that brought the disease to light for the general public as a potentially 
serious public health concern (Aguzzi and Weissmann, 1996; Ghani et al., 2002). Currently, CJD is 
the most common human prion disease, affecting approximately 1-2 people per million per year 
(Ladogana et al., 2005). There are 4 major forms of CJD: sporadic (sCJD), familial (fCJD) or 
otherwise known as genetic or inherited, iatrogenic (iCJD) and variant (vCJD). The most common is 
sCJD, which accounts for approximately 85% of the total incidence of CJD and arises from a 
spontaneous somatic mutation within the prion protein gene (PRNP) or through a random structural 
change of the prion protein itself (Colby and Prusiner, 2011).  
Prions have attracted the attention of the scientific community because they challenged the central 
dogma of molecular biology; that the biological information flows from nucleic acid to proteins and not 
the other way round. Indeed, according to the ‘prion hypothesis’ the infectivity is completely protein-
mediated. The infectious agent is an unconventional pathogen: a self-propagating, proteinaceous 
particle devoid of nucleic acids, known as scrapie prion (PrPSc) (Prusiner, 1982). PrPSc is a misfolded 
conformational variant of the host-encoded cellular prion protein (PrPC) (Prusiner, 1998); a 
glycosylphosphatidylinositol (GPI)-anchored protein that is highly abundant in the central nervous 
system. The presence and accumulation of PrPSc in the affected brains is the unifying hallmark of 
prion disorders. 
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Prion diseases are unique in many pathological and phenotypic traits, such as their long incubation 
periods, infectious nature, characteristic mode of propagation within and between species as well as 
the distinctive spongiform changes associated with neuronal loss and a failure to induce inflammatory 
response, but share several key features with other neurodegenerative disorders on the subcellular 
level (Aguzzi and Calella, 2009). Similar to Alzheimer’s, Parkinson’s and Huntington’s disease (AD, 
PD and HD respectively), prions are neurodegenerative disorders caused by the misfolding of normal 
cellular proteins. One of the earliest changes is synaptic dysfunction, followed by neuronal spine loss. 
These pathologies accumulate progressively within the brain tissue such that extensive damage 
typically precedes clinical symptom manifestation and neuronal loss.  
The clinical and histopathological phenotypes of prion diseases are highly heterogeneous. Signs 
include neurodegeneration, astrogliosis in the absence of inflammatory reaction, and, in some cases, 
spongiosis (due to neuronal vacuolation) and deposition of amyloid plaques. Clinical symptomatology 
is also variable; in humans dominant clinical features are fatigue, insomnia, dementia, weight loss, 
headaches and ill-defined pain sensations, whereas key neurological features include myoclonus, 
cerebellar ataxia, dysautonomia, pyramidal and extrapyramidal signs and in some cases cortical 
blindness and psychiatric features (Kubler et al., 2003).  
Despite significant advances in our understanding of prion diseases and the role of the infectious 
agent, many key questions concerning the nature of the prion, the mechanism of its replication and 
the underlying molecular events remain unanswered. The focus of the following paragraphs will be on 
the unresolved issues pertaining to early pathogenic events at the synapse and the role of PrPC-
interacting partners. 
 
1.9. Prion Protein - two main conformational isoforms  
Alper and Griffith first proposed that prion diseases are caused by an infectious agent devoid of 
nucleic acids; i.e. a protein (Alper et al., 1967; Griffith, 1967). Years later, this protein was isolated and 
termed “prion” due to its properties as a “proteinaceous infection particle” (Prusiner, 1982). The prion 
protein exists in two major conformational isoforms, the normal form termed cellular PrP (PrPC) and 
the infectious, misfolded form termed scrapie PrP (PrPSc).   
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PrPC is a glycoprotein anchored to the external surface of cells by a glycosylphosphatidylinositol (GPI) 
anchor (Stahl et al., 1987). Major elements of the protein are highly conserved among species 
suggesting an important biological role of PrPC (Wopfner et al., 1999). It consists of a flexible and 
unstructured N-terminal domain [23-120 amonicacids (aa)] and a structured C-terminal globular 
domain (121-131 aa) (Zahn et al., 2000). At the N-terminus, a 22 aa signal domain drives transport of 
the protein to the Golgi apparatus where it is glycosylated and further transported to the cellular 
membrane. Four octapeptide domains (PHGGGWGQ) are located within the octapeptide repeat (OR) 
region and favor binding to metal ions (Zn2+, Cu2+, Ni2+, Mn2+) (Jackson et al., 2001). The C-terminus 
includes two glycosylation sites (181N and 197N) that can be un-, mono- and di-glycosylated and a 
signal sequence for a GPI anchor. Biochemical analysis of PrPC showed that it is sensitive to 
chemical treatments and digestion by cellular proteases (e.g. Proteinase K (PK)) and is inactivated by 
either heat or ultraviolet (UV) radiation (Meyer et al., 1986). PrPC is typically tethered to the cell 
membrane by its GPI anchor and located in the lipid raft microdomains of the plasma membrane 
(Linden et al., 2008). Like other GPI-linked proteins, it is suggested to play a functional role in signal 
transduction and intracellular trafficking (Kasahara et al., 1999) (Figure 1.6.).   
(A) 
 
 
 
(B) 
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Figure 1.6. The normal cellular Prion Protein (PrPC) 
(A) Linear representation of the unprocessed human PrP depicting several features of the normal 
cellular prion protein (PrPC). It is a 253 amino acid (aa) residues in length and includes a signal 
peptide (SP) (aa 1-22), charged cluster 1 (CC1) (aa 23-30), four octapeptide repeats (OR) (aa 
59-90), charged cluster 2 (CC2) (aa 101-110), hydrophobic core (HR) (aa 114-121), alpha-helix 
1 (a1) (aa 145-153), alpha helix 2 (a2) (aa 166-194), alpha helix 3 (a3) (aa 200-226) and 
glycosylphosphatidylinositol (GPI) anchor (aa 232-253), proteinase K (PK). A linear 
representation of the PK resistance region is presented below [modified by: (Aguzzi and 
Heikenwalder, 2006)].  
(B) Schematic representation of the cellular prion protein (PrPC) anchored in the membrane. 
 
The infectious prion protein (PrPSc) was first discovered to co-purify in brain extracts from rodents 
infected with prions. In contrast to PrPC, proteinase K (PK) digestion of PrPSc results in a protease-
resistance fragment, 27-30kDa in size, called PrP27-30, which is the canonical biochemical hallmark 
of PrPSc. This fragment usually presents three different glycoforms (diglycosylated, monoglycosylated 
and unglycosylated) that can be easily identified in immunoblot analysis (Bolton et al., 1984; McKinley 
et al., 1991; Prusiner et al., 1982) (Figure 1.3.). 
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Figure 1.7. Proteinase K (PK) digestion immunoblots 
Immunoblot of proteinase K digested brain homogenate from cases of classical CJD and variant CJD 
(vCJD) [modified by (Nuvolone et al., 2016)] (left side). Immunoblot of proteinase K digested brain 
homogenate from RML6-infected, Tga20 mice and uninfected controls [modified by (Raeber et al., 
1997)] (right side). 
 
Although the two isoforms have the same amino acid sequence and main post-translational 
modifications (glycosylations, GPI anchor), their biochemical properties differ.  PrPC is α-helical, 
whereas PrPSc is at least 40% β−pleated sheet; PrPC is soluble in nondenaturing detergents, whereas 
PrPSc is insoluble; PrPC is completely degraded by proteases, whereas PrPSc has a relative resistance 
to proteases (Caughey et al., 1991; Meyer et al., 1986; Pan et al., 1993; Stahl et al., 1993) (Table1.1.) 
 
Prion isoforms α-helix 
content 
β-sheet 
content 
Proteinase 
resistance/ 
aggregation 
Form Cellular 
Localization 
Infectivity Effect  
of wt  
PrP 
PrPC high low       - Monomer Plasma membrane/ Rafts     - N/A 
PrPSc low high     ++ Multimer Plasma membrane/ Endosomes     + Required for toxicity 
 
 
Table 1.2. The main properties of the normal and the infectious prion protein isoforms 
The high β-sheet conformation of PrPSc exposes parts of the protein normally buried inducing a higher 
degree of “stickiness” between these proteins (Nelson et al., 2005). As a result, PrPSc is susceptible to 
aggregate into prion fibrils that consist of trimeric, left-handed β-pleated sheet units (Govaerts et al., 
2004; Wille et al., 2002).  Oligomers, protofibrils and fibrils [reviewed in (Caughey and Lansbury, 
2003)] are commonly observed in prion-infected brain tissue, yet, the soluble oligomers (sizes ranging 
from 17-27nm) exhibit the highest infectivity and activity of structural conversion (Silveira et al., 2005) 
(Silveira et al., 2005). These oligomeric entities are of equivalent mass to 14-28 PrP molecules, are 
composed solely of PrPSc and cause toxicity in neurons (Simoneau et al., 2007).  
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1.10. The “protein-only” hypothesis  
Alper and co-workers with a series of well-designed experiments were the first to demonstrate that the 
infectious agent was not a nucleic acid. The use of procedures that eliminate nucleic acids, such as 
high doses of inonizing radiation and UV, did not destroy the prion infectious material (Chaffin et al., 
1990). The same group also identified the minimum molecular weight of the unit that maintained 
infectivity (2 *105 Da), which was too small to be a virus or another microorganism (Rockman et al., 
2014). Based on this observations and the identification of the two conformational isoforms the 
“protein-only” hypothesis of prions was formed. The latter postulates that the infectious agent is a 
protein (PrPSc), which self-replicates in the absence of nucleic acids. Two models have been 
proposed to explain PrPSc propagation (Figure 1.8.). The “refolding or template-assisted model” which 
states that PrPSc exists in a monomeric state, thermodynamically more stable than PrPC. According to 
this model PrPSc binds to PrPC and induces the formation of an heteromeric PrPC-PrPSc unit and the 
subsequent conformational conversion of PrPC by lowering the energy barrier that separates the two 
states (Cohen, 1999). The model suggests that the conversion is rare (unless catalyzed by pre-
existing PrPSc units) and that the infectious unit is a monomer of PrPSc. This model was questioned by 
Caughey and colleagues who showed that small oligomers (<6 units of PrPSc) were non-infectious in 
Syrian hamsters. Actually, small, non-fibrillar oligomers  (14-28 units of PrPSc) exhibited the highest 
infectivity (Silveira et al., 2005). 
The second model, the “nucleated polymerization model” postulates that PrPC and PrPSc are in 
reversible thermodynamic equilibrium, shifted towards the normal PrPC conformer under normal 
conditions. The formation of an ordered stable oligomer is the limiting step for the “de novo” 
production of PrPSc units. These units act as nucleation seeds that recruit PrPC and incorporate it, 
after misfolding, into this amyloid-like oligomeric-structure. Fragmentation of these structures 
generates new nucleation seeds inducing the propagation of the infectious agent (Jarrett and 
Lansbury, 1993). Thus, in a self-propagating process, more disease-associated molecules 
accumulate, aggregate and are deposited in the brain. According to this model, PrPSc is only 
infectious as a highly ordered aggregate. Both mechanisms are considered credible, since they can 
explain the different aetiology of prion diseases –infectious or sporadic origin.  However, experimental 
evidence from the yeast prion model favors the “seeded nucleation” hypothesis (Serio et al., 2000). 
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Figure 1.8. Models for the conformational conversion of PrPC into PrPSc 
(A) The “refolding or template-assisted model” proposes an interation between exogenously 
introduced PrPSc and endogenous PrPC that induced the transformation of the latter into 
PrPSc. A high-energy barrier could hinder the spontaneous conversion of PrPC to PrPSc.  
(B)   The “seeding or nucleation-polymerization model” suggests that PrPC and PrPSc are in a 
reversible thermodynamic equilibrium. Only if several monomeric PrPSc units form a stable, 
highly-ordered seed, further monomeric PrPSc molecules can be recruited and eventually form 
an amyloid-like aggregate. Fragmentation of PrPSc aggregated seeds increases the number 
of seeding nuclei, which can recruit more PrPSc units and thus induce the propagation of the 
infectious agent  [modified by (Aguzzi and Polymenidou, 2004)]. 
 
Efficient conversion requires the donor PrPSc to come from the same species as the host PrPC. This is 
called the ‘species barrier’, it affects cross-species transmission time of prion diseases and is 
attributed to differences in the primary structure of PrPC amongst species (Collinge and Clarke, 2007). 
PrPSc prions, unlike their normal counterparts, have a long half-life, cannot be broken down and 
cluster in brain tissue forming aggregates. This leads to synaptic & dendrite loss, spongiform 
degeneration, brain inflammation and neuronal death – the hallmarks of prion disease (Aguzzi and 
O'Connor, 2010; Soto and Satani, 2011) (Figure 1.9.). 
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Figure 1.9. Neurodegenerative pathways implicated in prion diseases 
Abnormalities in the brain of individuals infected with prions include deposition of PrPSc 
aggregates, synaptic damage and dendrite loss, spongiform degeneration, brain inflammation 
and neuronal death. Dendrite degeneration was evaluated by Golgi-silver staining, spongiform 
degeneration was evaluated by hematoxylin and eosin staining, astrogliosis was detected by 
immunological staining of reactive astrocytes with an anti-GFAP (Glial fibrillary acidic protein) 
antibody and apoptosis was detected by caspase-3 antibody immunostaining (red indicated by 
white arrows). Control stainings are presented below [modified from (Soto and Satani, 2011)]. 
 
A key assumption of the protein-only hypothesis was that PrP expression by the host is essential for 
scrapie multiplication and disease progression. The advent of homologous recombination and 
molecular cloning techniques [cloning of the cDNA coding the entire open reading frame (ORF) of the 
mouse Prnp was published in 1986 (Locht et al., 1986) ] favored the generation of  Prnp-knockout 
(Prnp-/-) animals. The first Prnp-/- mice were produced by the Weissmann group. Mice developed 
normally and displayed no overt abnormalities in size, weight, fertility, behavior and appearance of 
brain, skeletal muscles and visceral organs (Bueler et al., 1992). The only remarkable findings were 
absence of prion propagation and resistance to scrapie infection (Bueler et al., 1993); confirming the 
initial hypothesis. Further support was provided by showing that pre-existing PrPSc can catalyze 
conversion of PrPC into PrPSc. This was achieved in a cell-free system, where [35S]methionine-labeled 
PrPC was converted into PrPSc in the presence of unlabelled purified PrPSc (Kocisko et al., 1994). It 
was also shown that the conversion rate relied on the initial concentration of PrPSc and was 
associated only with aggregates and not monomers; in compliance with the  nucleated polymerization 
mechanism (Caughey et al., 1995). However, the efficiency of this first cell-free conversion system 
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was low, as the amount of newly converted protein was significantly less compared to the initial 
concentration of PrPSc needed to trigger the conversion reaction. Recently, the in vitro PMCA (protein 
misfolding cyclic amplification) conversion system, confirmed another crucial prediction of the prion 
hypothesis – that prion replication is a cyclic process, in which the production of new PrPSc units 
induces further misfolding (Castilla et al., 2006; Saborio et al., 2001). 
Despite the compelling evidence in favor of the prion hypothesis, arguments against remained. First, 
prion strains were believed to arise from mutations or polymorphisms in the DNA (Manuelidis, 2003). 
This claim was debated by Bassen et al. who showed that each prion strain constitutes a different 
conformational state of PrPSc and can propagate only in the presence of host PrPC (Bessen et al., 
1995). Second, the presence and the quantity of PK-resistant PrPSc correlate with infectivity. This 
argument was debated by reports showing that infectivity is propagated even in the absence of 
detectable PK-resistant PrPSc (Hill et al., 2000; Lasmezas et al., 1997). It was further shown that there 
are infectious PrPSc forms that are not protease resistant (Safar et al., 1998).  
The main premise of the prion hypothesis that needed to be tested, which would also explain familial 
prion diseases, was that “de novo” mutations can induce the production of PrPSc units by icreasing the 
probability of a misfolding event. In order to determine whether familial PrP mutations can 
spantaneously give rise to infectivity, unique in vitro and animal models of prion disease were created. 
Transgenic mice over-expressing the P101L substitution, which is homologous to the human P102L 
GSS-related mutation, were generated and spontaneously developed neurological symptoms similar 
to those of prion diseases. Also, brain homogenates from these mice were reported to be infectious 
(Hsiao et al., 1990; Telling et al., 1996). However, these experiments were severily criticized due to 
the fact that brain homogenates from these mice were used to inoculate trangenic mice (expressing 
the same mutation) and not wt mice. Therefore, the most plausible interpretation of the former 
experiments would be that the inocula from the PrP-P101L over-expressing mice accelerated a pre-
existing disease process and did not cause “de novo”  prion infection (Nazor et al., 2005). 
Additional, transgenic mice were generated expressing the D177N substitution, the mouse equivalent 
of the human FFI-associated mutation. These mice showed neurological symptoms resembling the 
ones reported for FFI patients. Inocula from these mice caused prion disease in Tga20 mice, but 
failed to propagate the disease in Prnp-/- mice (Jackson et al., 2009). 
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The most irrefutable evidence in support of the revolutionary “protein-only” hypothesis would be to 
produce prions “de novo” in vitro.  Legname et al. generated amyloid fibers by in vitro polymerization 
of the recombinant PrP fragment (rPrP89-230) and used them to inoculate TG9949 (PrP89-230 
overexpressing) transgenic mice. Inoculated mice got sick and their brain tissue was used to induce 
TSE in wild-type mice. However, “in vitro prions” induced disease in Tg9949 mice after a very long 
incubation-time (much longer compared to the “natural” prion strains). Also these “synthetic prion 
fibrils” did not cause TSE to wild-type mice (Legname et al., 2004). It was suggested that the 
“synthetic prion fibrils” were either not “bona fide” infectious, and just accelerated a spontaneous, pre-
existing neurodegenerative process, or that they were many orders of magnitude less infectious than 
“natural” prion strains (Caughey et al., 2009; Weissmann, 2005). Further evidence in favor of the 
“protein-only” hypothesis were acquired when the infectious prion particles were produced in a test 
tube by experimental manipulation of recombinant or synthetic PrP in the absence of nucleic acids 
(Castilla et al., 2008). In a recent publication, full-length rPrP (converted to cross--sheet amyloid 
structure and subjected to annealing) was serially transmitted and inoculated to Syrian hamsters. It 
gave rise to prion disease, with neuropathological and clinical features resembling human TSEs 
(Makarava et al., 2010).  
An alternative approach for the generation of “synthetic infectious prions” was the protein misfolding 
cyclic amplification (PMCA) assay (Saborio et al., 2001). Crude brain homogenates were used as a 
substrate for the production of infectious material. These “synthetic prions” were inoculated to wt 
hamsters and induced a scrapie disease identical to the one produced by “natural prions” (Castilla et 
al., 2005). “De novo” generation of PrPSc in vitro was further achieved, using a modified PMCA 
procedure, from brain homogenate substrate without PrPSc seeds. Yet, poly (A) RNA was present in 
the preparation (Barria et al., 2009; Deleault et al., 2007). A bit later, infectious “bona fide” synthetic 
prions were produced by PMCA using purified rPrP as template together with a synthetic anionic lipid 
and liver RNA (Wang et al., 2010). Recently, infectious “synthetic PrP” generated by PMCA assay, 
caused TSE in wild-type mice that intracerebrally inoculated with these (Zhang et al., 2013). The fact 
that infectious synthetic prions were generated and caused disease in wt mice strongly supports the 
prion hypothesis. Whether cofactors, such as RNA or lipids, are important parts of the infectious unit 
or just catalyze the formation of prions (formed solely out of PrP) needs to be further clarified. 
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Figure 1.10. Timeline representation of the major milestones in the protein-only hypothesis 
[modified from (Kim et al., 2007)]. 
 
1.11. Cellular biology of PrPC: structure, biosynthesis and localization  
PrPC is encoded by the PrP gene (PRNP in human, Prnp in mouse and PrP gene in other species) 
(Basler et al., 1986). The gene is expressed in all mammals and many vertebrates (Lee et al., 1998; 
Wopfner et al., 1999). It is first expressed early in embryogenesis and in the adult it is highly 
expressed in the neuronal and glial cells of the CNS as well as in a number of peripheral cell types 
(Ford et al., 2002; Harris et al., 1993b; Manson et al., 1992; Moser et al., 1995). The PrP gene is 
located on chromosome 20 in humans and chromosome 2 in mice (Puckett et al., 1991a; Sparkes et 
al., 1986) (Figure 1.2). Only a single exon (exon 2 in human and exon 3 in mice respectively) is 
coding for the open reading frame (ORF) and the 3’ untranslated mRNA region of PrPC (Maas et al., 
2007; Puckett et al., 1991a).  
PRNP expression is regulated by sequences within the 5’-flanking region, the first intron and the 3’-
untranslated sequences. Prnp is considered a housekeeping gene, due to the absence of a TATA 
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box, presence of CpG islands, and the identification of several Sp1 binding sites (Basler et al., 1986; 
Puckett et al., 1991b) (Figure 1.11.).  
 
  
Figure 1.11. The prion gene 
Schematic diagram of the human PRNP and the mouse prnp genes - ORF: open reading frame (PrP 
coding region), hPRNP: human prion gene, mPRNP: mouse prion gene.  
 
The resulting protein, PrPC, is a protein of ~250 amino acids (aa) in length and 30-35kDa in size. The 
primary structure of PrPC is conserved across mammals and contains distinct domains: the N-terminal 
signal peptide, the octapeptide region (OR), a central domain (spanning amino acids 105-125 in the 
mouse polypeptide chain), and a C-terminal hydrophobic region (a detailed representation can be 
found in Figure 1.2.A). PrPC is synthesized in the endoplasmic reticulum (ER), transits the Golgi and 
reaches the cell surface. In the ER, the signal peptide at the N-terminus (22 amino acids) is cleaved 
soon after translation and the hydrophobic signal at the C-terminus (23 amino acids) is removed upon 
addition of the GPI anchor (Stahl et al., 1987; Turk et al., 1988). Also, the protein obtains N-linked 
glycosylation at residues 182 and 198 and a disulphide bond is formed between residues 180 and 215 
(Caughey et al., 1989). During transit to the Golgi, sialic acid residues are added to the 
oligosaccharides. At the steady state of the protein unglycosylated, monoglycosylated and fully 
glycosylated forms coexist and can be detected by Western blot analysis. PrPC is anchored to cell 
membrane by a GPI moiety and is preferentially localized in specialized domains of the cell 
membrane, rich in sphingolipids and cholesterol, known as lipid rafts. Lipid rafts mediate important 
physiological processes, such as signal transduction and transcytosis (Simons and Toomre, 2000). 
They are biochemically defined as detergent resistant membranes (DRM) because of their Triton X-
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100 detergent insolubility at 4°C. They are considered crucial for the PrPC-to-PrPSc conversion 
process (Naslavsky et al., 1997; Taraboulos et al., 1995). After reaching the cell surface, PrPC does 
not reside permanently in raft domains. In contrast, it is regularly transfered between the plasma 
membrane and the endocytic compartment. The internalization is induced by copper ions, which bind 
the octapeptide region (Shyng et al., 1993; Taylor et al., 2005).  
PrPC undergoes different post-translational modifications as part of its normal metabolism. These are 
mainly directed clevages. A first cleavage takes place within and very near the GPI-anchor by a cell 
surface phospholipase and by a metalloprotease and promotes the release of the polypeptide chain in 
the extracellular milieu (Borchelt et al., 1993; Harris et al., 1993a; Parkin et al., 2004). PrPC further 
undergoes two distinct endoproteolytic cleavages (Hooper, 2005), the α- and the β- cleavage. The α-
cleavage of PrPC occurs inside the highly conserved hydrophobic region of the protein by the 
members of the ADAM (a disintegrin and metalloprotease) family (Shyng et al., 1993; Taylor et al., 
2009; Vincent et al., 2001) leading to the formation of a 9 kDa soluble N-terminal fragment (N1) and a 
17 kDa C-terminal fragment (C1), still attached to the cell membrane through the GPI-anchor. The α-
cleavage can occur either in DRM (Taraboulos et al., 1995), or in a raft-independent manner within a 
late compartment of the secretory pathway (Walmsley et al., 2009). The β-cleavage of PrPC  occurs 
within or adjacent to the octapeptide repeats and produces a 7 kDa N-terminal fragment (N2) and the 
complementary 19 kDa GPI-anchored C-terminal fragment (C2) that typically accumulates in prion-
infected cells and brains (Caughey et al., 1989; Mange et al., 2004). The β-cleavage is mediated by 
reactive oxygen species and could play a role in cellular resistance to oxidative stress (Watt et al., 
2005). Apart from the GPI-anchored form, that is fully extracellular, two additional, topologically 
distinct PrP variants have been reported: NtmPrP (transmembrane segment of PrP, N-terminus on the 
exofacial surface) and CtmPrP (transmembrane segment of PrP, C-terminus on the exofacial surface). 
These forms have opposite orientations with respect to the lumen of the ER and are normally present 
in minute amounts in the absence of predisposing mutations (Hegde et al., 1998; Stewart and Harris, 
2001). Nuclear forms of PrP carrying stop-mutations at codon 145 and 160 have also been described 
(Lorenz et al., 2002; Zanusso et al., 1999).  
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1.12. Antibodies against the prion protein PrPC 
Active and passive immunotherapy can promote the clearance of pathological aggregates and thus 
represent legitimate therapeutic strategies in protein aggregation diseases (Aguzzi and O'Connor, 
2010). Preclinical studies in transgenic mouse models have illustrated the potency of active 
immunotherapy in the prevention of both AD and TSEs (Wisniewski and Boutajangout, 2010; 
Wisniewski and Goni, 2015). However, active immunotherapeutic strategies in prion diseases had 
neither significantly improved the survival time of prion inoculated mice (Magri et al., 2005; Sigurdsson 
et al., 2003) nor induced high-affinity immune responses to PrPC in wt mice (Polymenidou et al., 
2004). Passive immunotherapy turned out to be more efficient. Trangenic mice, expressing the heavy 
chain of an anti-PrPC antibody were protected from peripheral prion infection (Heppner et al., 2001). A 
later study showed that passive intraperitoneal immunization with the ICSM18 and ICSM35 anti-prion 
antibodies prevented peripheral infection with Rocky Mountain Laboratory (RML) strain (mouse 
adapted) scrapie prions. Unfortunately, the same antibody treatment did not induce any advantageous 
response against inracerebral inoculation with RML prions (White et al., 2003). Likewise, peripheral 
administration of the 31C6, 110 and 44B1 anti-prion antibodies increased survival of mice inoculated 
with the Chandler and Obihiro prion strains (Ohsawa et al., 2013). Intraventricular administration of 
the 31C6 anti-prion antibody through osmotic mini pumps also prolonged survival of prion inoculated 
mice (Song et al., 2008). A summary of the active or passive immunization preclinical studies are 
presented in the table below (Table 1.4.). 
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Table 1.3. Summary of the active and passive immunization preclinical trials in prion diseases 
(Reimann et al., 2016) 
 
However, certain antibodies against PrPC have also been reported to induce brain damage. Chronic 
intracerebral administration of the antiprion antibody 4H11 led to severe neuronal loss, gliosis, and 
microglial activation (Lefebvre-Roque et al., 2007). Likewise, stereotaxic injection of various anti-PrPC 
antibodies, such as POM, targeting the globular domain of PrPC, triggered neuronal apoptosis 
(Solforosi et al., 2004; Sonati et al., 2013).  
Toxic anti-PrPC antibodies induce damage by stimulating pathways similar to the bona fide prion 
infections, such as activation of calpains and PERK pathway and production of reactive oxygen 
species (Doolan and Colby, 2015; Falsig et al., 2012; Herrmann et al., 2015; Sonati et al., 2013). The 
proposed mechanism of action postulates that the amino-terminal, flexible tail of PrPC mediates the 
toxicity of antiprion antibodies by binding to the globular domain of PrPC (Sonati et al., 2013). 
Administration of the D13 anti-prion antibody, which also binds to the globular domain of PrPC, was 
also shown to induce neurotoxicity in Tga20 mice (Bueler et al., 1992; Fischer et al., 1996). However, 
Klöhn and co-authors did not replicate the reported neurotoxic effects of D13. Moreover, no acute 
toxicity of in vivo administration of ICSM18 and ICSM35 anti-prion antibodies was reported (Klohn et 
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al., 2012). Therefore, D13 and ICSM18, surprisingly, unlike the other globular-domain neurotoxic 
ligands were reported to be innocuous. The aforementioned discrepancy was recently addressed by 
Reimann et al. POM1, D13 and ICSM18 (all antiprion antibodies against a set of epitopes at the 
globular domain of PrPC) induced acute, dose-dependent neurotoxicity both ex vivo and in vivo 
(Reimann et al., 2016).  
Nevertheless, not all antiprion antibodies are intrinsically toxic. Out of 12 POM antibodies tested 
(Polymenidou et al., 2008), 5 were reported to be innocuous ex vivo in organotypic slice cultures. The 
innocuousness of POM2 (an octapeptide repeat ligand) was further confirmed in vivo in Tga20 mice 
(Sonati et al., 2013).   
  
Figure 1.12. POM antibodies 
Schematic diagram of the binding sites of POM, anti-PrPC, antibodies. POM6–9, 13, 15 and 17 bind 
helix a1 and compete with the toxic POM1 antibody. POM6 and POM7 (light orange) show additional 
binding sites at helix a2 (dark orange), whereas POM5 recognizes a unique epitope at the b2–a2 
transition (green). Innocuous antibodies (POM2, POM11, POM2; light blue) bind to the globular 
domain of PrPC [modified by (Sonati et al., 2013)].  
 
Likewise, 31C6, 44B1 and 110 antiprion antibodies did not show neurotoxicity at high doses in 
preclinical efficacy experiments (Ohsawa et al., 2013; Song et al., 2008). 
Altogether, the efficacy of antiprion antibodies seems to rely on both intrinsic factors (the targeting 
epitope on PrPC) and extrinsic factors (the route of administration and dosage). Despite the potential 
of immunotherapeutic studies for prion diseases, these issues need to be seriously taken into 
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consideration before conducting any human clinical trials. 
 
1.13. The physiological function of PrPC - insights gained from transgenic mice 
and interaction partners 
Like other GPI-linked proteins, PrPC is located on the extra-cytoplasmic milieu of the lipid bilayer and 
is mostly associated with membrane lipid rafts (Harris, 1999; Taraboulos et al., 1992). Despite 
decades of research the exact function of PrPC and its role in prion diseases remains unclear.  
However, the remarkable conservation of the Prnp gene (>85% homology between mouse and 
human sequences) and its ubiquitous expression in vertebrates indicate that the gene executes an 
essential function (Cotto et al., 2005; Wopfner et al., 1999).  There is little doubt that the formation and 
progressive accumulation of PrPSc in the brain is the triggering factor of neurodegeneration and 
disease. However, the mechanism by which PrPSc is involved in the disease pathogenesis and what is 
the role of PrPC remains largerly unknown. A better understanding of the function of PrPC in 
homeostasis could assist the evolutionary interpretation of the Prnp gene conservation, annotate its 
role in pathogenesis and hightlight the molecular pathways of prion diseases. The localization of PrPC 
at the membrane and the insertion of the GPI-anchor are suggestive of three potential functions: 
capture of an exogenous ligand, adhesion to cells or to the extracellular matrix and signalling. But how 
can PrPC, an extracellular GPI-linked protein, initiate intracellular signaling modifications? Most likely 
this process requires mediation by transmembrane constituents, and indeed many studies aimed at 
the identification of the elusive ‘protein X’; considered being an integral part of the pathogenic 
conformational conversion mechanism and pathology (Prusiner, 1998; Telling et al., 1995). In order to 
elucidate the normal function of PrPC researchers have utilized multiple techniques: deletion or 
knockout models in mice and other animals, human genetics, over/ectopic expression, biochemical 
techniques to identify critical PrPC-dependent cellular processes and interaction partners (Bosque et 
al., 1995). The techniques used and the putative functions will be discussed in detail in the following 
paragraphs. 
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1.13.1. Generation and properties of Prnp-/- mice 
In order to elucidate the normal function of PrPC researchers sought to produce animals in which the 
Prnp gene was deleted. The advent of homologous recombination and molecular cloning techniques 
[cloning of the cDNA coding the entire open reading frame (ORF) of the mouse Prnp was published in 
1986 (Locht et al., 1986) ] favored the generation of  Prnp-knockout (Prnp-/-) animals. The first Prnp-/- 
mice, designated Zurich I (ZrchI) were produced by the Weissmann group in a mixed C57BL/6J x 
129/Sv(ev) background, by replacing codons 4-187 (insertion into the only coding exon of Prnp) with a 
neomycin phosphotransferase (neo) expression cassette. Mice developed normally and displayed no 
overt abnormalities in size, weight, fertility, behavior and appearance of brain, skeletal muscles and 
visceral organs. Behavioral tests, such as Morris’ water maze, Y maze discrimination and a test 
scoring for the efficiency of distinct problem solving strategies, showed no defects in behavior or 
learning (Bueler et al., 1992). A second line of Prnp-/- mice under 129/Ola background, known as Npu 
or Prnp-/- Edinburgh (Edbg), was produced soon after by interruption of the Prnp ORF at position 93 
and insertion of the neo cassette after the splice acceptor site. Similar to the ZrchI, the Edbg mice did 
not present any overt developmental defects (Manson et al., 1994). The absence of any apparent 
phenotype in these Prnp-/- lines suggested that the function of PrPC is redundant or inert. The only 
remarkable finding was that host expression of PrPC is necessary to maintain prion replication and 
induce prion toxicity; since Prnp-/- lines show complete resistance to prion infections (Bueler et al., 
1993). In contrast, the next Prnp-/- mouse lines: the Nagasaki, (Katamine et al., 1998; Sakaguchi et 
al., 1996), the Rcm0 (Moore et al., 1999) and the Zurich II (Rossi et al., 2001) lines, generated with 
extensive deletions in the Prnp gene, displayed Purkinje cell loss and cerebellar ataxia. The striking 
phenotypic differences between the former and the latter group of Prnp-/- mouse lines were attributed 
to the deletion strategy (Weissmann et al., 1996), which drove the ectopic, chimeric  and over-
expression of a PrPC paralogue gene (Prnd) encoding Doppel (Dpl) (Li et al., 2000; Moore et al., 
1999). This was later confirmed by the re-introduction of Prnp in Prnd overexpressing mice. Prnp re-
introduction rescued the phenotypic alterations caused by ectopic expression of Dpl in thr brain, 
suggesting that it was the ectopic expression of Dpl in the absence of PrPC, rather than the absence 
of PrPC per se, that caused the phenotypic abnormalities (Moore et al., 2001; Nishida et al., 1999). An 
overview of the knock-out strategies for the generation of the above mentioned lines is presented 
below (Figure 1.13.). 
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Figure 1.13. Overview of the know-out strategies for the generation of Prnp-/- mouse lines 
Schematic diagram of the various strategies used to target the Prnp locus by homologous 
recombination for the generation of Prnp-/- mouse lines. The black boxes represent PrP ORFs; white 
boxes, non-coding Prnp regions; grey boxes, inserted sequences; dotted line, deleted regions; neo, 
neomycin phosphotransferase; HPRT, hypoxanthine phosphoribosyltransferase; loxP (black 
arrowhead), a 34-bp recombination site from phage P1 [modified by (Montrasio et al., 2000)]. 
 
The recent advent of site-specific recombination technology allowed the generation of conditional PrP 
knockout NFH-Cre/tg37 mice, to study the effects of PrP depletion on neuronal survival and function 
in the adult brain (Mallucci et al., 2002). These bigenic mice were generated by breeding a floxed PrP 
transgenic mouse with a NFH-Cre transgenic mouse [expressing the phage P1 enzyme Cre 
recombinase using the control elements of the murine neurofilament (NFH) gene].  Cre-mediated 
ablation of PrP in neurons was initiated at week nine. For up to 15 months post knock-out, no overt 
phynotype (signs of histopathological changes or neurodegeneration) was reported. Only subtle 
electrophysiological abnormalities [significant reduction of afterhyperpolarization potentials (AHPs)] in 
hippocampal CA1 cells were observed; suggesting a role of PrPC in the modulation of neuronal 
excitability.  
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Multiple functions for PrPC have been proposed based on the phenotyped of Prnp-/- mice.  However, 
all the aforementioned Prnp-/- mouse lines were generated in embryonic stem cells from the 129 
mouse strain and crossed to non-129 strains. This resulted in Prnp-linked polymorphic loci between 
129 and backcrossing strain. As an effect, erroneous conclusions were drawn due to insufficient 
accounting for systematic genetic confounders. Recently, TALEN-mediated genome editing 
techniques were used to generate the Zurich-3 (ZH3) Prnp-ablated allele on a pure C57BL/6J 
background (Nuvolone et al., 2016). Profound (genomic, transcriptional and phenotypic) 
characterization of these mice was performed and failed to identify any of the phenotypes reported in 
non-co-isogenic Prnp-/- mouse lines. Of note, aged Prnp (ZH3/ZH3) mice developed chronic 
demyelinating peripheral neuropathy supporting the described role of PrPC in peripheral myelin 
maintenance (Bremer et al., 2010; Kuffer et al., 2016).  
1.13.2. Generation and properties of PrP deletion mutant mice 
Although the physiological and molecular functions of PrPC still remain elusive, new insights were 
gained by the expression of partially deleted Prnp variants in cultured cells and transgenic mice. The 
main aim for the production of these constructs was to identify the essential domains for restoring 
prion susceptibility. But, these mice rather permitted the identification of functionally relevant domains 
within PrPC. Investigators reported that specific domain expression, in Prnp-/- background, induced 
spontaneous neurodegeneration [as reviewed in the figure below, (Figure1.14.)]. Often, these 
phenotypes were partially or fully rescued by co-expression of wt PrPC (Aguzzi et al., 2008). 
 
1.13.2.1 Amino-terminal deletion mutants of PrP 
Transgenic mice harboring deletions between residues 32-121 (PrP 32-121) or 32-134 (PrP 32-1 4), 
on a PrP-deficient genetic background, exhibited a spontaneous neurodegenerative illness (severe 
apoptosis of cerebellar granular neurons and ataxia) even without inoculations with scrapie prions 
(Shmerling et al., 1998). In these mice widespread white matter disease (severe demyelination and 
axonal loss in the spinal cord and the cerebellar white matter) was additionally observed, which could 
be rescued by expression of endogenous PrPC in both neurons and glia (Radovanovic et al., 2005).  
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PrPΔ32-134 and Dpl both lack the flexible N-terminal domain and have a similar structure.  Therefore 
they could also share the same mechanisms of neurodegeneration (Weissmann and Aguzzi, 1999). 
Indeed, it was shown that PrPΔ32-134 expression targeted to Purkinje cells of ZrchI Prnp-/- mice led to 
their selective degeneration, whereas the granule cell layer was unaffected (Flechsig et al., 2003). 
Mice with shorter deletions [32-80 (PrP∆32-80), 32-93 (PrP∆32-93), 32-106 (PrP∆32-106) had a 
normal phenotype, suggesting an important role for amino acids distal to residue 106. Transgenic 
mice expressing truncated PrPΔ94-134, but not those expressing a smaller deletion PrPΔ114-121 
(residues spanning the HC domain), also showed extensive central and peripheral myelin 
degeneration and early ataxia (Baumann et al., 2007b). Yet, transgenic animals expressing an even 
smaller truncation, PrPΔ105-125 (residues spanning the CC domain) showed a more acute pathology  
(Li et al., 2007). These mice developed a severe illness within two weeks of birth and died within one 
month. Pathological signs inlcuded: decreased body size and weight, immobility, impaired righting 
reflexes, myoclonus and tremor. Histopathological stainings revealed severe loss of cerebellar 
granule cells, cerebellar atrophy, gliosis and astrocytic hypertrophy. Notably, all the above mentioned 
degenerative phenotypes can be rescued by re-introduction of the wt PrP allele (Baumann et al., 
2007b; Li et al., 2007; Shmerling et al., 1998).  
1.13.2.2 Carboxy-terminal deletion mutants of PrP 
Transgenic mice harboring deletions at the C-terminal of PrPC also showed altered phenotypes.  
Mice expressing PrP mutants with deletions pertaining Helix 2 (PrPΔ177-200), Helix 3 (PrPΔ201-217) 
or both helices 2 and 3 (PrPΔ141-221), together with a deletion spanning the octapeptide region 
(residues 23-88) that is per se innocuous, exhibited neuronal storage disease associated with 
neurodegeneration, ataxia and features of cerebellar disorder (Muramoto et al., 1997). Contrary to the 
group of delection mutants affecting the CC and HC domains, none of C-terminal deletion associated 
diseases were transmissible to normal wt mice. Also, presence or absence of wt PrP didn’t affect 
manifestation and progression of the disease.  
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Figure 1.14. Overview of the PrP deletion mutants 
Schematic drawing of full-length murine PrPC, including the signal peptide of the precursor protein 
(SP; brown box). All the major domains are also included: charged cluster 1 (CC1), charged cluster 2 
(CC2), octarepeat region (OR), hydrophobic core (HC) and alpha helixes 1-3 (H1-H3). Mouse PrP 
also contains a disulphide bond (S-S) and a GPI-anchor. The first column denotes the individual 
mutants (defined as deletions of specific residues, e.g. the construct which harbors the deletion of 
residues 32-80 is defined as PrP∆32-80). The four columns on the right indicate presence or absence 
of phenotypic abnormalities in transgenic mice when expressed on a PrP-deficient genetic 
background, transmissibility of the phenotype to recipient mice, rescue of the phenotype by co-
The Role of Group I Metabotropic Glutamate Receptors in Prion Induced Toxicity PhD Dissertation 
 
 
73  Despoina G. Goniotaki – October, 2016  
  
expression of wt PrP and susceptibility of transgenic mice to prions after intracerebral inoculation with 
a mouse adapted strain of scrapie prions [modified by (Aguzzi et al., 2008)]. 
1.13.3. PrPC and divalent ions 
One of the first suggestions was that PrPC plays a role in copper metabolism. This hypothesis was 
supported by the identification of two copper binding domains (at residues 96 and 111) as well as 
copper (Cu2+) ion binding at the histidine-containing octapeptide repeat region of PrPC (Brown et al., 
1997a). Therefore, it was hypothesized that PrPC could function as a transporter for copper. This was 
tested in an inducible cell system, where the levels of PrPC correlated with the amount of Cu2+ binding 
to the membranes, but not with its transportation rate (Rachidi et al., 2003). In addition the 
transportation of Cu2+ ions to synaptosomes was reported to be independent of the expression of 
PrPC (Giese et al., 2005). Additionally, the binding of copper to PrPC seemed to protective against 
oxidative stress by preventing reactive oxygen species (ROS) generation via free Cu2+-mediated 
redox reactions. Cultured Prnp-/- neurons were more vulnerable than wt to high levels of Cu2+. This 
was blocked by treatment with a synthetic PrPC 59–91 peptide (Brown et al., 1998). Likewise, brain 
tissue from PrP knockout mice exhibited biochemical changes indicative of oxidative stress, such as 
increased levels of protein carbonyls and lipid peroxidation products (Wong et al., 2001). In addition, 
Prnp-/- mice were more susceptible to brain lesions induced by hypoxia and ischemia (Sakurai-
Yamashita et al., 2005; Spudich et al., 2005). The exact mechanism by which copper and PrPC are 
functionally related is still not clear. Three different mechanisms were suggested: a) PrPC exerts a 
copper-dependent superoxide dismutase (SOD) activity, b) Cu2+-induced endocytosis of PrPC induces 
an antioxidative defence signal (Brown et al., 2001; Brown et al., 1999) and c) a  PrP-dependent 
increase in the expression of antioxidant enzymes, such as catalase and glutathione reductase (Klamt 
et al., 2001; White et al., 1999) . Yet, a couple of other studies failed to confirm an effect of PrPC on 
SOD level or an intrinsic dismutase activity of PrPC (Hutter et al., 2003; Waggoner et al., 2000). 
Alterations in copper transport and homeostasis, leading to CNS dysfunction, have been documented 
in humans and animals in multiple neurodegenerative diseases. The evidence that PrPC plays a role 
in copper metabolism may be important in understanding the pathogenesis of prion diseases, since 
loss of this copper-related function (as a result of conversion to PrPSc) could be accountable for 
certain phenotypes. Interestingly, early studies reported that cuprizone, a copper-chelating agent, 
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induces neuropathological changes in mice similar to those found in prion diseases (Waggoner et al., 
1999), suggesting a role for copper in these disorders. 
Apart from copper, PrPC was shown to bind to other divalent ions, such as manganese (Mg2+), iron 
(Fe2+) and zink (Zn2+). Using the PMCA technique, Kim et al., showed that manganese, like copper, 
can bind to PrPC and induce the generation of PrPSc (Kim et al., 2005). Also, mice infected with PrPSc 
exhibit significant differences in the content of metal ions in blood, muscle and brain, compared to 
non-infected mice. Interestingly, the PrPSc infected mice had increased Mg2+ and decrease Cu2+ 
content, suggesting a role of altered metal content in the disease manifestation and progression 
(Thackray et al., 2002). Last but not least, the presence of Mg2+ has also been shown to favor the 
formation of PK resistant forms of PrPC (Brown et al., 2000). With regards to iron, Fernaus et al. 
showed that PrPSc infection disrupted the normal regulation and processing of iron, resulting in 
increased levels of the labile iron pool (LIP), decreased levels of ferittin and the formation of ROS, in 
mouse neuroblastoma N2a cells. These findings suggest scrapie infection results in cell death by 
altering iron metabolism and reducing the cell’s capacity to counteract the presence of excessive iron 
(Fernaeus et al., 2005a; Fernaeus and Land, 2005; Fernaeus et al., 2005b).  Zinc on the other hand, 
similar to Cu2+, induces transfer of the prion protein from the plasma membrane to a subset of early 
endosomes and the Golgi (Brown and Harris, 2003). Also Cu2+ and/or Zn2+ binding mediate the 
aggregation and the neurotoxic properties of the PrP106-126 peptide (Jobling et al., 2001).  
1.13.4. Anti-oxidative and anti-apoptotic activity of PrPC   
Several lines of evidence indicated that PrPC might have a cytoprotective activity. Multiple 
experimental systems, including cultured mammalian cells, yeast and mice have been used to test 
this hypothesis. Immortalized hippocampal neurons (HpL3-4 cells) derived from Prnp-/- mice were 
highly sensitive to serum deprivation compared to their wt counterparts (Kuwahara et al., 1999). The 
ability of PrPC to counteract cell death was shown by transfection of knockout cells with Prnp. The 
mechanism seemed to involve Bax, a pro-apoptotic member of the Bcl-2 family, that plays a major 
role in postmitotic neurons of the central nervous system (Yuan and Yankner, 2000). The ability of 
PrPC to counteract Bax-dependent apoptotic pathway was documented in multiple experimental 
systems, but the molecular pathways involved remain largely unknown (Roucou and LeBlanc, 2005). 
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Additionally, primary cultures of cortical and cerebellar granular neurons from ZrchI Prnp-/- mice 
undergo cell death faster compared to their wt counterparts upon oxidative stress (Brown et al., 2002; 
Brown et al., 1997c). Oxidation of both proteins and lipids was documented to contribute to the 
observed phenotype (Brown et al., 2002). Moreover, Prnp-/- mice were reported to be more sensitive 
to seizures caused by kainic acid (Walz et al., 1999). 
An additional function attributed to PrP was its role in myelin maintenance in adult mice (Shmerling et 
al., 1998). Bremer et al elegantly demonstrated the association in 2010. In three independently 
targeted PrP strains (ZrchI, GFP and Edbg) (Bremer et al., 2010) and later a forth (ZH3) (Nuvolone et 
al., 2016) ablation of PrPC, specifically in neurons, triggered progressive chronic demyelinating 
polyneuropathy (CDP) associated with reduced grip strength and nociception. The fact that this 
phenotype persisted on four genetic backgrounds (C57BL6/6, 129, Balb/c and mixed) further supports 
the initial hypothesis. Mechanistic insights into the nature of axonal PrPC’s role in the maintenance of 
peripheral nervous system (PNS) myelin, were recently provided by the same group. PrPC was 
reported to act as an agonistic ligand of the G protein-coupled receptor Adgrg6, causing a reduction of 
the cAMP concentration levels of the sciatic nerves from PrPC-deficient mice (Kuffer et al., 2016). 
Unlike mice, the knockdown of the Prnp horthologs (PrP1 and PrP2) in zebrafish resulted in a loss of 
function phenotype. Knockdown of PrP1 cuased impairment of E-cadherin-mediated cell adhesion 
and signaling in the zebrafish embryos as well as arrested gastrulation, whereas knockdown of PrP2 
had an effect on later developmental stages (impairing proliferation and differentiation of developing 
neurons) (Malaga-Trillo et al., 2009).  
 
1.13.5. Functional roles of PrPC in neuronal excitability and synaptic activity 
PrPC is thought to play a role in synaptic structure, function and maintenance. Experiments on the 
localization of the PrP-EGFP tagged protein, as well as data from light and electron microscopy 
studies, indicated that PrPC is enriched along axons and in pre-synaptic terminals (Herms et al., 1999; 
Medrano et al., 2008; Mironov et al., 2003) and subject to anterograde and retrograde axonal 
transport (Borchelt et al., 1994; Moya et al., 2004). Yet, PrPC is also present in postsynaptic densities 
(Haeberle et al., 2000). The presence of PrPC at both pre- and post-synaptic sites advocates that it 
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plays a role in synaptic plasticity and neuronal communication. Consistent with this, synaptic 
pathology is often a prominent feature of prion diseases (Jeffrey et al., 2000). 
Electrophysiological recordings from hippocampal slices of Prnp-/- mice (ZrchI and Edbg lines), 
showed impaired long-term potentiation (LTP) at physiological temperature, associated with reduced 
GABAA receptor mediated fast inhibition (Collinge et al., 1994; Manson et al., 1995). This was rescued 
by addition of a transgene encoding PrPC (Whittington et al., 1995). In contrast, no deficits in cell 
excitability, synaptic inhibition, reversal potential or LTP were reported in another study, in which 
hippocampal slices from Prnp-/- mice (three different genetic backgrounds) were examined at room 
temperature (Lledo et al., 1996).  Also, no changes in the activity of GABAA receptors  were reported 
in outside-out membrane patches of cerebellar Purkinje cells from Prnp-/- mice (Herms et al., 1995). 
However, recently it was shown that post-tetanic potentiation and LTP  were significantly reduced in 
the CA1 hippocampal region of aged Prnp-/- mice (ZrchI and Edbg lines), when compared with 
younger animals, possibly due to increased levels of oxidative stress during aging (Curtis et al., 2003). 
Further studies also supported a positive correlation between the expression level of PrPC and the 
facilitation of the excitatory synaptic transmission. Experiments in PrP-over-expressing mice showed 
supra-physiological responses (Carleton et al., 2001); due to more efficient recruitment of pre-synaptic 
fibers.  
A consistent electrophysiological phenotype in Prnp-/- mice is a reduction in the slow (late) 
afterhyperpolarization potential (AHP) (Asante et al., 2004; Colling et al., 1996; Fuhrmann et al., 2006; 
Mallucci et al., 2002; Powell et al., 2008). Slow AHP is a property of many neurons. It is triggered by a 
series of repetitive action potentials, is mediated by an unknown Ca2+-dependent K+ channel and 
controls the post action potential firing. Although the absence of PrPC was reported to influence Ca2+ 
homeostasis in cerebellar granular cells (Herms et al., 2000), it did not alter the K+ channels directly. It 
indirectly influences them by reducing Ca2+ influx through L-type voltage gated calcium channels 
(VGCCs) in CA1 hippocampal neurons (Fuhrmann et al., 2006) or by changing the maximal amplitude 
of Ca2+-activated K+ currents in cerebellar Purkinje cells (Herms et al., 2001). Alternatively, the 
observed reduced slow AHP in Prnp-/- neurons could be attributed to an increased Ca2+ buffering at 
the endoplasmic reticulum (ER), due to an increased activity of the sarco/endoplasmic reticulum 
calcium ATPase (SERCA) (Powell et al., 2008). Conditional PrPC ablation in adult neurons led to 
reduced AHP and thus increased neuronal excitability , due to loss of PrPC function (Mallucci et al., 
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2002). A few years later, re-introduction of PrPC rescued the impairment of Ca2+-activated K+ currents 
in Purkinje cells from Prnp-/- mice (Herms et al., 2001). 
Further evidence on the role of PrPC in neuronal excitability is provided by studies of Prnp-/- mice 
which show lower threshold to proconvulsant drug-induced seizures (Rangel et al., 2007; Walz et al., 
1999) as well as by  studies in Tga20 mice which show that PrPC over-expression is associated with 
increased susceptibility to kainate-induced seizures (Rangel et al., 2009). Consistent with the 
aforementioned neuronal excitability data in Prnp-/- mice, anatomical changes within the hippocampus 
were reported, suggesting a re-organization of the neuronal circuitry resembling the “epileptic 
neuronal network” (Colling et al., 1997). The observed susceptibility to neuronal damage in Prnp-/- 
mice correlated with altered expression of AMPA/kainate and NMDA glutamate receptors (Maglio et 
al., 2004; Rangel et al., 2007). More specifically, it was shown that PrPC suppressed NMDA receptor 
activation and blocked excitotoxic Ca2+ influx by binding to NMDA receptors containing NR2D subunit 
(Khosravani et al., 2008; Senatore et al., 2012). Although PrPC ablation increased neuronal excitability 
in the hippocampus, juvenile (up to 25 days of age) Prnp-/- mice showed defective neuronal excitability 
and synaptic plasticity in the cerebellar granular layer and thus impaired motor control. The phenotype 
was associated with a delayed maturation of cerebellar granule cells and dissipated P40–P50 along 
with the recovery of normal motor behaviour; indicating a role of PrPC in motor control and formation 
of the cerebellum (Prestori et al., 2008).  
Despite the numerous studies indicating a role of PrPC in synaptic plasticity and neuronal excitability, 
the precise molecular mechanisms remain largerly unknown. It was proposed that PrPC acts as a 
copper uptake protein and buffers Cu2+ levels in the synaptic cleft so as to reduce Ca2+ influx via 
VGCCs, regulate synaptic calcium homeostasis and neurotransmission (Vassallo and Herms, 2003) 
and protect synapses from oxidative damage (Brown, 2001b). 
Altogether, these studies identify a role of PrPC in modulating various neuronal processes. PrPC 
seems to affect not only neuronal proliferation and differentiation but also essential mechanisms of 
neuronal function: excitability and synaptic transmission. The observed experimental discrepancies 
could be attributed to differences in the genetic background of the knockout lines that were used in 
the studies. Further experiments are needed to clarify the issue.  
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1.14. PrPC-interactors mediated effects  
An alternative method for resolving the physiological function of PrPC would be to identify other 
cellular proteins with which PrPC interacts. These interactors are likely to be units of the physiological 
pathways in which PrPC plays a role (Linden et al., 2008; Oesch et al., 1990). 
There are certain structural features within PrPC that could allow it to interact with other proteins; such 
as a copper binding domain (58-110 aa), an amphipathic helix near the middle of the molecule and 
the GPI anchor which may internalize and deliver signals. Multiple potential PrPC-interacting partners 
have been detected so far using conventional yeast two-hybrid screens, co-immunoprecipitation, 
crosslinking as well as other methods. Quite a few groups have reported that PrPC binds and 
internalizes copper ions (Brown et al., 1997b; Hornshaw et al., 1995; Viles et al., 1999). This action 
enhances the activity of superoxide dismutase (SOD) enzymes and thus increases the resistance 
against oxidative stress (Brown and Besinger, 1998; Brown et al., 1997c). 
The localization of PrPC at the the plasma membrane additionally regulates its neuroprotective effects. 
For example, in four different cell lines (GT1-7 neurohypothalamic cells, 1C11 neuroectodermal 
precursor, 1C11 differentiated neuronal cells and BW5147 lymphoid cells) antibody-mediated 
dimerization of PrP triggered rapid phosphorylation of extracellular regulated kinases (ERK) 1 and 2, 
supporting neuronal survival. Especially in 1C11 differentiated neuronal cells, Fyn kinase activation 
triggers the ERK1/2 stimulation (Grewal et al., 1999; Mouillet-Richard et al., 2000; Schneider et al., 
2003a). In these studies, PrPC is considered a cellular redox homeostasis regulator. Interaction of PrP 
with the plasma membrane stress-inducible protein 1 (Stip 1) also triggers neuroprotection (Zanata et 
al., 2002). In another study, mouse primary cerebellar granular neurons seeded onto a PrPC-
expressing substrate (either PrP-coated dishes or Chinese hamster ovary cells overexpressing PrPC 
at their cell surface) exhibit increased neurite outgrowth and neuronal survival. The related 
mechanisms include activation of the phosphatidyl-inositol-3-kinase/Akt and the mitogen-activated 
protein kinase/ERK kinases pathways (Chen et al., 2003; Graner et al., 2000). 
A well-established neuroprotective function of PrPC is mediated through its connection with laminin 
receptor precursor 37LRP/67LR (Rieger et al., 1997). The latter is a membrane-associated protein, 
which interacts with laminins and triggers a range of dynamic events (filopodia formation, directional 
motility and changes in gene expression). PrPC also acts as specific, high affinity receptor for laminin; 
their interaction domain residing at the carboxy-terminal decapeptide (RNIAEIIKDI) of the laminin γ-1 
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chain (Graner et al., 2000). The PrPC-laminin complex also binds to the heparan-sulphate 
proteoglycan (HSPG) and in competition with 37LRP/67LR (Hundt et al., 2001; Warner et al., 2002). 
Interestingly, PrPC-interaction with integrins (also laminin receptors) was reported to form a cluster 
that promotes neurotrophic signalling (Tzu and Marinkovich, 2008). Moreover, the PrPC-vitronectin 
(Vn) binding was shown to stimulate axonal growth during embryogenesis as well as during cerebellar 
development (Hajj et al., 2007; Hajj et al., 2009). 
Given that PrPC binds to both laminin and vitronectin, it was suggested that it could be involved in the 
development of the cerebellum. The hypothesis was supported by data from Prnp-/- mice. During 
development, Prnp-/- mice exhibited altered excitability of cerebellar granular neurons and impaired 
synaptic transmission associated with motor abnormalities; due to a delay in granule cell maturation 
(Prestori et al., 2008). 
The neuroprotective role of PrPC was further supported by studies showing that PrPC -binding to 
astrocyte-secreted stress-induced protein 1 (STI1), promoted neuritogenesis, neuronal survival as 
well as memory formation and consolidation (Coitinho et al., 2007; Lima et al., 2007). PrPC contacts 
STI1 through interaction with the “co-chaperone Hsp70/Hsp90 protein/STI1 (hop/STI1)” organizing 
complex. PrPC-hop/STI1 interaction controls protein synthesis in neurons via the PI3K-Akt-mTOR and 
ERK1/2 pathways. The data were further validated in PrPSc-infected cells where protein synthesis was 
partially impaired due to prion infection; suggesting that prion infection may contribute to neuronal 
dysfunction and neurodegeneration (Roffe et al., 2010).   
Likewise, PrPC also associates with several proteins on the neuronal cell surface to promote neural 
development. One of these molecules is  the vesicle-associated protein synapsin Ib (Spielhaupter and 
Schatzl, 2001). Another is the neural cell adhesion molecule (NCAM) (Santuccione et al., 2005). PrP 
has been identified in a complex with NCAM by chemical cross-linking (Schmitt-Ulms et al., 2001). In 
primary neuronal cultures it was shown that NCAM undergoes PrPC-mediated recruitment in lipid rafts 
to activate the p59 fyn kinase pathway (Bodrikov et al., 2008) which induces neuritogenesis, neural 
development and synaptic plasticity (Ditlevsen et al., 2008). NCAM also employs signalling molecules 
involved in cell adhesion; a process in which PrPC may also plays a role. Subversion of PrPC 
interactions with various membrane proteins has been suggested to promote neurotoxic signaling 
cascades in prion-induced toxicity (Hernandez-Rapp et al., 2014). 
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Among the mebrane proteins interacting with PrPC are glutamate receptors. N-methyl-D-aspartate 
receptors (NMDAR) are crucial regulators of glutamatergic transmission, and loss of both synapses 
and neurons has been attributed to inappropriate NMDAR activation (Khosravani et al., 2008). The 
group-I metabotropic glutamate receptors (group I mGluRs), mGluR1 and mGluR5, can both 
associate with PrPC and induce similar intracellular pathways (Beraldo et al., 2011). Metabotropic 
glutamate receptors (mGluRs) were also reported to play a role in prion diseases. Impairment of the 
mGluR1/1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase 1 (PLC1)/protein kinase C (PKC) 
signaling pathway has been observed in a murine model of BSE; abnormal mGluR1 signaling 
correlated with PrPSc deposition, histological changes, and clinical scores (Rodriguez et al., 2006).  
A role for group-I mGluRs is emerging in a multitude of CNS disorders including Fragile X syndrome, 
ischemia, multiple sclerosis, amyotrophic lateral sclerosis, Huntington’s, and Parkinson’s disease 
(Aguilar-Valles et al., 2015; Caraci et al., 2012; Dinamarca et al., 2012; Dolen and Bear, 2008; 
Michalon et al., 2014; Milanese et al., 2014; Scharf et al., 2015). In AD, PrPC and mGluR5 may 
directly contribute to disease manifestation and toxicity of Amyloid β (Aβ) aggregates. Aβ oligomers 
can bind to PrPC at the cell surface (Lauren et al., 2009) and form complexes that contain mGluR5 
receptors (Haas et al., 2014). These receptors couple to G-proteins and trigger subcellular events that 
ultimately result in elevated intracellular Ca2+
 
levels.  
In a mouse model of Aβ deposition, cognitive decline and synaptic alterations were rescued by 
mGluR5 inhibition (Um et al., 2013).  
                                                   
Figure 1.15. mGluR5 acts as a co-receptor which couples A o-PrPC to intracellular Fyn kinase.  
Schematics which depict the Aβo in complex with PrPC at post synaptic densities (PSD). The first 
schematic proposes that an unknown signal transducer is required to activate Fyn kinase signalling. 
The mGluR5 was identified as the unknown receptor [modified by (Um et al., 2013)].  
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Furthermore, PrPC-mGluR5 coupling was involved in Aβ-mediated inhibition of LTP and Aβ-facilitated 
LTD in vivo (Hu et al., 2014). Also, genetic ablation of mGluR5 reversed disease-related memory 
deficits in a murine model of AD (APPswe/PS1∆E9) (Hamilton A. et al., 2014). In another study, 
exposure of cortical APPswe/PS1∆E9 neuronal cultures to Aβ oligomers upregulated mGluR1 and 
PrPC α-cleavage, whereas activation of group-I mGluRs increased PrPC shedding from the membrane 
(Ostapchenko et al., 2013). In primary hippocampal neurons, membrane-bound Aβ oligomers induce 
toxicity by promoting clustering of mGluR5 in synapses, resulting in elevated intracellular calcium and 
synaptic failure (Renner et al., 2010). All these studies speak in favor of an role of group-I mGluRs in 
the pathogenesis of AD. On the other hand, others have reported that neither PrPC ablation nor 
overexpression had any effect on neurotoxicity in AD models (Balducci et al., 2010; Calella et al., 
2010; Cisse et al., 2011; Kessels et al., 2010). As a possible explanation for these discrepancies, it 
has been suggested that only a defined oligomeric fraction of Aβ (Kostylev et al., 2015) interacts with 
mGluR5 (Haas et al., 2016).  
In prion diseases, changes in mGluR1 expression levels, leading to reduced expression levels of 
phospholipases, were observed in the cerebral cortex of Creutzfeldt-Jakob disease (CJD) patients 
(Rodriguez et al., 2005).  
Collectivelly, group I mGluRs have emerged as potential targets for drug therapy in Parkinson’s 
disease, Alzheimer’s disease (Gasparini et al., 2013), Fragile X syndrome (Dolen and Bear, 2009), 
schizophrenia (Vinson and Conn, 2012) and major depressive disorder (Deschwanden et al., 2011), 
and finally prion diseases (Rodriguez et al., 2005). The role of group I mGluR-PrPC interaction as well 
as the aberrant group I mGluR signaling in prion- and prion-mimetic antibody-mediated toxicity is of 
utmost importance to the current study, as it will be defined in the aim of the study. Before this, the 
molecular and cellular pathways that lead to synaptic pathology will be discussed in detail.  
1.15. Molecular and cellular pathways leading to neurodegeneration and 
synaptic pathology in prion diseases 
Neuronal loss is a common feature in prion diseases and could account for some of the other 
observed pathologies such as astrogliosis and vacuolation. However, the identity of the misfolded, 
toxic PrP species and the pathways that induce neurodegeneration in prion disease are still elusive. 
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Given the relative lack of classical immunological response in TSE-affected brain (Brown, 1990), 
neurodegeneration in prion diseases was expected to follow a programmed cell death (PCD) and not 
necrotic pathway. Events that may lead to neuronal apoptosis include oxidative stress, dysfunction of 
endosomal-lysosomal systems, endoplasmic reticulum stress, synaptic alterations and dendritic 
atrophy, and microglial activation. 
1.15.1. Apoptotic and authophagic cell death 
Apoptosis is a process of programmed cell death, characterized by cell shrinkage, DNA 
fragmentation, condensation of chromatin and formation of apoptotic bodies (Liberski et al., 2008). 
The first observations of apoptotic cell death in prion diseases were made in the brains of patients 
with sporadic CJD and mice with experimental scrapie. Exposure to PrPSc resulted in cells with 
fragmented nuclei, DNA laddering and caspase activation (mainly caspase 3) (Ferrer, 2002; Siso et 
al., 2002). Apoptosis was also reported in the cerebellum of Tg(PG14) mice (Chiesa et al., 2000). The 
morphological aspects of apoptosis were also detected in GT1 hypothalamic cells, following infection 
with scrapie prions (Schatzl et al., 1997). The same features were observed  upon prion infection of 
primary cultured neurons and astrocytes (Cronier et al., 2004). Apoptotic changes were also induced 
by the neurotoxic synthetic peptide PrP106–126 (Forloni et al., 1993) as well as by mature amyloid 
fibrils produced from full-length recombinant mammalian prion protein (rPrP) in cultured cells and 
primary hippocampal and cerebellar neurons (Novitskaya et al., 2006). 
Autophagy, a process of orderly degragation and recycling of cellular components, could also be 
involved in prion diseases. Autophagic vacuoles were described in experimentally induced scrapie, 
CJD, GSS disease, and FFI (Liberski et al., 2004); represented by membrane sequestration, by 
concentric arrays of double membranes and formation of autophagic vacuoles in all parts of the 
neuron including synaptic endings. Intraneuronal accumulation of PrPSc, which overload the catabolic 
machinery, is suggested as the culprit of the observed phenotype. Autophagy could also participate in 
the spongiform changes (Liberski et al., 2004). At the molecular level, autophagic cell death correlated 
with the upregulation of the scrapie regulated gene 1 (Scrg1), which encodes a protein associated 
with the Golgi apparatus, as well as with autophagic vacuoles of degenerative neurons (Dron et al., 
2006).  
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1.15.2. Oxidative stress 
Oxidative stress refers to the inability of a biological system to readily remove abundand reactive 
intermediates or to repair the damage caused by their accumulation.  
Immunohistochemical studies in prion infected mouse brains showed the presence of nitrotyrosine, 
eme-oxygenase 1, and lipid oxidation markers; suggesting that oxidative stress may play a role in the 
prion pathology (Brown, 2005). In CJD brains, oxidative nucleic acid damage correlated with disease 
duration but not with PrPSc deposition (Guentchev et al., 2002). Also, cells infected with scrapie or 
treated with the neurotoxic PrP106–126 peptide showed decreased levels of antioxidants and 
oxidative damage (Brown, 2005). In bioaminergic neuronal cells treatment with the PrP106-126 
peptide causes oxidative stress by activating a PrPC-caveolin-Fyn signalling pathway and thus 
stimulating NADPH-oxidase activity (Pietri et al., 2006; Schneider et al., 2003b). In vivo, NOX2, an 
important NADPH oxidase, was markendly upregulated in microglia of CJD patients. Also, prion-
infected, NOX2-deficient mice showed delayed onset of motor deficits and increased survival (Sorce 
et al., 2014). 
 
1.15.3. The endosomal-lysosomal system 
In cell cultures, it was reported that the endosomal-lysosomal system is involved in the processing of 
both PrPC and exogenous PrPSc (Campana et al., 2005; Peters et al., 2003; Taraboulos et al., 1992); 
suggesting a role of these compartments in the PrPC to PrPSc transformation (Caughey and Baron, 
2006). It has also been proposed that pathogenic PrP oligomers could be directly released from host 
cells into the extracellular space by endosomal recycling and/or by exosome secretion (Fevrier et al., 
2004; Marijanovic et al., 2009). Additionally, cysteine protease (lysosomal protease) inhibitors have 
been shown to inhibit PrPSc accumulation (Doh-Ura et al., 2000; Fournier et al., 2000; Laszlo et al., 
1992). Moreover, degenerating neurons showed an increased volume of cathepsin-D-immunoreactive 
lysosomes; suggesting an overloading of the endosomal-lysosomal system (Kovacs et al., 2007). 
1.15.4. Endoplasmic reticulum stress 
Endoplasmic reticulum (ER) stress has been proposed as a potential mechanism of neuronal death in 
prion diseases. ER responds to cellular stress by activating adaptive pathways, termed unfolded 
protein response (UPR). This leads to reduced translation, induction of ER chaperones and 
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degradation of misfolded proteins (Bonifacino and Weissman, 1998). Prolonged ER stress results in 
alteraction of Ca2+ homeostasis and the cell death. Upregulation of several ER-related chaperones 
and activation of the ER-related caspase-12 have been reported in models of prion disease (Hetz et 
al., 2007; Hetz et al., 2003). ER stress induced by PrP peptides has also been linked to changes in 
Ca2+ homeostasis (Ferreiro et al., 2004). ER stress has been also shown to induce the generation of a 
misfolded PrP formsthat (Hetz et al., 2007); suggesting that ER stress could accelerates prion 
replication. However, genetic ablation of caspase or the X-box-binding protein-1 (XBP-1), a key 
effector of UPR, had no effect on prion infected mice (Hetz et al., 2008; Steele et al., 2007). 
1.15.5. Astroglial and microglial activation 
Activation of microglia and astrocytes is an early event in prion diseases (Prusiner, 1994). Astrocytic 
enzymes such as glial fibrillary acidic protein (GFAP) are up-regulated, following an increase in PrPSc, 
before the development of neuropathological lesions; suggesting a potential role of astrocytic 
activation in tissue damage (Liberski et al., 2004). In vitro, addition of the toxic PrP82-146 peptide 
induced astrocyte proliferation (Fioriti et al., 2007).  
Microglia activation is generally confined to regions with spongiform change and PrPSc deposition 
(Brown, 2001a). Activated microglia, the resident immune cells of the CNS, respond to neuronal 
damage by rapid up-regulation or de novo expression of a variety of cytokines, chemokines and cell 
surface antigens (Perry and Gordon, 1988). Microglia activation is an early event in murine prion 
disease (Betmouni et al., 1996; Cunningham et al., 2003a; Cunningham et al., 2005); sensitive to 
changes in neuronal homeostasis and early synaptic damage. For example, anti-inflammatory 
response of microglia, following neurodegeneration in synaptic boutons, has been reported in mice 
infected with the ME7 prion strain at the early stages of the disease (Boche et al., 2006). However, 
chronic microglial activation induces neuronal damage, associated with induction of proinflammatory 
cytokines, ROS, proteases, and complement proteins (Chiarini et al., 2006). Microglia recruitment 
close to PrP aggregates is regulated by chemokines, acting through the activation of specific G-
protein-coupled receptors. Moreover, PrPSc accumulation triggered the up-regulation of the 
chemokine RANTES, through the activation MAPK/ERK1/2 pathways (Marella and Chabry, 2004). A 
role of microglia in the propagation of oxidative stress in prion diseases has also been hypothesized. 
Addition of the toxic PrP106-126 peptide to neuron/glia co-cultures elicited an over-production of the 
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pro-inflammatory cytokines IL-1β and IL-6 by microglial cells (Peyrin et al., 1999). Microglial cells 
exacerbated the toxic effect of PrP106-126 peptide on neuronal cultures by producing ROS (Brown et 
al., 1996). In vivo, NOX2 levels were significantly increased in microglia of CJD patients. Also, prion-
infected, NOX2-deficient mice showed delayed onset of motor deficits and increased survival (Sorce 
et al., 2014). 
1.15.6. Synaptic and dendritic pathology  
Several immunohistochemical studies showed accumulation of PrPSc at the synaptic terminals; 
suggesting synaptic pathology as a primary event in prion diseases. Indeed, in rodent models of prion 
disease synaptic accumulation of PrPSc and prominent synaptic degeneration was detected at the 
early stages of the disease process, before any overt signs of neuronal death (Bouzamondo-
Bernstein et al., 2004; Cunningham et al., 2003a; Gray et al., 2009; Jeffrey et al., 2000). Disruption of 
presynaptic boutons and degeneration of axon terminals did not strictly correlate with PrPSc 
deposition. This suggested that other toxic intermediates, likely soluble and PK-sensitive oligomeric 
species of abnormal PrP, also injured synapses (Gray et al., 2009; Jeffrey et al., 2001) and 
compromised synaptic function before PrPSc deposition could be detected (Cunningham et al., 2003a; 
Mallucci et al., 2007). In brain samples from CJD patients, PrPSc deposition at the presynapstic 
terminals has been reported (Kovacs et al., 2005; Siso et al., 2002). PrPSc deposition was associated 
with reduced level of presynaptic proteins such as synaptophysin, synapsin I, SNAP-25 (Ferrer et al., 
2000).  
Another prominent feature of prion diseases is dendritic atrophy (Jamieson et al., 2001); characterized 
by distorted dendritic arborization and dendritic atrophy in CJD brains. The associated molecular 
mechanism involved activation of Notch (a known regulator of dendritic growth and maturation). 
Indeed, in the neocortex of infected mice, higher level of Notch-1 mRNA and nuclear translocation of 
Notch-1 intracellular domain (NICD), correlated with PrPSc accumulation. In vitro, in N2a 
neuroblastoma cells, the expression of NICD was also increased following scrapie infection. 
Morphologically, N2a cells showed synaptic abnormalities, such as shorter dendritic processes 
(Ishikura, 2007; Ishikura et al., 2005). 
The role of synaptic pathology in neuronal degeneration is still elusive. It has been proposed that 
accumulation of PrPSc at the synapse directly affects the synaptic function by altering the balance 
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between excitatory and inhibitory transmission. Indeed, enhanced glutamatergic excitatory 
transmission (through NMDARs) as well as impairment of inhibitory GABAergic signalling, has been 
described in both mouse and human models of prion diseases (Bouzamondo-Bernstein et al., 2004; 
Ratte et al., 2008).  
1.15.7. Ca2+ deregulation and prion pathophysiology 
So far, conclusive evidence about the exact pathogenic mechanism of prion toxicity is still missing. 
Moreover, the physiological function of PrPC as well as its role in prion pathogenesis remains largerly 
unknown. Nonetheless, latest evidence propose that the loss of PrPC function per se, and not the 
effect of PrPSc formation alone, contributes to the observed neurodegeneration. It is suggested that 
PrPC acts by regulating crucial cellular processes - determining both the life and the death of a cell- 
such as Ca2+ homeostasis. Indeed, Ca2+ is a key regulator of multiple intracellular processes that are 
crucial for cell survival. However, if not finely regulated, Ca2+ is also known to switch into a threat for 
the cell.  If this were true, Ca2+ could turn out to be the common denominator for the multiple roles 
ascribed to PrPC. Yet, it is worth underlying that PrPC faces the extracellular milieu and cannot directly 
influence calcium signaling. Accordingly, there are two possible mechanism of action. The first one 
suggests that PrPC interacts with transmembrane molecular systems involved in Ca2+ homeostasis 
(such as Ca2+ channels, metabotropic glutamate receptors). The second one postulates that PrPC, as 
member of membrane multicomponent signalling complexes, controls downstream signaling events 
that coordinate the expression of Ca2+-related proteins (Peggion et al., 2011). 
Several findings suggested a link between prion pathology and impaired Ca2+ control. For example 
pioneer work in neuronal cell lines exhibited reduced Ca2+ responses following prion infection 
(Kristensson et al., 1993; Wong et al., 1996). Also, treatment of cells and neurons with prions or the 
fibrillogenic and neurotoxic peptide encompassing PrP amino acid residues 106–126 (PrP (106–126)), 
induced the downregulation of N-type voltage-gated Ca2+ channels (VGCCs) (Florio et al., 1998; 
Forloni et al., 1993; Sandberg et al., 2004; Thellung et al., 2000). Mechanistically, however, it is still 
unknown whether prions or PrP (106–126), acted directly on VGCC and modulated their activity or 
prion toxicity indirectly caused an alteration in Ca2+ homeostasis. Furthermore, electrophysiologic and 
morphologic synaptic abnormalities, such as alterations of presynaptic/postsynaptic potentials, 
neuronal depolarization leading to increased excitability, loss of slow after hyperpolarization (AHP), 
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impaired generation and maintenance of long-term potentiation (LTP), and loss of dendritic spines 
with abnormal dendritic morphology (Cunningham et al., 2003b; Johnston et al., 1997; Johnston et al., 
1998a; Johnston et al., 1998b) have been reported in prion infected brains and/or cultured neurons. 
These pathologies could be attributed to changes in Ca2+ homeostasis.  
In support of the first hypothesis, a number of intracellular effectors of PrPC-mediated signaling, 
including p59fyn, mitogen-activated kinases (MAPKs) Erk1/2, PI3K/Akt, and cyclic adenosine 
monophosphate (cAMP)-dependent protein kinase A (PKA) have been reported (Sorgato et al., 2009). 
The interaction of PrPC and glutamate receptors also seems to be critical for Ca2+ regulation. Zamponi 
and coworkers have reported that blocking NMDAR activity can reverse the increased excitability of 
Prnp-/- hippocampal neurons. From a molecular point of view, this observation was explained by the 
ability of PrPC to interact and selectively inhibit the NR2D subunit of the NMDAR (Khosravani et al., 
2008). Laminin γ1 chain-PrPC interaction was reported to activate group I mGluRs. This triggers Ca2+ 
release from InsP3 -sensitive ER stores and the subsequent cytosolic Ca2+. The latter promotes PKC-
mediated neuritogenesis (Beraldo et al., 2011). However, in an AD disease model this interaction has 
also been shown to be the effector of neurodegeneration (Um et al., 2013). A similar mechanism has 
been described for the interaction between PrPC and STI1. In this case, PrPC-STI1 interaction 
promotes coupling of PrPC with the a7 nicotinic acetylcholine receptor (a7nAChR) and activation of 
the latter. The resulting increase of cytosolic Ca2+ would then trigger either neuronal differentiation or 
survival, depending on downstream activated pathways, one MAPK Erk1/2 or PKA, respectively 
(Beraldo et al., 2010; Lopes et al., 2005). 
In support of the second hypothesis, Lazzari et al. showed a direct role of PrPC in the regulation of 
local Ca2+ movements in cerebellar granular neurons.  More specifically, primary cerebellar granular 
neurons (CGNs) were prepared from both wt and Prnp-/- mice. Both preparations were transduced 
with an aequorin (AEQ) lentiviral vector. The use of a plasma membrane (PM)-targeted AEQ allowed 
monitoring of Ca2+ flunctuations in the cytosolic domains close to the plasma membrane. Intracellular 
store depletion or membrane depolarizations were used to trigger the entry of Ca2+ ions into the cell. 
Prnp-/- primary CGNs exhibited much higher Ca2+ peak transients in PM subdomains compared to 
their wt counterparts. Also, the absence of PrPC strongly delayed the re-establishment of basal Ca2+ 
levels, due to the reduced number of PM and ER Ca2+ -ATPases. Importantly, addition of PrPC 
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restored the physiological PrPC levels and reversed the aforementioned phenotype (Lazzari et al., 
2011). Because both the infection by prions and the absence of PrPC mainly affect the CA1 region of 
the hippocampus, several studies have analyzed the electrophysiological features of this region in 
acute hippocampal slices. They reported a significantly reduced slow AHP in Prnp-/- CA1 cells and 
pyramidal neurons compared to their wt counterparts (Asante et al., 2004; Colling et al., 1996; 
Fuhrmann et al., 2006; Mallucci et al., 2002; Powell et al., 2008); mediated by Ca2+-activated K+ 
currents (Sah and Davies, 2000). This impairment has been attributed to either reduced Ca2+ influx 
through L-type VGCC (Fuhrmann et al., 2006) or to increased activity of the sarco-ER Ca2+-ATPase 
(SERCA) and cell Ca2+-buffering capacity (Powell et al., 2008), both phenomena resulting in 
decreased cytosolic Ca2+ levels. Interestingly, decreased depolarization-induced Ca2+ rise and 
reduced Ca2+-activated K+ currents were also observed in Prnp-/- cerebellar Purkinje cells (Herms et 
al., 2001). 
From what reported so far, it seems that deregulation of processes carefully orchestrated by Ca2+ 
signalling is common to both AD and prion disease, and that Aβ fragments and (the good and bad) 
PrP isoforms as well as PrPC per se or through its interactions significant roles in the Ca2+-based cell 
network. The exact mechanism of these interactions remains to be elucidated.  
1.16. Aims of the thesis 
Prion diseases are fatal neurological disorders, characterized by accumulation of aggregated, 
misfolded proteins and progressive neurological dysfunction and neurodegeneration. The decisive 
event in the pathogenesis of prion diseases is the conversion of the normal cellular prion protein 
(PrPC) into an aggregated conformational variant called PrPSc. However the molecular mechanisms of 
the disease progression are largerly unknown. It is proposed that this process is partially mediated by 
PrPC interaction partner. Key interactors are group I metabotropic glutamate receptors (mGluRs). 
Group I mGluRs couple with PrPC and laminin γ chain (PrPC-Ln γ1)  and promote neuronal 
differentiation (Graner et al., 2000). Beraldo and colleagues further showed that upon formation of the 
group I mGluRs -PrPC -Ln γ1 complex, group I mGluRs are activated and transduce signals for 
neuritogenesis (Beraldo et al., 2011).  However, this interaction does not always promote 
development.   
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Recent studies in AD shed light into “the dark side” of PrPC-group I mGluRs interaction. Aβ oligomers 
can bind to PrPC at the cell surface (Lauren et al., 2009) and form complexes that contain mGluR5 
(Haas et al., 2014). Inhibition of mGluR5, in vivo, rescued cognitive decline and synaptic alterations 
caused by exposure to Aβ-aggregates (Um et al., 2013). Furthermore, PrPC-mGluR5 coupling is 
involved in Aβ-mediated inhibition of LTP and Aβ-facilitated LTD in vivo (Hu et al., 2014), and genetic 
ablation of mGluR5 reverses disease-related memory deficits in a murine model of AD 
(APPswe/PS1∆E9) (Hamilton A. et al., 2014). Exposure of cortical APPswe/PS1∆E9 neuronal cultures 
to Aβ oligomers upregulated mGluR1 and PrPC α-cleavage, whereas activation of group-I mGluRs 
increased PrPC shedding from the membrane (Ostapchenko et al., 2013). All these studies speak in 
favor of an involvement of group-I mGluRs in the pathogenesis of AD. On the other hand, others have 
reported that neither PrPC ablation nor overexpression had any effect on neurotoxicity in AD models 
(Balducci et al., 2010; Calella et al., 2010; Cisse et al., 2011; Kessels et al., 2010). As a possible 
explanation for these discrepancies, it has been suggested that only a defined oligomeric fraction of 
Aβ (Kostylev et al., 2015) interacts with mGluR5 (Haas et al., 2016). Evidence exists that PrPC-group I 
mGluRs interaction also plays a role in prion disease. Changes in mGluR1, leading to reduced 
expression levels of phospholipases, were observed in the cerebral cortex of Creutzfeldt-Jakob 
disease (CJD) patients (Rodriguez et al., 2005). Also, impairment of the mGluR1/1-
phosphatidylinositol 4,5-bisphosphate phosphodiesterase 1 (PLC1)/protein kinase C (PKC) signaling 
pathway has been observed in a murine model of BSE; abnormal mGluR1 signaling correlated with 
PrPSc deposition, histological changes, and clinical scores (Rodriguez et al., 2006). The aim of the 
current thesis was to study the role of mGluR1 and mGluR5 in prion diseases and to elucidate the 
mechanisms involved in this process.  
First, we tested whether toxicity induced by prion infection (RML6 prion strain) (Falsig et al., 2012) or 
prion mimetic anti-PrPC antibodies (Sonati et al., 2013), namely globular domain ligands (GDLs), 
could be rescued in cerebellar and hippocampal organotypic cultured slices (COCS and HOCS, 
respectively) upon pharmacological inhibition of either mGluR5 or mGluR1 (treatment with MPEP and 
YM202074 respectively). Dose-dependent treatment potential of the pharmacological inhibitors was 
also performed. Rescue was defined by morphometric assessment of the area of the cerebellar 
granule cell layer (CGL) or pyramidal hippocampal neurons immunoreactive to antibodies against the 
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neuronal NeuN antigen. 
Second, so as to evaluate the specificity of the therapeutic potential of group I mGluR inhibitors a 
group of cerebellar slices was also treated with the selective agonist of group III (L-AP4)) and the 
potent antagonist of group II and group III (CPPG) metabotropic glutamate.  
Third, we sought to evaluate whether there exists a specific interaction of PrPC with all members of 
the mGluR superfamily. Brain homogenate from wt and Prnp-/- mice was subjected to 
immunoprecipitation by POM1 (monoclonal anti-PrPC antibody) followed by immunobloting using 
polyclonal antibodies against the different mGlu receptors and PrPC. Control conditions such as 
unconjugated beads, IgG bound beads and POM1 blocked by recombinant PrPC were run in 
parallel to ensure the specificity of the selected antibodies.  
Forth, after verifying the specificity of the interaction with group I mGluRs pharmacologically we 
decided to move on with the genetic model. We tested whether toxicity induced by prion infection 
(RML6 prion strain) or prion mimetic anti-PrPC antibodies could be rescued in cerebellar and 
hippocampal slices (COCS and HOCS) upon genetic deletion of mGluR5 (groups included in the 
study and compared in parallel are: Grm5-/-, Grm5+/- and control wt littermates). Rescue was defined 
by morphometric assessment of the area of the cerebellar granule cell layer (CGL) or pyramidal 
hippocampal neurons immunoreactive to antibodies against the neuronal NeuN antigen. 
Fifth, we probed mouse brain homogenate derived from transgenic amino-proximal deletion mutants 
of PrPC
 
to define (a) the type of interaction-direct or indirect, and (b) where the region of interaction 
between mGluR1-PrPC and mGluR5-PrPC may lie. Towards this end, a series of transgenic mouse 
lines that express variants of full length PPC, possessing an intact globular domain (GD) but extensive 
deletions in the flexible tail (FT) region of PrPC, were utilized (Figure 1.16.). Also known as amino-
proximal deletion mutants (ΔC, ΔCC, ΔF, ΔOR), these truncated variants induce pathological features 
in Prnp-/- background that can be rescued by introduction of full-length PrPC [reviewed in (Aguzzi et 
al., 2008)] 
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Figure 1.16. Schematic representation of the PrPC deletion mutants utilized in this study 
Sixth, we sought to assess a possible therapeutic effect of MPEP on prion pathogenesis in vivo. 
C57BL/6J male mice were inoculated intracerebrally with 3 or 5 log LD50 units of RML6 prions as 
previously described (Kranich et al., 2010), and chronically treated with MPEP.  Control mice were 
inoculated with NBH. In order to record the neurological deficits associated with prion disease, we 
utilized the rotarod behavioral test which measures a combination of motor performance, coordination, 
and balance (Brooks and Dunnett, 2009). At the terminal stage of the disease mice were sacrifized 
and brain samples (whole brain as well as specific brain regions, such as cortex, hippocampus and 
cerebellum) were collected and further processed. Immunohistochemical staining (Iba1, GFAP, 
SAF84) of brain sections was performed and analysis included: vacuole area and number counting, 
percentage of reactive astrogliosis, percentage of microglia activation and PrPSc accumulation 
respectively. 
Seventh, after verifying the therapeutic potential of pharmacological inhibition of mGluR5 we decided 
to test the genetic inhibition model. We tested whether toxicity induced by prion infection (RML6 prion 
strain) upon genetic deletion of mGluR5 (groups included in the study and compared in parallel are: 
Grm5-/-, Grm5+/- and control wt littermates). In order to record the neurological deficits associated with 
prion disease, we utilized the rotarod behavioral test which measures a combination of motor 
performance, coordination, and balance (Brooks and Dunnett, 2009). At the terminal stage of the 
disease mice were sacrifized and brain samples (whole brain as well as specific brain regions, such 
as cortex, hippocampus and cerebellum) were collected. Unfortunately, no significant therapeutic 
effect was observed upon deletion of Grm5 in vivo. However, this observation led us to examine the 
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potential for epistasis between mGlu1 and mGlu5 receptors. 
Eight, we sought to the mechanism of the observed toxicity (GDL-induced toxicity) and how this is 
mediated through PrPC-mGluR5 interaction. In AD, it has been reported that clusters of mGluR5s 
accumulate around excitatory synapses, and increase the size of synaptic mGluR5s clusters. This 
increase is associated with toxic calcium influx (Renner et al., 2010; Shrivastava et al., 2013; Um et 
al., 2013). Therefore, we sought to identify whether the prion-mimetic POM1 antibody altered the 
clustering of mGluR5s or the fluorescent intensity of mGluR5s in dendritic spines. Immunofluorescent 
analysis of mGluR5s clusters was performed on primary hippocampal neurons following exposure to 
the anti-PrPC F(ab)1 antibody fragments, toxic POM1 and control POM2, and POM3 (Sonati et al., 
2013). Also, the fluorescence level of mGluR5s in dendritic spines of neurons expressing mGluR5-
pHluorin was quantified. Furthermore, in order to assess the specificity of the interaction for mGluR5 
(and not other excitatory glutamate receptors) after exposure of the primary hippocampal cultures to 
toxic POM1 antibodies, the cluster size and the fluorescent intensity of NMDA and AMPA receptors 
were also assessed. The membrane clustering of mGluR5s following exposure to toxic POM1 
antibodies was further assessed by cell surface biotinylation experiments. 
Nine, with the aim to assess changes in Ca2+ homeostasis in prion diseases novel transgenic mice 
expressing the potent Ca2+ reporter (RCamp1.07) were generated. In brief, embryonic stem (ES) cell 
culture and gene targeting of the RCaMP1.07 reporter gene into the TIGRE locus were carried out 
and the targeted ES cells were microinjected into B6N-Tyrc blastocysts. Chimeras were tested for 
transgene expression and inheritance by Southern blotting using specific 5’ and 3’ external probes. 
Transgenic mice were further crossbred with R26phiC31o mice (Raymond and Soriano, 2007) for 
removal of the AttB/AttP-flanked hygro-TK cassette. Following removal of the cassette, mice were 
mated with either Camk2a-tTA (Mayford et al., 1996) or ROSA:LNL:tTA (Wang et al., 2008) 
transgenic mice to allow for the generation of compound mutant mice in which expression of the 
reporter gene can be defined by the chosen Cre-recombinase and turned off by the addition of 
tetracycline (or its analog doxycycline). Expression of the transgene was evaluated both in fixed brain 
sections as well as in organotypic slice cultures. 
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In summary, our results demonstrate that pharmacological inhibition of mGluR1 and mGluR5 
antagonizes dose-dependently the neurotoxicity triggered by prion infection and by exposure to prion-
mimetic anti-PrPC antibodies in organotypic brain slices. Prion-mimetic antibodies increase mGluR5 
clustering around dendritic spines mimicking a mechanism of toxicity documented for Aβ oligomers, 
whereas prion-protective antibodies reduce mGluR5 clustering. Treatment with the protective 
antibodies reduces mGluR5 clustering. Interestingly, pre-blocking of the toxic POM1 antibodies with 
the protective POM1 antibodies significantly reduces the cluster size; similar to MPEP treatment. 
Although genetic deletion of mGluR5 was not protective against prion infections in vivo, oral treatment 
with the mGluR5 pharmacological inhibitor MPEP, delayed the onset of motor deficits and prolonged 
survival of prion-infected mice. Group-I mGluR inhibition was not curative, yet these results suggest 
that it may have the potential to alleviate the neurological dysfunctions induced by prion diseases. 
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Chapter 2: MATERIALS AND METHODS                            
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2.1. Mice 
Prnp-/- (or Prnpo/o) and Prnpo/o; tga20+/+ (Tga20), were on a mixed 129Sv/BL6 background (Fischer 
et al., 1996). Transgenic mice expressing mutated PrPC were utilized for immunoprecipitation 
experiments. The production and relevance to disease phenotype of the transgenic mice 
expressing N-terminal deletion mutants of PrPC (termed ∆C, ∆CC, ∆F, ∆OR and ∆HC) PrPC 
has been previously reported (Baumann et al., 2007a; Bremer et al., 2010; Flechsig et al., 
2000; Shmerling et al., 1998). Grm5+/- embryos (Jia et al., 1998; Lu et al., 1997) were acquired 
from Dr. Gasparini and were revitalized at the transgenics facility of the University Hospital of 
Zurich. GRM5 null mice were derived from breeding of these mice. 
2.2. Transgenic mice generation 
Embryonic stem (ES) cell culture and gene targeting of the RCaMP1.07 reporter gene into the TIGRE 
locus were carried out as previously described (Madisen et al., 2015; Madisen et al., 2010). Targeted 
ES cells were microinjected into B6N-Tyrc blastocysts and chimeras were bred with C57BL/6J mice. 
DNA was extracted from the biopsied tails of mouse pups and the F1 generation was identified by 
Southern blotting using the following 5’ and 3’ external probes. The former was generated by PCR 
using a primer pair of 5’-tagggaagcactggccaaaggaa-3’ and 5’-tcacggtaaccgcggcataaaac-3’, and the 
latter by 5’-cgaactgcccgctgttctgc-3’ and 5’- gtagcgcgtctgctgctcca-3’. Transgenic mice were further 
crossbred with R26phiC31o mice (Raymond and Soriano, 2007) for removal of the AttB/AttP-flanked 
hygro-TK cassette. Following removal of the cassette, mice were mated with either Camk2a-tTA 
(Mayford et al., 1996) or ROSA:LNL:tTA (Wang et al., 2008) transgenic mice to allow for the 
generation of compound mutant mice in which expression of the reporter gene can be defined by the 
chosen Cre-recombinase and turned off by the addition of tetracycline (or its analog doxycycline).  
2.3. Organotypic slice culture preparation 
Organotypic cerebellar cultured slices, 350 µm thick, were prepared from 9–12 day-old pups 
according to a previously published protocol (Falsig et al., 2008). Organotypic hippocampal 
cultured slices, 350 µm thick, were prepared from 4–6 day-old pups according to a previously 
published protocol (Gogolla et al., 2006). Cultures were kept in a standard cell incubator (37 °C, 5% 
CO2, 95% humidity) and the culture medium was changed three times per week. 
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2.4. Prion inoculation and GDLs treatment 
Inoculations were performed with either infectious brain lysate (RML6) or non-infectious brain 
homogenate (NBH). Slices were inoculated (as free-floating sections for 1 h at 4°C) with 100µg 
brain homogenate per 10 slices. After washing in GBSSK, they were cultured on a 6-well 
Millicell-CM Biopore PTFE membrane insert (Millipore) according to previously published protocol 
(Falsig et al., 2012). Drug-treated tga20 slices were maintained until 45 dpi, fixed and analyzed 
by NeuN morphometry (analySIS vc5.0 software). Neurotoxicity was defined as significant NeuN+ 
neuronal layer loss over NBH treatment. Slices prepared from Grm5-/-, Grm5+/- and Grm5+/+ 
littermates were maintained until 60 dpi, fixed and analyzed by NeuN morphometry (analySIS 
vc5.0 software). Neurotoxicity was defined as significant NeuN+ neuronal layer loss over NBH 
treatment. For globular domain ligand (GDL) treatment, toxicity in slices was induced by exposure 
to ligands, toxic anti- PrPC antibodies targeting the globular domain, such as full length POM1 
antibody and/or (sc)POM1 mini-antibody, after a 14-day recovery  period;  allowing  the  initial  
gliosis  induced  by  tissue preparation to subside, according to previously published protocol 
(Sonati et al., 2013). Tga20 COCS were exposed to POM1 (67 nM, 14 dpe)/ scPOM1 (200 nM, 
8 dpe), or to control treatment (67 nM POM1/140nM recPrP, 14 dpe)/ (200 nM scPOM1/210nM 
recPrP, 8 dpe), immunostained for the neuronal marker NeuN and counterstained with DAPI. 
Slices were imaged and analysed as previously described. Antibody treatment was randomly 
assigned to individual wells. 
2.5. Pharmacological treatment of slices 
Treatment with the specific inhibitors 2-Methyl-6-(phenylethynyl)-pyridine (MPEP) (Gasparini et 
al., 1999) or N-cyclohexyl-6-N- methylthiazolo[3,2-a]benzimidazole-2-carboxamide (YM202074) 
(Kohara et al., 2008) was initiated at the time of GDL addition (14dpe) for the GDL toxicity 
model (treated slices were maintained until 28 dpe for POM1 treatment and until 22dpe for 
scPOM1 treatment) (Sonati et al., 2013) and at 21 days post-inoculation (dpi) for prion infected 
slices, when PrPSc accumulation  was  already  discernible (Falsig et al., 2008).  Drug treatments 
were re-added at every media change (Gasparini et al., 1999).  Post-treatment slices were fixed 
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in 4% paraformaldehyde (PFA), immunostained for the neuronal marker NeuN and 
counterstained with DAPI. Slices were imaged at 4x magnification on a fluorescence microscope 
(BX-61, Olympus) analyzed by NeuN morphometry (analySIS vc5.0 software). Neuroprotection 
was defined as significant neuronal layer rescue over toxic-antibody treated, non-drug treated 
slices. 
 
2.6. Prion Inoculations 
Inoculum of the RML6 strain of mouse-adapted scrapie prion was prepared from pooled 10% w/v 
brain homogenates of RML6 terminally sick CD1 mice. C57BL/6J mice were inoculated with 
serial dilutions (10-3 and 10-5) of the RML6 inoculum. C57BL/6J mice were injected intracerebrally 
with 30l of brain homogenate prepared in a solution of PBS/5% BSA, containing 3log LD50 
units or 5log LD50 units of the RML6 strain. Control mice received 30µl of NBH derived from 
healthy CD1 mice. Scrapie was diagnosed according to clinical criteria (ataxia, kyphosis, 
priapism, and hind leg paresis). Mice were sacrificed on the day of onset of terminal clinical 
signs of scrapie. The operator was blinded to drug treatment. 
2.7. Rotarod 
The rotarod test was used to assess motor coordination and endurance at defined timepoints after 
prion inoculations. A rotarod machine (Ugo Basile) with five cylinders (3cm diameter) separated 
by dividers (25cm diameter) in five lanes, each 57mm wide, was utilized. Before the training 
sessions, the mice were habituated to stay on the rotating rod (4rpm lowest speed) for 3 
sessions lasting 1-2 minutes each and separated by 10’ intervals. Test phase started 30 minutes 
after the last habituation session and consisted of 3 trials separated by 1 inter-trial intervals. For 
each test session the mouse was placed on a rotating rod, which accelerated from 5 to 40 
rpm. Each test session lasted a maximum of 5min. Latency to fall was assessed when the 
mouse was no longer capable of riding on the accelerating rod, due to slipping from the drum 
or clinging to the rod and rotating with it. Test sessions were always performed at the same time 
of the day, mice were tested in a randomized manner and the operator was blind to drug 
treatment. 
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2.8. Brain Homogenization and Immunoprecipitation experiments 
Adult mice Prnpo/o, Prnpo/o, tga20+/+ (Tga20) and C57BL/6J mice were euthanized and brain 
was dissected. Brain samples were snap frozen in liquid nitrogen. Samples were subsequently 
homogenized in ice cold Lysis Buffer (50 mM Tris-Cl, 1% Igepal (NP-40), 75 mM NaCl, pH 7.4) 
supplemented with protease (EDTA-free) and phosphatase inhibitor cocktail mix (Roche). Protein 
concentration was determined using the bicinchoninic acid assay (Pierce). Following 
immunoprecipitation of PrPC with a specific anti-PrP monoclonal antibody (POM1) and addition of 
dynabeads (Life Technologies), samples were prepared in loading buffer (NuPAGE, Invitrogen) 
and boiled at 95 °C for 5 min. The samples were migrated on 4-12% NuPage gels and 
transfered onto the Polyvinylidene difluoride (PVDF) membrane. 
2.9. Whole-genome single nucleotide polymorphisms analysis 
Tail biopsies from Grm5-/-, Grm5+/- and Grm5+/+ littermates were collected and sent to Taconic 
Laboratories so as to perform whole-genome SNP analysis, using the Illumina Mouse MD 
Linkage Panel array. Results were compared with data from reference strains (129S6/SvEvTac, 
C57BL/6JBomTac). 
2.10. Antibodies and Chemicals 
All compounds were purchased from Sigma-Aldrich unless otherwise stated. Monoclonal anti 
PrP antibody POM1 (1:5000) was generated as described previously (Polymenidou et al., 2008). 
Anti-mGluRs antibodies against representative receptors of each group, targeting the N-terminal 
domain were utilized: anti-mGluR5 #ab53090 (AbCam) or AB5675 (Millipore), anti-mGluR1 
[EPR13540] (ab183712) (AbCam), anti-mGluR2+3 #ab6438 (AbCam) and anti-mGluR6 #AGC-
026 (Alomone labs). Secondary antibodies were horseradish peroxidase (HRP)- conjugated rabbit 
anti–mouse IgG1  (1:10,000, Zymed)  and  goat  anti-rabbit IgG1  (1:10,000,  Zymed).  Blots were 
developed using SuperSignal West Pico chemiluminescent substrate (Pierce) and visualized 
using the VersaDoc system (model 3000, Bio-Rad).  Rocky Mountain Laboratory strain (RML; 
passage #6) prions (RML6) were amplified in CD1 mice by intracerebral inoculation into the 
lateral forebrain of 30 µl of 1% (wt/vol) brain homogenate. The mGluR5 antagonist MPEP was 
a gift from Novartis. The mGluR1 antagonist YM202074 was purchased from Tocris Bioscience 
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(Ellisville, USA). 
2.11. Immunohistochemistry and NeuN morphometry 
Immunohistochemistry of fixed organotypic slices and subsequent NeuN morphometric analysis 
was performed according to previously published protocols (Falsig et al., 2012; Sonati et al., 
2013).  
2.12. Histology and immunohistochemistry 
Stainings were performed on sections from brain tissues fixed in formalin and treated with 
concentrated formic acid to inactivate prions. Partially protease-resistant prion protein deposits, 
astrogliosis and microglia deposition were visualized by staining brain sections with the SAF84 
antibody (1∶200, SPI bio), GFAP (1∶1000, Millipore) and IBA1 (1∶2500, WAKO) respectively on 
a NEXES immunohistochemistry robot (Ventana instruments) using an IVIEW DAB Detection 
Kit (Ventana), after preceding incubation with protease 1 (Ventana). Images of DAB stained 
sections were acquired using the NanoZoomer scanner (Hamamatsu Photonics) and 
NanoZoomer digital pathology software (NDPview; Hamamatsu Photonics). Quantifications of 
IBA1, GFAP staining and vacuoles in mouse sections were performed on acquired image 
regions of interest were drawn on a Digital Image Hub (Leica Biosystems) and analyzed as 
previously described (Sorce et al., 2014). 
2.13. Primary neuron culture 
Hippocampal neurons were prepared from embryonic day 18 (E18) C57/BL6 mice (Janvier 
Labs, France). Freshly dissociated (trypsin) cells were plated (80,000 cells per 18 mm coverslip 
per ml) in neuronal attachment media consisting of 10% horse serum, 1 mM sodium pyruvate, 
and 2 mM glutamine in MEM for 3h. The attachment medium was replaced and cells were 
maintained in serum-free neurobasal medium supplemented with B27 (1X) and glutamine (2 
mM). 300 µl of fresh medium was added once a week. 
2.14. Plasmids and Transfection 
mGluR5-pHllorin construct was generated and kindly provided by Lili Wang and Christian Specht. 
Dendra2 was inserted between residues Q222 and A223 of mouse prion protein. GluN2A-GFP 
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was kindly provided by Andrea Yao and Pierre Paoletti. Transfection was performed on DIV 17-
18 neurons using Lipofectamine® as described recently (Shrivastava et al., 2015). Transfection 
medium (TM) was composed of 1 mM sodium pyruvate and 2 mM glutamine in nerobasal medium 
(Invitrogen). 0.5 µg of plasmid and 2 µl of lipofectamine- 2000 reagent were used for each 
coverslip. Experiments were performed on DIV 21-22. 
2.15. Immunocytochemistry and Image Analysis 
Immunocytochemistry of mGluR5 (rabbit polyclonal, Millipore, AB5675, 1:200 dilution) or GluR2-
AMPA receptor (rabbit polyclonal, Synaptic System, 182103, 1:400 dilution) was performed 
following methanol fixation/permeabilization (10 min at -20ºC; methanol pre-stored at -20º). 
Image thresholding using wavelet decomposition to identify fluorescent clusters (mGluR5 and 
GluR2-AMPA immunoreactivity or GluN2-GFP fluorescence) has been described in previous 
studies (Shrivastava et al., 2015; Renner et al., 2010). Images were acquired using Leica 
Inverted Spinning Disk microscope (DM5000B, Coolsnap HQ2 camera, Cobolt lasers) using 100X 
objective (field of view = 1392 x 1040 pixels) and a pixel size of 60.5nm. For estimation of 
mGluR5 fluorescence within dendritic spines, ratio of fluorescence within a circular region of 
fixed size (6 pixel) on spine head to the shaft below was measured using ImageJ program.
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3.1. Pharmacological inhibition of group-I mGluRs rescues prion-induced 
neurotoxicity in organotypic slice cultures 
Cerebellar and hippocampal organotypic cultured slices (COCS and HOCS, respectively) (Falsig et 
al., 2008; Gogolla et al., 2006) prepared from PrPC overexpressing (tga20) mice can be efficiently 
infected with the Rocky Mountain Laboratory (RML) strain of prions and undergo neurodegeneration 
after ca. 5 weeks (Falsig et al., 2008). The time course and extent of neurodegeneration can be 
reliably measured by morphometric assessment of the area of the cerebellar granule cell layer (CGL) 
immunoreactive to antibodies against the neuronal NeuN antigen. We therefore inoculated COCS and 
HOCS with brain homogenate from CD1 mice infected with RML prions (passage #6, henceforth 
called RML6). For control, slices were inoculated with non-infectious brain homogenate (NBH) derived 
from healthy CD1 mice. Starting at 21 days post infection, slices were treated with a range of 
concentrations of either N-cyclohexyl-6-N-methylthiazolo[3,2-a]benzimidazole-2-carboxamide 
(YM202074) (Kohara et al., 2008) or 2-methyl-6-(phenylethynyl)-pyridine (MPEP) (Gasparini et al., 
1999) which specifically inhibit mGluR1 and mGluR5, respectively. Morphometry revealed that MPEP 
and YM202074 significantly prevented CGL loss in treated COCS at concentrations as low as 10 nM 
(Figure 3.1.A-B) and 500 nM (Figure 3.1.C-D), respectively. Higher MPEP concentrations (3-10 M) 
were not intrinsically toxic (Figure 3.2.A), as previously reported (Gasparini et al., 1999), but failed to 
protect against prion toxicity (Figure 3.2.B). Expression levels of mGluR5 in COCS were assessed 
(Figure 3.2.C-D). MGluR5 expression in the cerebellum was comparable to that of hippocampus and 
cortex. Results were in accordance with previous studies reporting high mGluR5 levels at early 
developmental stages (Romano et al., 1996a). Also in HOCS, prepared from 4-6 days old tga20 mice, 
MPEP significantly suppressed neuronal loss after prion infection at concentrations as low as 36 nM 
(Figure 3.1.E-F).  
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Figure  3.1. Group-I mGluR inhibition rescues prion neurotoxicity in organotypic slice cultures 
(A-B) Treatment with the mGluR5 inhibitor (MPEP) rescued neurodegeneration in tga20 RML6-
treated COCS. (A) Fluorescence micrographs of tga20 COCS, showing ablation of the cerebellar 
granular layer (CGL) induced by RML6 infection, that is significantly ameliorated by addition of MPEP, 
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the mGluR5 inhibitor, (C=10nM-1µM). (B) Graphical representation of NeuN morphometry of tga20 
COCS exposed to RML6 or NBH and treated with MPEP from 21–42 days post inoculation (dpi). (C-
D) Treatment with the mGluR1 inhibitor (YM202074) rescued neurodegeneration in tga20 RML6-
treated COCS. (C) Fluorescence micrographs of tga20 COCS, showing ablation of the cerebellar 
granular layer (CGL) induced by RML6 infection, that is significantly ameliorated by addition of  
YM202074, the mGluR1 inhibitor, (C=500nM-1µM).  (D) Graphical representation of NeuN 
morphometry of tga20 COCS exposed to RML6 or NBH and treated with YM202074 from 21–42 dpi. 
(E-F) Treatment with the mGluR5 inhibitor (MPEP) rescued neurodegeneration in tga20 RML6-treated 
HOCS.  (E) Fluorescence micrographs of tga20 HOCS, showing ablation of the hippocampal neuronal 
layer induced by RML6 infection (middle), that is significantly ameliorated by addition of the IC50 
concentration of MPEP (C=36nM) (right). (F) Graphical representation of NeuN morphometry of tga20 
HOCS exposed to RML6 or NBH and treated with MPEP from 21–42 dpi.  
For (B), (D) and (F) panels: Scatter dot plots represent NeuN relative signal intensity as percentage of 
NBH samples; each dot corresponds to a pool of 7-10 cerebellar slices or 4-6 hippocampal slices 
cultured in the same well; Data are presented as mean ± s.d.; One-way ANOVA followed by Dunnet’s 
post-hoc test. Panel (B): (NBH, n = 30 pools; RML6, n = 30 pools; RML6+10nM MPEP, n = 31 pools; 
RML6+36nM MPEP, n = 18 pools; RML6+100nM MPEP, n = 18 pools; RML6+500nM MPEP, n = 18 
pools; RML6+1µM MPEP, n = 17 pools; *: P < 0.05, **: P < 0.01, ***: P < 0.001. Panel (D): (NBH, n = 8 
pools; RML6, n = 8 pools; RML6+500nM YM202074, n = 8 pools; RML6+1µM YM202074, n = 8 pools); 
***: P < 0.001. Panel (F): (NBH, n = 7 pools; RML6, n = 8 pools; RML6+36nM MPEP, n = 15 pools); **: 
P < 0.01, ***: P < 0.001.  
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Figure 3.2. Assessment of mGluR5 expression levels and the effect of high concentrations 
of the mGluR5 inhibitor (MPEP) in cerebellar organotypic cultured slices (COCS) 
(A) Fluorescence micrographs of COCS, showing no toxicity on slices treated with high 
concentrations (C=3-10µM) of MPEP. (B) Fluorescent micrographs of COCS, infected with 
RML6 and treated with high concentrations (C=3-10µM) of MPEP. High concentrations of MPEP 
are not protective against prion infection. (C) MGluR5 localization in Tga20 COCS. MGluR5 
(green) is highly expressed in neuronal and non- neuronal cell populations in the cerebellar 
slices. Neurons were stained with an antibody against NeuN (red), nuclei were counterstained 
with DAPI (blue). Granular cell layer was imaged by confocal microscopy. (D) Cerebellar 
extracts from Grm5-/-, Grm5+/- and Grm5+/+ mice, collected at postnatal day 10 (comparable 
with the organotypic slices), were subjected to western blot analysis to control for endogenous 
levels of mGluR5. MGluR5 expression in the cerebellum was comparable to that of 
hippocampus and cortex.  
3.2. MPEP alleviates the clinical signs of prion disease in mice  
The beneficial effects of mGluR5 inhibition ex vivo encouraged us to assess a possible therapeutic 
effect of MPEP on prion pathogenesis in vivo. C57BL/6J male mice were inoculated intracerebrally 
with 3 or 5 log LD50 units of RML6 prions as previously described (Kranich et al., 2010), and 
chronically treated with MPEP.  Control mice were inoculated with NBH. In order to record the 
neurological deficits associated with prion disease, we utilized the rotarod behavioral test which 
measures a combination of motor performance, coordination, and balance (Brooks and Dunnett, 
2009). Rotarod performance was similar in RML6- and NBH (control)-inoculated mice until 18 weeks 
following prion inoculation. Starting from 19 weeks post inoculation, mice receiving control food 
showed a progressive decline in rotarod performance, whereas the performance of MPEP-treated 
mice declined significantly less. This improvement was lasting and detectable until the very late 
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stages of the disease (22-23 weeks post inoculation; Figure 3.3.A-B), suggesting that the progression 
of the disease was delayed by MPEP.  
At very late time points, the general health status of all mice deteriorated to an extent that made it 
impossible to accurately measure their rotarod performance. Nevertheless, MPEP-treated mice 
showed a modest, though significant, prolongation of survival (Figure 3.3.C-D). The median survival 
for untreated vs MPEP-treated RML6-inoculated C57BL/6J mice was, respectively, 183 vs 190 days 
post inoculation (dpi) after injection with 3 log LD50 units of prions and 188 vs 195 dpi after inoculation 
with 5 log LD50 units (P=0.0008 and 0.0231 respectively; log-rank test). Control mice injected with 
NBH and treated with MPEP exhibited stable rotarod performance during the entire test period, up to 
23 weeks post-injection (Figure 3.4.A). No significant changes in average food and water 
consumption were observed between control and treatment groups during the experiment (Figure 
3.4.B). So as to determine the exposure of the brain to MPEP, mice treated with control and MPEP 
food were sacrificed in two different timepoints, corresponding to the active and the inactive phase of 
the mice across the circadian circle. Average brain to blood ratio for the MPEP concentration was 
measured to be around 1, suggesting good access of MPEP to the brain (Figure 3.4.C).  
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Figure 3.3. mGluR5 inhibition delays clinical manifestation of prion disease in wt mice 
(A-B) mGluR5 pharmacological inhibition (MPEP treatment) significantly improves motor performance 
in mouse models of prion disease.  Motor abilities of MPEP treated and MPEP untreated C57BL/6J 
males were assessed with the rotarod test at specified time points after i.c. inoculation with 3log LD50 
(A) and 5log LD50 (B) units of RML6 prions respectively. Scatter dot plots show the time spent by 
each mouse on the rotating rod (latency to fall) expressed in seconds (s). Each dot corresponds to a 
mouse. Two-way ANOVA per each time point revealed a significant difference between MPEP treated 
and MPEP untreated groups at 19-22wpi (*: P <0.05 and **: P <0.01) for mice injected with 3log LD50 
RML6 units and at 21-23wpi (*: P <0.05 and **: P <0.001) for mice injected with 5log LD50 RML6 units 
respectively, n=10 mice per group. (C-D) mGluR5 inhibition (MPEP treatment) significantly prolongs 
survival in mouse models of prion disease. Survival curves of MPEP treated and MPEP untreated 
C57BL/6J males, inoculated i.c. with 3log LD50 and 5log LD50 units of RML6 prions respectively. (C) 
Mice inoculated with 3log LD50 RML6 units: MPEP untreated group, n=10, median incubation time 183 
days post inoculation (dpi). MPEP treated group, n=10, median incubation time 190dpi; P=0.0008; 
log-rank test. (D) Mice inoculated with 5log LD50 RML6 units: MPEP untreated group, n=10, median 
incubation time: 188.5 dpi, P=0.0008; MPEP treated group, n=10, median incubation time: 195dpi, 
P=0.0231; log-rank test.   
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Figure 3.4. MPEP is effectively delivered to the brain, does not induce changes in food and 
water consumption and rotarod performance of non-infectious brain homogenate (NBH) 
inoculated mice 
(A) Control mice injected with NBH and treated with MPEP exhibited stable rotarod 
performance during the entire test period, up to 23 weeks post-injection. Each dot corresponds 
to a mouse. Two-way ANOVA per each time point revealed no significant difference in the latency 
to fall of NBH-injected, MPEP treated mice during the course of the study.  (B) No significant 
changes in average food and water consumption were observed between control and treatment 
(MPEP) groups during the experiment; Data are presented as mean ± s.d.; One-way ANOVA 
followed by Dunnet’s post-hoc test. (C) Mice treated with control and MPEP food were 
sacrificed in two different timepoints, corresponding to the active and the inactive phase of 
the mice across the circadian circle to determine the exposure of the brain to MPEP. The 
results indicated the average brain to blood ratio for the MPEP concentration to be around 1; 
suggesting that the current treatment scheme allows good exposure of the brain to MPEP.  
3.3. mGluR5 and mGluR1 inhibitors protects against prion-mimetic antibodies 
Antibody-derived molecules targeting the globular domain (GD) of PrPC (termed GDLs) are acutely 
neurotoxic (Sonati et al., 2013) and activate similar cascades as bona fide prion infection (Herrmann 
et al., 2015).  To investigate if pharmacological inhibition of mGluR1 and mGluR5 rescues GDL 
toxicity, we exposed tga20 COCS to the GDL agent POM1, followed by YM202074 and MPEP 
treatments. Treatment with POM1 led to almost complete CGL loss within 14 days of treatment. No 
CGL loss occurred in control treatment where POM1 was blocked by pre-incubation with a molar 
excess of recombinant PrP (recPrP). Treatment with MPEP significantly reduced CGL loss in POM1-
treated slices. As with prion infections, MPEP treatment (at concentrations as low as 10 nM) was 
sufficient to rescue the loss of CGL, whereas high concentrations (≥1µM) did not show protective 
activity (Figure 3.5.A-B). 
Single chain POM1 miniantibodies (scPOM1), fusion proteins containing only the variable regions of 
the heavy (VH) and light chains (VL) of the antibody connected with a short linker peptide, were 
previously shown to be sufficient to induce toxicity in COCS (Sonati et al., 2013). The toxicity of 
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scPOM1 was also significantly reduced in the presence of the specific mGluR1 inhibitor (YM202074), 
with protective concentrations as low as 200nM (Figure 3.5.A-B) as well as in the presence of the 
specific mGluR5 inhibitor MPEP (C=36nM) (Figure 3.6.A). No protection was observed upon 
treatment with the selective agonist of group III (L-2-amino-4-phosphonobutyrate (L-AP4)) (Tones et 
al., 1995) and the potent antagonist of group II and group III ((RS)-α-Cyclopropyl-4-phosphonophenyl
glycine (CPPG)) (Toms et al., 1996) metabotropic glutamate receptors (Figure 3.6.C-D). 
Similarly to COCS, HOCS treated with scPOM1 exhibited conspicuous toxicity after 8 days of 
treatment. As in previous experiments, we observed somewhat stronger toxicity of the single-chain 
version of the GDL (scPOM1), perhaps because of its smaller size leading to improved tissue 
penetration. Neuronal loss was monitored by morphometric analysis of NeuN immunofluorescence, 
and was readily visible in GDL-treated samples. In comparison, the survival of hippocampal neurons 
exposed to scPOM1 (Figure 3.5.E-F) was greatly increased by treatment with MPEP.  We conclude 
that toxicity of both infectious prions and prion-mimetic GDLs was prevented by pharmacological 
inhibition of mGluR1 or mGluR5.   
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Figure 3.5. Group-I mGluR inhibition protects against GDL toxicity in organotypic slice 
cultures 
(A-B) Treatment with the mGluR5 inhibitor (MPEP) rescued neurodegeneration in tga20 POM1-
treated COCS. (A) Representative images of tga20 COCS, showing ablation of the cerebellar 
granular layer (CGL) induced by exposure to toxic POM1 antibody, that is significantly ameliorated by 
addition of low concentrations of MPEP (C=10nM-100nM). Higher concentrations of MPEP (C=1µM) 
did not rescue POM1 toxicity. (B) Graphical representation of NeuN morphometry of tga20 slices 
exposed to POM1 or control (POM1 blocked with recPrP) and treated with MPEP from 14–28 days 
post exposure (dpe). (C-D) Treatment with the mGluR1 inhibitor (YM202074) rescued 
neurodegeneration in tga20 scPOM1-treated COCS. (C) Representative images of COCS, showing 
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ablation of the cerebellar granular layer (CGL) induced by exposure to toxic POM1 antibody, that is 
significantly ameliorated by addition of low concentrations of YM202074 (C=200nM-1µM). (D) 
Graphical representation of NeuN morphometry of tga20 slices exposed to scPOM1 or control 
scPOM1 blocked with recPrP and treated with MPEP from 14–22 dpe.  (E-F) Treatment with MPEP 
rescued neurodegeneration in tga20 scPOM1-treated COCS. (E) Representative images of HOCS, 
showing ablation of the hippocampal neuronal layer induced by exposure to toxic scPOM1 antibody 
(middle), that is significantly ameliorated by addition of MPEP (C=36nM). (F) Graphical representation 
of NeuN morphometry of tga20 slices exposed to scPOM1 or control (scPOM1 blocked with recPrP) 
and treated with MPEP from 14–22 dpe.  For (B), (D) and (F) panels: Scatter dot plots represent 
NeuN relative signal intensity as percentage of POM1+recPrP or scPOM1+recPrP control samples; 
each dot corresponds to a pool of 7-10 cerebellar slices or 4-6 hippocampal slices cultured in the 
same well; Data are presented as mean ± s.d.; One-way ANOVA followed by Dunnet’s post-hoc test. 
Panel (B): (Ctrl (POM1+recPrP), n = 18 pools; POM1, n = 18 pools; POM1+10nM MPEP, n = 12 pools; 
RML6+36nM MPEP, n = 7 pools; RML6+100nM MPEP, n = 7 pools; RML6+1µM MPEP, n = 4 pools; ***: 
P < 0.001. Panel (D): (Ctrl (scPOM1+recPrP), n = 7 pools; scPOM1, n = 7 pools; scPOM1+200nM 
YM202074, n = 7 pools; scPOM1+500nM YM202074, n = 7 pools; RML6+1µM YM202074, n = 7 pools; 
1µM YM202074, n = 7 pools); ***: P < 0.001. Panel (F): (Ctrl (scPOM1+recPrP), n = 7 pools; scPOM1, 
n = 7 pools; scPOM1+36nM MPEP, n = 7 pools); ***: P < 0.001. 
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Figure 3.6. Treatment with MPEP, but not L-AP4 and CPPG rescues GDL toxicity in 
cerebellar organotypic cultures slices 
(A-B) Treatment with the mGluR5 inhibitor (MPEP) rescued neurodegeneration in Tga20 scPOM1-
treated COCS. (A) Representative images of Tga20 COCS, showing ablation of the cerebellar 
granular layer (CGL) induced by exposure to toxic scPOM1 antibody, that is significantly 
ameliorated by addition MPEP (C=36nM). (B) Graphical representation of NeuN morphometry of 
Tga20 slices exposed to scPOM1 or control (POM1 blocked with recPrP) and treated with MPEP 
from 14–24 days post exposure (dpe). (C-D) Treatment with the selective agonist of group III (L-
AP4)) and the potent antagonist of group II and group III (CPPG) metabotropic glutamate 
receptors did not rescue neurodegeneration in Tga20 scPOM1-treated COCS. (A) Representative 
images of Tga20 COCS, showing ablation of the cerebellar granular layer (CGL) induced by 
exposure to toxic scPOM1 antibody, that is not ameliorated by addition of L-AP4 (C=500nM) or 
CPPG (C=200nM). (B) Graphical representation of NeuN morphometry of Tga20 slices exposed to 
scPOM1 or control (POM1 blocked with recPrP) and treated with L-AP4 or CPPG from 14–24 dpe. 
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For panels (B) and (D): Scatter dot plots represent NeuN relative signal intensity as percentage of 
POM1+recPrP or scPOM1+recPrP control samples; each dot corresponds to a pool of 7-10 cerebellar 
slices in the same well; Data are presented as mean ± s.d.; One-way ANOVA followed by Dunnet’s 
post-hoc test. Panel (B): (Ctrl (scPOM1+recPrP), n = 8 pools; POM1, n = 7 pools; RML6+36nM MPEP, 
n = 7 pools; ***: P < 0.001. Panel (D): (Ctrl (scPOM1+recPrP), n = 12 pools; scPOM1, n = 10 pools; 
scPOM1+500nM L-AP4, n = 5 pools; scPOM1+200nM CPPG, n = 5 pools; 500nM L-AP4, n = 5 pools; 
200nM CPPG, n = 4 pools. 
 
3.4. Toxicity of prions and prion-mimetic antibodies in Grm5-/- mice 
 Cerebellar organotypic slice cultures from Grm5-/-, Grm5+/- and Grm5+/+ littermates were treated with 
the anti-GD antibody POM1 (Polymenidou et al., 2008), which acts as a prion-mimetic compound. 
Exposure to POM1 led to the loss of cerebellar granular layer (CGL) neurons in Grm5+/+ slices, but not 
in Grm5-/- and Grm5+/- slices (Figure 3.7.A-B). Cerebellar and hippocampal organotypic slice cultures 
from Grm5-/-, Grm5+/- and Grm5+/+ littermates were then inoculated with brain homogenate from CD1 
mice infected with RML prions (RML6) or control NBH homogenate. In both COCS and HOCS, 
genetic ablation of mGluR5 was protective against prion induced toxicity (Figures 3.7.C-D and 4.7.E-
F). 
To assess the role of mGluR5 in prion infections in vivo, we infected Grm5-/-, Grm5+/-, and control 
Grm+/+ littermates with RML6 prions (5 log LD50). Again, we utilized the rotarod test. All RML6 
inoculated mice showed similar rotarod performance during monitoring; with Grm5-/- mice showing a 
tendency towards better motor performance in general (Figure 3.7.G).  However, no significant 
difference in survival was observed between Grm5-/-, Grm5+/- and Grm5+/+ mice (Figure 3.8.A).  
The group-I metabotropic glutamate receptors, mGluR1 and mGluR5, can both associate with PrPC 
and induce similar intracellular pathways (Beraldo et al., 2011) suggesting functional redundancy 
between these two receptors. In order to detect any epistasis between mGluR1 and mGluR5, we 
assessed mGluR1 and mGluR5 protein levels in hippocampus and cerebellum of Grm5-/-, Grm5+/- and 
Grm5+/+ mice. Expression decreased in all brain regions with increasing age. In hippocampi we 
observed increased expression of the mGluR1 in samples from Grm5-/- mice at 10-day and 53-d old, 
compared to heterozygous and wild type control littermates. (Figure 3.8.D right panel, lanes 3 and 9). 
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We additionally analyzed whole-brain lysates to control for mGluR1 and mGluR5 level changes 
between young and old mice.  Samples from 44-day old Grm5-/- mice show higher expression levels 
of mGluR1 to heterozygous and wt control littermates. At later time points expression levels of 
mGluR1 were similar between samples (Figure 3.8.F). These results point to compensatory 
mechanisms between mGluR1 and mGluR5. We further sought to evaluate whether treatment with 
MPEP has a similar effect on the expression of mGluR1. MGluR1 expression levels were assessed in 
whole-brain lysates from 1-year old control wt mice, NBH-inoculated wt mice, and NBH-inoculated wt 
mice that received MPEP food. No differences were observed in the mGluR1 expression levels 
between the samples (Figure 3.8.B). 
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Figure 3.7. Grm5 ablation protects against GDL and prion-induced neurotoxicity in slice 
cultures but does not prolong survival in vivo 
 (A-B) Genetic ablation of Grm5 rescued GDL-induced neurodegeneration in COCS. (A) 
Representative images of COCS, showing ablation of the cerebellar granular layer (CGL) induced by 
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exposure to 67nM of toxic POM1 antibody in control GRM5+/+ slices, that is significantly ameliorated 
by the genetic deletion of GRM5 (GRM5+/- and GRM5-/- slices). (B) Graphical representation of NeuN 
morphometry of GRM5+/- and GRM5-/- and GRM5+/+ slices exposed to POM1 or control (POM1 
blocked with recPrP) from 14–42 dpe.  
(C-D) Genetic ablation of Grm5 rescued prion-induced neurodegeneration in COCS. (C) 
Representative images of COCS, showing ablation of the cerebellar granular layer (CGL) induced by 
RML6 infection in control GRM5+/+ slices, that is significantly ameliorated by the genetic deletion of 
GRM5 (GRM5+/- and GRM5-/- slices). Slices were maintained in culture for 60dpi. (D) Graphical 
representation of NeuN morphometry of GRM5+/- and GRM5-/- and GRM5+/+ slices exposed to RML6 
or NBH. (E-F) Genetic ablation of Grm5 rescued prion-induced neurodegeneration in HOCS. (E) 
Representative images of HOCS, showing ablation of the hippocampal neuronal layer induced by 
RML6 infection in control GRM5+/+ slices, that is significantly ameliorated by the genetic deletion of 
GRM5 (GRM5-/- slices). Slices were maintained in culture for 60dpi.  (F) Graphical representation of 
NeuN morphometry of GRM5+/- and GRM5-/- and GRM5+/+ slices exposed to RML6 or NBH. RML6-
induced neurodegeneration is rescued in the GRM5+/- and GRM5-/- HOCS. 
For (B), (D) and (F) panels: Scatter dot plots represent NeuN relative signal intensity as percentage of 
control samples (Grm5+/+, NBH or POM1+recPrP) ; each dot corresponds to a pool of 7-10 cerebellar 
slices or 4-6 hippocampal slices cultured in the same well; Data are presented as mean ± s.d.; One-
way ANOVA followed by Dunnet’s post-hoc test. Panel (B): (Ctrl (Grm5+/+, POM1+recPrP), n = 8 
pools; Grm5+/+, POM1, n = 18 pools; Grm5+/-, POM1+recPrP, n = 6 pools; Grm5+/-, POM1, n = 6 pools; 
Grm5-/-, POM1+recPrP, n = 7 pools; Grm5-/-, POM1, n = 15 pools; ****: P < 0.0001. Panel (D): (Ctrl 
(Grm5+/+, NBH), n = 5 pools; Grm5+/+, RML6, n = 8 pools; Grm5+/-, NBH, n = 5 pools; Grm5+/-, RML6, 
n = 4 pools; Grm5-/-, NBH, n = 7 pools; Grm5-/-, RML6, n = 11 pools; *: P < 0.05, **: P < 0.01. Panel (F): 
(Ctrl (Grm5+/+, NBH), n = 5 pools; Grm5+/+, RML6, n = 7 pools; Grm5+/-, NBH, n = 5 pools; Grm5+/-, 
RML6, n = 6 pools; Grm5-/-, NBH, n = 7 pools; Grm5-/-, RML6, n = 12 pools; *: P < 0.05. (G) MGluR5 
genetic deletion does not significantly improve motor performance in mouse models of prion disease. 
Motor abilities of GRM5+/+, GRM5+/- and GRM5-/- mice were assessed with the rotarod test at specified 
time points after i.c. inoculation with 5log LD50 units of RML6 prions. Scatter dot plots show the time 
spent by each mouse on the rotating rod (latency to fall) expressed in seconds (s). Each dot 
corresponds to a mouse. Two-way ANOVA per each time point revealed a non-significant difference 
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(ns: P>0.05) between GRM5+/+, GRM5+/- and GRM5-/- groups at 7-22wpi for mice injected with 5log 
LD50 RML6 units respectively, n=7-13 mice per group. 
  
Figure 3.8. Grm5 genetic deletion does not significantly prolong survival of prion-infected 
mice - a compensatory mechanism between mGlu1 and mGlu5 receptors 
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(A) Survival curves of GRM5+/+, GRM5+/- and GRM5-/- groups, inoculated i.c. with 5log LD50 
units of RML6, n=4-6 males per group. Each dot corresponds to a mouse. Two-way ANOVA 
per each time point revealed a non-significant difference between GRM5+/+, GRM5+/- and GRM5-
/- groups. (B) Total brain extracts from mice inoculated with NBH and received control or mpep 
foods, as well as control wt brain lysates, were subjected to western blot analysis to evaluate 
whether mpep treatment changes the expression of mGlu1 receptor. No differences were 
observed in the mGluR1 expression levels between the samples. (C-D) Epistatic expression of 
mGlu1 and mGlu5 receptors. Total brain extracts from different brain regions - cerebellum 
(C), hippocampus (D) -  were subjected to western blot analysis to control for endogenous 
levels of both mGluR1 (right panel) and mGluR5 (left panel) in samples collected from different 
age groups (10day, 44day, 53day) of Grm5-/-, Grm5+/- and Grm5+/+  mice. At postnatal day 10 
(comparable with the organotypic slices), mGluR5 expression in the cerebellum is similar to that 
of hippocampus. Over time, expression decreases in both brain regions. In hippocampi we 
observed increased expression of the mGluR1 in samples from Grm5-/- mice at 10-day and 53-d 
old, compared to heterozygous and wild type control littermates. (figure 3.8.D: right panel, lanes 
3 and 9). (E) Total brain extracts from 44day, 53day and 122 days old Grm5-/-, Grm5+/- and 
Grm5+/+ were in parallel subjected to western blot analysis to control for endogenous levels of 
mGluR1 and mGluR5 in young and old mice. Samples from 44-day old Grm5-/- mice show 
higher expression levels of mGluR1 to heterozygous and wild type control littermates. In the 
later time points expression levels of mGlur1 are comparable between the samples. #: band 
corresponds to the mGluR1 or mGluR5 monomer. ##: band corresponds to the mGluR1 or 
mGluR5 dimer. 
3.5. PrPC interacts with mGluR1 and mGluR5 in vivo 
PrPC has been reported to interact with mGluR1 and mGluR5 (Beraldo et al., 2011; Um et al., 2013). 
To test whether PrPC interacts with group-I mGluRs in vivo, brain homogenates from wild-type 
(C57BL/6J) or Prnp knockout mice (Prnpo/o) were subjected to immunoprecipitation using antibody 
POM1 against PrPC, followed by western blotting with antibodies to mGluR1 and mGluR5. The group-
I mGlu receptors, which migrate as functionally active oligomers at 250kDa (Romano et al., 1996b), 
were found to co-precipitate with PrPC (Figure 3.9.A left and right panels, lanes 5). For control, we 
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performed immunoprecipitations in the presence of non-specific pooled immunoglobulins (IgG) and 
blocked the antigen-recognition domain of POM1 with recombinant PrP. Under neither condition did 
we observe mGluR1 and mGluR5 co-immunoprecipitating with PrP (Figure 3.10.A left and right 
panels, lanes 3 and 4). Western blots from the total brain lysates (TEs) did not reveal any changes in 
the concentration of mGluR1 and mGluR5 protein between wild-type and Prnpo/o homogenates 
(Figure 3.10.A, lanes 7-8). Other mGluRs (mGluR6, mGluR2/3) did not co-precipitate, confirming the 
specificity of the interaction (Figure 3.10.B).  
The PrPC residues 91-153 participate to the interaction with mGluR5 (Haas et al., 2014).We sought to 
confirm these findings and to identify the domain of PrPC mediating its interaction with mGluR1. We 
studied a panel of transgenic mice expressing variants of PrPC bearing deletions in the flexible tail 
(FT) regions, designated ∆C, ∆CC, ∆F, ∆OR, and ∆HC (Figure 3.10.C). The relevance of these 
mutants to prion disease was previously reported (Baumann et al., 2007a; Bremer et al., 2010; 
Flechsig et al., 2000; Shmerling et al., 1998; Weissmann et al., 1998). As expected, mGluR1 and 
mGluR5 co-precipitated with PrPC. Deletions affecting residues 32-110 (as in the transgenic lines C 
and CC, lacking the central domain and the charge cluster regions of PrPC, respectively) reduced the 
interaction of PrPC with mGluR5 (Figure 3.9.B, lanes 3 and 5). Deletions extending from residues 51 
to 90, as in the transgenic line ∆OR, (Figure 3.9.B, lane 4) increased the interaction with mGluR5, yet 
reduced the interaction with mGluR1 (Figure 3.9.C, lane 4). These results suggest that the interaction 
domain between PrPC and mGluR5 is larger than previously inferred, with residues 32-110 
participating to the in vivo interaction.   
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Figure 3.9. Mapping the mGluR1 and mGluR5 interacting regions on PrPC  
(A) PrPC interacts with group I metabotropic glutamate receptors. Brain homogenate from wild-type 
(C57BL/6J) and Prnpo/o mice was subjected to immunoprecipitation by POM1 (monoclonal anti-PrPC 
antibody) followed by immunobloting using polyclonal anti-mGluR5 (right panel) or anti-mGluR1 (left 
panel) and anti-PrPC antibodies to detect mGluR5/mGluR1 and PrPC respectively. Control conditions 
(POM1 blocked by recombinant PrPC) were run in parallel to ensure the specificity of the selected 
mGluR5/mGluR1 antibodies. A specific band of 250kDa was detected in wild-type immunoprecipitates 
only when immunoblotting with the specific mGluR5 antibody. Specific bands of 250kDa and 150kDa 
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(corresponding to the dimer and monomer of the receptor) were detected in wild-type 
immunoprecipitates only when immunoblotting with the specific mGluR1 antibody.  Total brain 
extracts were in parallel subjected to Western blot analysis to control for endogenous levels of 
mGluR5/1 and PrPC. (B-C) Mapping the mGluR1 and mGluR5 interacting domains on PrPC. Brain 
homogenate from wild-type and Prnpo/o and aminoterminal deletion mutants was subjected to 
immunoprecipitation by POM1, followed by immunobloting using polyclonal anti-mGluR5 (B) or anti-
mGluR1 (C) and anti-PrPC antibodies to detect mGluR5/1 and PrPC respectively. Deletions extending 
from residues 32-93 and 94 to 110- corresponding to the ∆C (deletion of the central domain) and the 
∆CC (deletion of the charged cluster region of PrPC), reduced the interaction with mGluR5, whereas 
deletions extending from residues 51 to 90, corresponding to the ∆OR (deletion of the octarepeat 
region on PrPC), decreased the interaction with mGluR1. Total brain extracts (TEs) were subjected to 
Western blot analysis to control for endogenous levels of mGluR5/1 and PrPC. Densitometric 
quantitation of mGluR1 or mGluR5 signal from the immunoprecipitation was normalized over the 
ration of Grm/Actin signal in TEs. Graph bars represents mGluR1 or mGluR5 relative signal intensity; 
N=3-5; One-way ANOVA followed by Tukey’s post-hoc test; ns: P>0.05.  
*: band corresponds to the light chain of the POM1 antibody.  **: band corresponds to recombinant 
PrP. #: band corresponds to the mGluR1 monomer.  ##: band corresponds to the mGluR1 dimer.  
 
The Role of Group I Metabotropic Glutamate Receptors in Prion Induced Toxicity PhD Dissertation 
 
 
127  Despoina G. Goniotaki – October, 2016  
  
  
Figure 3.10. PrPC specifically interacts with mGluR1/5 and not with group II and III mGluRs 
(A) Brain homogenate from (C57BL/6J) and Prnpo/o
 
mice was subjected to immunoprecipitation by 
POM1 (monoclonal anti-PrPC antibody) followed by immunobloting using polyclonal anti-mGluR5 
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(left panel) or anti-mGluR1 (right panel) and anti-PrPC antibodies to  detect  mGluR5/mGluR1  and  
PrPC respectively. Control conditions (unconjugated beads, IgG bound beads and POM1 
blocked by recombinant PrPC) were run in parallel to ensure the specificity of the selected 
mGluR5/mGluR1 antibodies. A specific band of 250kDa was detected in wild-type 
immunoprecipitates only when immunoblotting with the specific mGluR5 antibody. Specific 
bands of 250kDa and 150kDa (corresponding to the dimer and monomer of the receptor) were 
detected in wild-type immunoprecipitates only when immunoblotting with the specific mGluR1 
antibody. Total brain extracts were in parallel subjected to Western blot analysis to control for 
endogenous levels of mGluR5/1 and PrPC. *: band corresponds to the light chain of the POM1 
antibody.  **: band corresponds to the recombinant PrP. #: band corresponds to the mGluR1 
monomer. ##:  band corresponds to the mGluR1 dimer. (B) Brain homogenate from wild-type 
(C57BL/6J) and Prnpo/o mice was subjected to immunoprecipitation by POM1 (monoclonal, anti-
PrPC antibody) followed by immunoblotting using polyclonal anti-mGluR2/3and anti-mGluR6, or 
anti-PrPC antibodies to detect group II and III glutamate receptors and PrPC, respectively. Group 
II and III receptors (mGluR2/3 and mGluR6) were not associated with PrPC, indicating a 
specificity of this interaction for group-I mGluRs. (C) Schematic representation of PrPC 
deletion mutants. 
3.6. MPEP treatment reduces vacuole size and astrogliosis in prion-infected 
mice 
PrPSc deposition is accompanied by neurodegeneration, vacuole formation and activation of microglia 
and astrocytes (Brown and Sassoon, 2004). MPEP treatment did not affect the accumulation of PrPSc 
in prion-infected mice and slices (Figure 3.12.A-B). However, it did affect vacuole formation. We 
analyzed the extent of vacuolation in the granular layer of the cerebellum (CGL) and in the 
hippocampus. Although the numbers of vacuoles in control and MPEP treated groups were similar, 
vacuole size was significantly reduced in cerebella and hippocampi of MPEP-treated mice (Figure 
3.11.A-B).  Astrogliosis, assessed by immunohistochemistry for glial fibrillary acidic protein (GFAP), 
was prominent at the terminal stage of prion infected mice but not in NBH-inoculated mice. 
Astrogliosis was unaltered by MPEP in the cerebellar granule cell layer (Figure 3.12.C), but was 
markedly reduced in the hippocampus of MPEP-treated, RML6-infected (3 log) group (Figure 3.10.C).  
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Figure 3.11. MPEP treatment reduces vacuole size and astrogliosis in prion-infected mice 
(A-B) Representative images of hematoxylin and eosin-stained cerebellar and hippocampal sections 
from C57BL/6J mice injected i.c. with NBH or RML6 prions and treated with control or MPEP-
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containing food respectively. Number of spongiform vacuoles was quantified in cerebellar cortex and 
hippocampal CA (Cornu Ammonis) areas. Cerebellum: control-food treated animals: vacuole area 
(0.4m2), MPEP-food treated animals: vacuole area (0.1µm2), Hippocampus: control-food treated 
animals: vacuole area (0.18µm2), MPEP-food treated animals: vacuole area (0.03µm2). Each graph 
corresponds to a treatment group. 10 regions of interest per slice, 4 slices per mouse and 4 mice per 
treatment group were used for quantification. (C) Astrocyte proliferation was analyzed by 
immunohistochemistry with the GFAP antibody in paraffin-embedded sections of hippocampal areas 
from C57BL/6J mice injected i.c. with NBH or RML6 prions and treated with control or MPEP-
containing food respectively. Number of GFAP+ cells was quantified in the hippocampus. Each graph 
corresponds to a treatment group. GFAP staining was markedly reduced in the MPEP-treated, RML6 
3log group. Dot blots represent mean ± SD GFAP expression, quantified as the percentage of the 
surface occupied by the GFAP staining over the total measured area; 10 regions of interest per slice, 
4 slices per mouse and 4 mice per treatment group were used for quantification. ***P<0.0001; two-
way ANOVA followed by Bonferroni's post-hoc test. 
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Figure 3.12. PrPSc accumulation in prion-infected slices or in the brain of prion-infected mice 
is not altered by MPEP treatment 
(A) Total PrP and PrPSc levels (detected by addition of proteinase K (PK)) in homogenates 
from different brain regions (cortex, hippocampus, and cerebellum) of terminal C57BL/6J mice 
injected i.c. with NBH or RML6 prions and treated with control or MPEP-containing food 
respectively. Control NBH and RML6 samples, with or without addition of PK were run in parallel. 
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(B) Total PrP and PrPSc levels (detected by addition of proteinase K (PK)) in homogenates from 
RML6 infected cerebellar slices prepared from Tga20 or PrPo/o mice. Cerebellar slices infected 
with RML6 prions were also treated with MPEP according to the previously described protocol. 
Control NBH samples, with or without addition of PK were run in parallel. (C) Astrocyte 
proliferation was analyzed by immunohistochemistry with the GFAP antibody on cerebellar sections 
from C57BL/6J mice injected i.c. with NBH or RML6 prions and treated with control or MPEP-
containing food respectively. Number of GFAP+ cells was quantified in the cerebellar granular 
layer (CGL). Dot blots represent mean ± SD GFAP expression, quantified as the percentage of the 
surface occupied by the GFAP staining over the total measured area; 10 regions of interest per 
slice, 4 slices per mouse and 4 mice per treatment group were used for quantification; two-way 
ANOVA followed by Bonferroni's post-hoc test. 
3.7. Prion-mimetic antibodies increase mGluR5 and PrPC translocation to 
dendritic spines 
Clusters of mGluR5s accumulate around excitatory synapses, and increased size of synaptic 
mGluR5s clusters is associated with toxic calcium influx (Renner et al., 2010; Shrivastava et al., 2013; 
Um et al., 2013). Therefore, we asked whether the prion-mimetic POM1 antibody altered the 
clustering of mGluR5s. Immunofluorescent analysis of mGluR5s clusters was performed on primary 
hippocampal neurons following exposure to the anti-PrPC F(ab)1 antibody fragments, POM1, POM2, 
and POM3 (Sonati et al., 2013). Exposure of cultures to POM1, but not to POM2 or POM3, increased 
the fluorescence intensity of mGluR5s clusters (Figure 3.13.A-B). In contrast, the cluster size of 
NMDA and AMPA receptors was not modified by anti-PrP antibodies (Figure 3.14.). Next, we 
quantified the fluorescence level of mGluR5s in dendritic spines of neurons expressing mGluR5-
pHluorin. We observed increased accumulation of mGluR5s in dendritic spines following exposure to 
POM1, but not to POM2 or POM3 (Figure 3.13.C-D).  
Both mGluR5 and PrPC are enriched in postsynaptic densities (PSD) (Um et al., 2013). In order to 
assess if the changes in mGluR5s level in spines correlated with PrPC level in spines, we performed 
photo-activated localization microscopy (PALM) on neurons expressing a PrPC-Dendra fusion protein 
(Figure 3.13.E). PALM images were obtained from single-molecule detection events rendered with a 
pixel size of 20 nm. The PrPC-Dendra fluorescence patterns showed both clustered and diffuse 
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staining (Figure 3.13.E, control); we observed increased enrichment within dendrites spines following 
POM1 but not POM1+2 exposure (Figure 3.13. E-F). Furthermore, exposure to Fab1-POM2, which 
was previously found to protect against POM1 toxicity (Sonati et al., 2013), induced a subtle but 
significant reduction in PrPC enrichment within dendritic spines. Therefore, Fab1-POM1 and Fab1-
POM2 have opposite effects on the topology and size of mGluR5 clusters, with POM1 inducing 
abnormal accumulation and translocation to dendritic spines.  
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Figure 3.13. Exposure to Fab1-POM1 increases mGluR5 and PrPC translocation to dendritic 
spines 
(A-B) mGluR5 immunoreactivity following Fab1-POM1 administration to live neurons. Quantification of 
fluorescence intensity (B) showed increased size of mGluR5 clusters following exposure of live 
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neurons to Fab1-POM1, but not to Fab1-POM2 or Fab1-POM3. “ex vivo”: antibody administration to 
live neurons; “post mortem”: administration to fixed neurons. One-way ANOVA with Dunnett’s post-
hoc test relative to control. The number of fields-of-view analyzed was: 88 (control), 90 (POM1/live), 
59 (POM2/live), 60 (POM3/live), and 30 (POM1/fixed; POM2/fixed; POM3). Results were pooled from 
three independent experiments. (C-D) Increased mGluR5s immunoreactivity in dendritic spines 
following Fab1-POM1 exposure. (C) Representative images showing the expression of mGluR5-
pHluorin in untreated and Fab1-POM1-treated neurons (1 µg, 1 h). (D) Fluorescence ratio 
(spine/shaft) emphasizing the increase in mGluR5-pHluorin level in spines following exposure to Fab1-
POM1, but not to Fab1-POM2 or a mixture of Fab1-POM1 and Fab1-POM2. Number of spines 
analyzed (n): 1070 (control), 1190 (Fab1-POM1), 1082 (Fab1-POM2), 908 (Fab1-POM1+2). Mann-
Whitney test on data from three independent experiments. (E-F) Spine enrichment of PrPC following 
exposure to Fab1-POM1. (E) Single-molecule detection of PrPC-Dendra by photoactivated localization 
microscopy (PALM) on dendritic spines and shafts. Aantibody treatment: 1µg, 1h. (F) Ratio of 
molecular density in spine versus dendritic shaft emphasizing spine-enrichment of PrPC-Dendra 
following exposure to Fab1-POM1 but not to other antibodies. Number of spines analyzed (n): 318 
(control), 328 (POM1), 364 (POM2), 331 (POM1+2), 416 (POM3). Mann-Whitney test; *p<0.05, 
***p<0.001, ns= non-significant. Scale bars: 2µm. 
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Figure 3.14. POM antibodies do not alter AMPA and NMDA receptor clustering 
(A) Representative image (control condition) showing the immunoreactivity of GluR2 subunit of 
AMPA receptor following methanol fixation / permeabilization. (B) Quantification of the 
fluorescence intensity indicates that cluster size was not modified following POM antibodies 
application (One-way ANOVA with Dunnett’s post-hoc test relative to control; field of view (n): 
Control-22, POM1-22, POM2-22, POM3-22 from 2 independent experiments). (C) 
Representative image (control condition) showing the fluorescence of GluN2A-GFP subunit of 
NMDA receptor ~48 h after transfection and paraformaldehyde fixation. (D) Quantification of 
fluorescence intensity indicate that the cluster size was not modified following POM antibodies 
application (One-way ANOVA with Dunnett’s post-hoc test relative to control; field of view (n): 
Control-22, POM1-22, POM2-22, POM3-20 from 2-independent experiments).  Scale bar: 2µm. 
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3.8. Prion-mimetic antibodies increase the cell surface expression of mGluR5 
and PrPC  
A number of different mechanisms and signalling pathways, such as Ca2+/CaMKIIa and PLC, regulate 
the processes of activation and internalization of mGlu5 receptor and thus its signalling. Seeking to 
investigate the effect of toxic versus protective POM antibodies and the group I mGluR5 antagonist, 
MPEP, on mGluR5 activation/desensitization in cerebellar organotypic slice cultures we used cell 
surface biotinylation with a cell impermeable reagent. Single chain POM1 miniantibodies (scPOM1), 
fusion proteins containing only the variable regions of the heavy (VH) and light chains (VL) of the 
antibody connected with a short linker peptide, were previously shown to be sufficient to induce 
toxicity in COCS (Sonati et al., 2013). At 2h after addition of the toxic scPOM1 antibody, we observed 
an increase in the surface mGluR5 levels (quantified as a surface/total; mGluR5 ratios). Exposure to 
scPOM2 antibody yielded surface mGluR5s ratios more similar to untreated, scPOM1/recPrP or 
MPEP controls. Interestingly, pre-blocking of scPOM1 with the scPOM2 or combined POM1/MPEP 
treatment significantly reduced the cell surface expression of mGluR5s. The observed increase in the 
surface/total mGluR5 ratios after POM1 addition may represent capturing of the receptors in stable 
complexes as previously descibed in AD upon exposure to Aβ-oligomers (Renner et al., 2010; Um 
and Strittmatter, 2013).  
To conclude, exposure to toxic scPOM1 antibodies seems to induce an increase in the cell surface 
expression of mGluR5s. Interestingly, blocking of toxic scPOM1 with protective scPOM2 significantly 
reduces the mGluRs surface expression slightly similar to treatment with the specific mGluR5 inhibitor 
MPEP.  These results support our previous observations showing increase of mGluR5 clusters in 
dendritic spines after addition of toxic POM1 antibodies. 
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(A)                                                                            (B) 
 
         
 
 
 
 
(C)                                                                     (D) 
                
  
Figure 3.15. POM1 antibodies increase the cell surface expression of mGlu5 receptors 
(A) Representatives images of cerebellar organotypic slice cultures from Tga20 mice untreated or 
treated with 400nM scPOM1 blocked with rPrP or 400nM scPOM1 or 400nM scPOM1 with 500nM 
MPEP or 500nM MPEP for 2h. Subsequently, cell surface proteins were biotinylated and then 
isolated with NeutrAvidin conjugated beads. Isolated cell surface and total lysate proteins were 
assessed by anti-mGluR5 (upper panel: mGluR5 pull down, lower panel: mGluR5 lysate) and anti-
PrP immunoblot. (B) Quantification of surface expression of mGluR5 normalized to total mGluR5 
level after 2h treatment in Tga20 COCS (n=3, Mean ± SE, unpaired t-test, P values: i. 
scPOM1+recPrP vs scPOM1, P=0.0057/ ii. scPOM1 vs scPOM1+MPEP, P=0.0043/ iii. 
scPOM1+MPEP vs MPEP, P=0.3824). (C) Representatives images of cerebellar organotypic slice 
cultures from Tga20 mice treated with 400nM scPOM1 blocked with rPrP or 400nM scPOM1 or 
400nM scPOM1 blocked with 400nM scPOM2 or 400nM scPOM2 for 2h. Subsequently, cell surface 
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proteins were biotinylated and then isolated with NeutrAvidin conjugated beads. Isolated cell surface 
and total lysate proteins were assessed by anti-mGluR5 (upper panel: mGluR5 pull down, lower 
panel: mGluR5 lysate) and anti-PrP immunoblot (D) Quantification of surface expression of 
mGluR5 normalized to total mGluR5 level after 2h treatment in Tga20 COCS (n=3, Mean ± SE, 
unpaired t-test, P-values: i. scPOM1+recPrP vs scPOM1, P=0.0311/ ii. scPOM1 vs 
scPOM1+scPOM2, P=0.0099/iii. scPOM1+scPOM2 vs scPOM2, P=0.087/ iv. scPOM1 vs scPOM2, 
P=0.0317)  
3.9. Characterization of novel transgenic mice expressing the RCaMP1.07 
calcium indicator 
Aiming to assess changes in Ca2+ homeostasis in prion diseases novel transgenic mice expressing 
the potent Ca2+ reporter (RCamp1.07) were generated. In brief, embryonic stem (ES) cell culture and 
gene targeting of the RCaMP1.07 reporter gene into the TIGRE locus were carried out and the 
targeted ES cells were microinjected into B6N-Tyrc blastocysts. Chimeras were tested for transgene 
expression and inheritance by Southern blotting using specific 5’ and 3’ external probes. Transgenic 
mice were further crossbred with R26phiC31o mice (Raymond and Soriano, 2007) for removal of the 
AttB/AttP-flanked hygro-TK cassette. Following removal of the cassette, mice were mated with either 
Camk2a-tTA (Mayford et al., 1996) or ROSA:LNL:tTA (Wang et al., 2008) transgenic mice to allow for 
the generation of compound mutant mice in which expression of the reporter gene can be defined by 
the chosen Cre-recombinase and turned off by the addition of tetracycline (or its analog doxycycline). 
Expression of the transgene was evaluated both in fixed brain sections as well as in organotypic slice 
cultures (as indicated in the figure below). 
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Figure 3.16. Evaluating the expression of RCaMP1.07 fixed brain section and HOCS prepated 
from the CaMK2a-TITL-RCaMP-Syn Cre mice 
 
(A) Schematic representation of the preparation of coronal brain sections  
(B) Expression of the RCamp1.07 reporter in coronal brain sections from CaMK2a-TITL-RCaMP-Syn 
Cre positive mice (upper panel). Control sections from CaMK2a-TITL-RCaMP-Syn Cre negative mice 
were run in parallel. Red: internal expression of RCaMP1.07 reporter, Blue: DAPI counterstaining post 
fixation. Left panel (upper and lower): coronal brain section 20x magnification, Right panel (upper and 
lower): coronal brain section 40x magnification 
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(C) Expression of the RCamp1.07 reporter in hippocampal organotypic cultured slices (HOCS) from 
CaMK2a-TITL-RCaMP-Syn Cre positive mice (upper panel). Slices from CaMK2a-TITL-RCaMP-Syn 
Cre negative mice were run in parallel. Red: internal expression of RCaMP1.07 reporter, Blue: DAPI 
counterstaining post fixation. Left panel (upper and lower): coronal brain section 20x magnification, 
Right panel (upper and lower): coronal brain section 40x magnification. 
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Chapter 4: DISCUSSION                            
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4.1. Summary 
The aim of the present study was to ascertain both the physical and functional relevance of PrPC and 
group I mGluRs in prion (RML6) and GDL-induced (POM1) toxicity as well as the role of this 
interaction in disease both in vitro (primary neuronal cultures and organotypic slices cultures) and in 
vivo (mouse models of prion diseases). Upon validation of a specific interaction between group I 
mGluRs and PrPC in brain homogenates, the region of PrPC necessary for its interaction with group I 
mGluRs was examined utilizing a series of amino-proximal deletion mutants of PrPC. The suggested 
site of interaction between PrPC and mGluR1 spans amino acid residues 51 to 90; the suggested site 
of interaction between PrPC and mGluR5 spans amino acids 32 to 134. Although the definitive 
causality of this relationship has yet to be identified, association of group I mGluRs with PrPC has 
been suggested in multiple processes, such as developmental processes, synaptic transmission, 
synaptic plasticity as well as neurotoxic signaling cascades (Bruno et al., 1995; Lopez-Bendito et al., 
2002; Salinska and Stafiej, 2003). Also, it has been reported that clusters of mGluR5s accumulate 
around excitatory synapses, and increased size of synaptic mGluR5s clusters is associated with toxic 
calcium influx in Alzheimer’s disease (AD) (Renner et al., 2010; Shrivastava et al., 2013; Um et al., 
2013). Aiming to shed light into the mechanistic angles of this interaction in prion toxicity we 
performed cell surface biotinylation experiments on organotypic slice cultures and live cell imaging of 
primary hippocampal neurons after exposure to the toxic prion –mimetic POM1 antibody. 
Immunofluorescent analysis of mGluR5s-PrP clusters following exposure to the anti-PrPC F(ab)1 
antibody fragments, POM1, POM2, and POM3 (Sonati et al., 2013), showed that exposure of cultures 
to POM1, but not to POM2 or POM3, increased the number of mGluR5s clusters as well as the 
fluorescent intensity of mGluR5s in dendritic spines of neurons. In contrast, the cluster size of NMDA 
and AMPA receptors was not modified by anti-PrP antibodies. Likewise, exposure of cerebellar 
organotypic slice cultures to toxic scPOM1 antibodies induced an increase in the surface/total 
mGluR5 ratios. Interestingly, blocking of toxic scPOM1 with protective scPOM2 significantly reduces 
the mGluRs surface expression slightly similar to treatment with the specific mGluR5 inhibitor MPEP.  
These results most probably represent capturing of the receptors in stable, immobile complexes at the 
neck of the dendritic spines upon prion-mimetic antibody induced toxicity and resemble a toxicity 
mechanism previously descibed in AD upon exposure to Aβ-oligomers (Renner et al., 2010; Um and 
Strittmatter, 2013).  
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Having identified a specific interaction between group I mGluRs and PrPC and its potential role in 
protein toxicity in vitro, we sought and further examine the contribution of group I mGluRs in prion and 
GDL-induced toxicity ex vivo and in vivo. To observe the effects of mGluR1 and mGluR5, cerebellar 
and hippocampal organotypic slice cultures (COCS and HOCS respectively) were subjected to prion 
(RML6) and GDL (POM1, scPOM1)-induced toxicity and concomitant pharmacological inhibition of 
the respective receptor (addition of MPEP and YM202074 for mGluR5 and mGluR1 inhibition 
respectively). We demonstrated that dose-dependent treatment with specific pharmacological 
inhibitors of group I mGluRs rescues cerebellar granule or pyramidal hippocampal neurons 
immunoreactive to antibodies against the neuronal NeuN antigen in slices (COCS and HOCS). In 
contrast, treatment of cerebellar slices with the selective agonist of group III (L-AP4)) and the 
potent antagonist of group II and group III (CPPG) metabotropic glutamate did not rescue the 
observed granular cell layer (GCL) ablation.  We additionally identified the therapeutic effect of Grm5 
gene ablation in rescuing prion and GDP-induced neuronal death, by utilizing Grm5-/-, Grm5+/- and wt 
littermates as controls.  After identifying the protective effect of the pharmacological inhibition of 
mGluR5 (MPEP treatment) ex vivo we sought to assess a possible therapeutic effect of MPEP 
treatment on prion pathogenesis in vivo. C57BL/6J male mice were inoculated intracerebrally with two 
different concentrations 3 or 5 log LD50 units of RML6 prions as previously described (Kranich et al., 
2010), and chronically treated with MPEP (MPEP-containing food).  Control mice were inoculated with 
NBH. In order to record the neurological deficits associated with prion disease, we utilized the rotarod 
behavioral test which measures a combination of motor performance, coordination, and balance 
(Brooks and Dunnett, 2009). At the terminal stage of the disease mice were sacrifized and brain 
samples (whole brain as well as specific brain regions, such as cortex, hippocampus and cerebellum) 
were collected and further processed. Immunohistochemical staining (Iba1, GFAP, SAF84) of brain 
sections was performed and analysis included: vacuole area and number counting, percentage of 
reactive astrogliosis, percentage of reactive microgliosis and PrPSc accumulation. After verifying the 
therapeutic potential of pharmacological inhibition of mGluR5 we decided to test the genetic inhibition 
model. We tested whether toxicity induced by prion infection (RML6 prion strain) upon genetic 
deletion of mGluR5 (groups included in the study and compared in parallel are: Grm5-/-, Grm5+/- and 
control wt littermates). In order to record the neurological deficits associated with prion disease, we 
utilized the rotarod behavioral test At the terminal stage of the disease mice were sacrifized and brain 
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samples (whole brain as well as specific brain regions, such as cortex, hippocampus and cerebellum) 
were collected. Unfortunately, no significant therapeutic effect was observed upon deletion of Grm5 in 
vivo. However, this observation led us to examine the potential for epistasis between mGlu1 and 
mGlu5 receptors. Indeed, we could see an increase in the expression levels of mGluR1 in the Grm5-/- 
and Grm5+/- mice. 
In conclusion, this study provides insights into the interaction of PrPC with group I mGluRs and its 
effect in in vitro, ex vivo and in vivo models of prion diseases. The above data suggest that group-I 
mGluRs inhibition may attenuate dysfunctions associated with prion diseases, for which there are no 
disease-modifying therapies. MGluR5 antagonists were expected to have only a moderate effect on 
survival, since this therapeutic modality is likely to affect downstream consequences of prion toxicity. 
However, given the fact that they are well-tolerated and have high bioavailability and blood-brain-
barrier penetration (Gasparini et al., 2013; Pop et al., 2014; Schaefer et al., 2015), mGluR5 
antagonists may be considered for enhancing the quality of life of prion patients. 
4.2. Specific Interaction of PrPC with group I mGluRs 
Protein-protein interactions at defined regions of the post-synaptic membrane-surface, namely at 
microdomains referred to as post-synaptic densities (PSDs), are a critical site for the examination of 
localized proteins such as PrPC. Group I mGluRs are also situated within PSDs and modulate 
neuronal activity by interacting with multiple partners (Baundry M. et al., 2012). Group I mGluRs and 
PrPC co-localization in PSDs and participation in neuritogenesis (through the additional interaction 
with laminin) (Beraldo et al., 2011) provided the necessary grounds to further examine their potential 
interaction in disease.  
While PSDs were not isolated in this study, brain homogenates from wt and Prnp-/- mice were 
subjected to immunoprecipitation using antibody POM1 against PrPC, followed by western blotting 
with antibodies to mGluR1 and mGluR5. The group-I mGlu receptors, which migrate as functionally 
active oligomers at 250kDa (Romano et al., 1996b), were found to co-precipitate with PrPC. In addition 
upon control immunoprecipitation conditions we did we observe mGluR1 and mGluR5 co-
immunoprecipitating with PrP. Furthermore, western blots from the total brain lysates (TEs) did not 
reveal any changes in the concentration of mGluR1 and mGluR5 protein between wild-type and 
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Prnpo/o homogenates. Last but not least, mGlu receptors from the group II and III subtypes (mGluR6, 
mGluR2/3) did not co-precipitate with PrPC, confirming the specificity of the interaction. These results 
are in accordance with previous reports showing specific interaction of PrPC with group I mGluRs 
(Beraldo et al., 2011; Um et al., 2013). Additional experiments were performed in order to map the 
interaction between PrPC and group I mGluRs onto PrPC. The PrPC residues 91-153 were previously 
reported to participate to the interaction with mGluR5. This interaction was shown to promote Aβ-
induced toxicity in an experimental model of AD (Haas et al., 2014). With regards to this, recent 
reports utilizing both in vitro and in vivo models highlighted the role of mGluR5 as a co-receptor of 
PrPC and Aβ oligomers and the effector of Aβ and Aβ oligomers toxicity (Renner et al., 2010). As 
group I mGluRs are also reported to contribute to prion pathophysiology (Rodriguez et al., 2005; 
Rodriguez et al., 2006), we sought to identify which region of PrPC may be critical for the binding of 
group I mGluRs. We used a panel of transgenic mice expressing variants of PrPC bearing deletions in 
the flexible tail (FT) regions, designated ∆C, ∆CC, ∆F, ∆OR, and ∆HC. The relevance of these 
mutants to prion disease was previously reported (Baumann et al., 2007a; Bremer et al., 2010; 
Flechsig et al., 2000; Shmerling et al., 1998; Weissmann et al., 1998). As expected, mGluR1 and 
mGluR5 co-precipitated with PrPC. Deletions affecting residues 32-110 (as in the transgenic lines ∆C 
and ∆CC, lacking the central domain and the charge cluster regions of PrPC, respectively) reduced 
the interaction of PrPC with mGluR5. Conversely, deletions extending from residues 51 to 90, as in the 
transgenic line ∆OR, increased the interaction with mGluR5, yet reduced the interaction with mGluR1. 
These results suggest that the interaction domain between PrPC and mGluR5 is larger than previously 
inferred, with residues 32-110 participating to the in vivo interaction.  
 
4.3. Pharmacological Inhibition of group I mGluRs rescues prion and GDL-
induced toxicity in organotypic slices from Tga20 mice  
 
So as to identify the effect of group I mGluR pharmacological inhibition, we utilized an ex vivo model 
of prion diseases. More specifically, COCS and HOCS were inoculated with brain homogenate from 
CD1 mice infected with RML prions. For control, slices were inoculated with non-infectious brain 
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homogenate (NBH) derived from healthy CD1 mice. Infected slices were treated with a range of 
concentrations of either YM202074 (Kohara et al., 2008) or MPEP (Gasparini et al., 1999) which 
specifically inhibit mGluR1 and mGluR5, respectively. Following treatment, slices were collected and 
stained for the specific neuronal marker NeuN. Morphometric analysis of NeuN revealed that MPEP 
and YM202074 significantly prevented CGL loss, in a dose-dependent manner, in treated COCS and 
HOCS at concentrations as low as 36 nM and 500 nM, respectively.  
We further sought to identify the effect of group I mGluR pharmacological inhibition in our GDL-
induced toxicity model. GDLs are antibody-derived molecules targeting the globular domain (GD) of 
PrPC (termed GDLs) are acutely neurotoxic (Sonati et al., 2013) that activate similar cascades as 
bona fide prion infection (Herrmann et al., 2015).  To investigate if pharmacological inhibition of 
mGluR1 and mGluR5 rescues GDL toxicity, we exposed tga20 COCS to the GDL agent POM1, 
followed by YM202074 and MPEP treatments. Treatment with POM1 led to almost complete CGL 
loss within 14 days of treatment, whereas treatment with MPEP or YM202074 significantly reduced 
CGL loss in POM1-treated slices. As with prion infections, MPEP treatment was sufficient to rescue 
the loss of CGL. So, how do group I mGluRs inhibition rescues prion (RML6)- or prion-mimetic 
antibody-induced toxicity? We hypothesize that group I mGluRs inhibition reduces glutamatergic 
signaling and calcium overload in prion-infected cells (Falsig et al., 2012), similarly to models of 
Alzheimer’s disease (Ostapchenko et al., 2013; Renner et al., 2010; Um et al., 2013). Conversely, no 
protection was observed upon treatment with the selective agonist of group III (L-2-amino-4-
phosphonobutyrate (L-AP4)) (Tones et al., 1995) and the potent antagonist of group II and group III 
((RS)-α-Cyclopropyl-4-phosphonophenylglycine (CPPG)) (Toms et al., 1996) metabotropic glutamate 
receptors; despite reportrs of group III mGluR association with prion diseases (Sanchez-Juan et al., 
2014). The latter, suggest a specific role of group I mGluRs in prion toxicity. 
4.4. Pharmacological Inhibition of mGluR5 rescues prion-induced toxicity in 
vivo 
The beneficial effects of mGluR5 inhibition ex vivo encouraged us to assess a possible therapeutic 
effect of MPEP on prion pathogenesis in vivo. C57BL/6J male mice were inoculated intracerebrally 
with 3 or 5 log LD50 units of RML6 prions as previously described (Kranich et al., 2010), and 
chronically treated with MPEP.  Control mice were inoculated with NBH. In order to record the 
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neurological deficits associated with prion disease, we utilized the rotarod behavioral test. Rotarod 
performance was similar in RML6- and NBH (control)-inoculated mice until 18 weeks following prion 
inoculation. Starting from 19 weeks post inoculation, the rotarod performance of mice receiving 
control food declined, whereas the performance of MPEP-treated mice declined significantly less. 
This improvement was lasting and detectable until the very late stages of the disease (22-23 weeks 
post inoculation); suggesting that the progression of the disease was delayed by MPEP. In contrast, 
control mice injected with NBH and treated with MPEP exhibited stable rotarod performance during 
the entire test period, up to 23 weeks post-injection. Treatment with MPEP also has a positive effect 
on the survival of prion infected mice, as MPEP-treated mice showed a modest, though significant, 
prolongation of survival. The selected in vivo MPEP dose (30mg/ml) has been previously reported to 
have analgesic effects even in mGluR5-/- mice and MPEP has been reported to have a short plasma 
half-life (Montana et al., 2009). In order to control for brain and plasma exposure to MPEP, receptor 
occupancy, MPEP activity and mGluR5-independent actions, mice treated with control and MPEP 
food were sacrificed in two different timepoints, corresponding to the active and the inactive phase of 
the mice across the circadian circle. Pharmacokinetic and pharmakodynamic analysis showed a good 
delivery of MPEP to the brain (brain to plasma ratios above 1), without induction of changes in food 
and water consumption or rotarod performance of treated mice. PK analysis showed that the MPEP 
levels in the brain are around 150nM during the inactive phase and around 260nM during the active 
phase of the mice life cycle. The values are 8 times above the IC50 (during the active phase) 
suggesting that the likelihood of completely inhibiting the receptor is very high. Even during the 
inactive phase values are far above the IC50. In addition, the values detected in this study are far 
below any reported off-target effect. Therefore we conclude that the brain and plasma exposure to 
MPEP is adequate to induce mGluR5-specific effects. Detailed information about the exact levels of 
MPEP both in the brain and plasma of all animals involved in the study are provided in tables at the 
appendix section.  
Still the effect of the MPEP-treatment in the disease phenotype remained unclear. It has been 
previously reported that upregulation of mGluR5 can go along with glial activation (D'Antoni et al., 
2008; Shelton and McCarthy, 1999; Shrivastava et al., 2013). Indeed, we observed reactive 
astrogliosis (measured as GFAP immunoreactivity) in the hippocampi of prion-infected animals. 
Interestingly, treatment with MPEP resulted in a decrease of GFAP immunoreactivity in the 
The Role of Group I Metabotropic Glutamate Receptors in Prion Induced Toxicity PhD Dissertation 
 
 
151  Despoina G. Goniotaki – October, 2016  
  
hippocampi of prion-infected mice. Conversely, MPEP was unable to suppress glial activation in adult 
cerebella where mGluR5 expression is low. Taken together, these results suggest that dampened 
neuroinflammation was overall beneficial. Although an effect on microgliosis was not observed, a 
significant effect on vacuolation was identified. Vacuolation per se was not halted; the number of 
vacuoles was the same between the MPEP-treated versus control animals. However, the area of 
vacuoles was significantly reduced. 
Although mGluR5 inhibition delayed neurological deterioration, survival was only modestly (though 
significantly) improved. These findings support the concept that mGluR5 inhibition alleviates the 
symptoms of the disease whereas prion replication progresses unabated. 
4.5. Genetic ablation of mGluR5 rescues prion and GDL-induced toxicity in 
cerebellar and hippocampal organotypic slices but not in vivo 
To further assess the role of mGluR5 in prion toxicity, cerebellar organotypic slice cultures from 
Grm5-/-, Grm5+/- and Grm5+/+ littermates were treated with the anti-GD antibody POM1 (Polymenidou 
et al., 2008), a prion-mimetic compound. Exposure to POM1 led to the loss of cerebellar granular 
layer (CGL) neurons in Grm5+/+ slices, but not in Grm5-/- and Grm5+/- slices. Cerebellar and 
hippocampal organotypic slice cultures from Grm5-/-, Grm5+/- and Grm5+/+ littermates were further 
inoculated with brain homogenate from CD1 mice infected with RML prions (RML6) or control NBH 
homogenate. In both COCS and HOCS, genetic ablation of Grm5 was protective against prion 
induced toxicity; further supporting a primary role of mGluR5 in prion toxicity.  
To assess the role of mGluR5 ablation in prion infections in vivo, we infected Grm5-/-, Grm5+/-, and 
control Grm5+/+ littermates with RML6 prions (5 log LD50). Again, we utilized the rotarod test. All RML6 
inoculated mice showed similar rotarod performance during monitoring; with Grm5-/- mice showing a 
tendency towards better motor performance in general.  Moreover, no significant difference in survival 
was observed between Grm5-/-, Grm5+/- and Grm5+/+ mice.  
MPEP treatment rescued prion-induced neuronal loss in slices, delayed neurological deterioration and 
modestly improved survival in mice. Genetic ablation of Grm5 rescued prion-induced neuronal loss in 
slices but was not protective against prion-induced toxicity in mice. It could be hypothesized that the 
prion load may exert neurotoxicity through mGluR5-independent mechanisms (including mGluR1 
activation). Indeed, not all neurons express mGluR5 (Boer et al., 2010; Lopez-Bendito et al., 2002). It 
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could be hypothesized that neurons essential for survival are mGluR5- (and possibly mGluR1+) and 
are therefore not influenced by mGluR5 ablation.   
In order to investigate a potential epistasis between mGluR1 and mGluR5, we analyzed whole-brain 
lysates to control for mGluR1 and mGluR5 level changes between young and old mice.  We observed 
higher expression levels of mGluR1 in samples from 44-day old Grm5-/- mice compared to 
heterozygous and wt control littermates. At later time points expression levels of mGluR1 were similar 
between samples. These results point to compensatory mechanisms between mGluR1 and mGluR5 
at least at certain developmental stages. We further sought to evaluate whether treatment with MPEP 
has a similar effect on the expression of mGluR1. mGluR1 expression levels were assessed in whole-
brain lysates from 1-year old control wt mice, NBH-inoculated wt mice, and NBH-inoculated wt mice 
that received MPEP food. No differences were observed in the mGluR1 expression levels between 
the samples: suggesting that pharmacological inhibition of mGluR5 does not influence the expression 
levels of mGluR1. 
 
4.6. Exposure to toxic POM1 antibodies increases cell surface expression of 
mGluR5 and PrPC-mGluR5 cluster formation at dendritic spines 
Early features of prion diseases include synaptic degeneration and dendritic atrophy. In rodent 
models of prion disease synaptic accumulation of PrPSc and prominent synaptic degeneration was 
detected at the early stages of the disease process, before any overt signs of neuronal death 
(Bouzamondo-Bernstein et al., 2004; Cunningham et al., 2003a; Gray et al., 2009; Jeffrey et al., 
2000). Disruption of presynaptic boutons and degeneration of axon terminals did not strictly correlate 
with PrPSc deposition. Also, in brain samples from CJD patients, PrPSc deposition at the presynapstic 
terminals has been reported (Kovacs et al., 2005; Siso et al., 2002). PrPSc deposition was associated 
with reduced level of presynaptic proteins such as synaptophysin, synapsin I, SNAP-25 (Ferrer et al., 
2000). Another prominent feature of prion diseases is dendritic atrophy (Jamieson et al., 2001); 
characterized by distorted dendritic arborization and dendritic atrophy in CJD brains. In the neocortex 
of infected mice, higher level of Notch-1 mRNA and nuclear translocation of Notch-1 intracellular 
domain (NICD), correlated with PrPSc accumulation; suggesting a role of Notch signalling. In vitro, in 
N2a neuroblastoma cells, the expression of NICD was also increased following scrapie infection. 
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Morphologically, N2a cells showed synaptic abnormalities, such as shorter dendritic processes 
(Ishikura, 2007; Ishikura et al., 2005). 
Prion toxicity is mediated by unfolded-protein responses (Moreno et al., 2013; Moreno et al., 2012), 
yet it is unclear how these are triggered by extracellular PrPSc.  We identified a specific group I mGluR 
interaction with PrPC and a therapeutic effect of mGluR5 inhibition in ex vivo and in vivo models of 
prion diseases. However, the mechanism of the observed protection was still missing.We reasoned 
that group-I metabotropic glutamate receptors mGluR5 and mGluR1, G-protein coupled receptors that 
interact with PrPC (Lauren et al., 2009; Renner et al., 2010; Um et al., 2013), may represent one such 
link. We hypothesized that if prion toxicity depends on the direct interaction of PrPC to group-I 
mGluRs, it may modify the subcellular distribution of mGluR5. To investigate this we used both toxic 
and protective anti-PrPC antibodies (Polymenidou et al., 2008; Sonati et al., 2013). 
Toxic anti-PrPC antibodies induce damage by stimulating pathways similar to bona fide prion 
infections, such as activation of calpains and PERK pathway and production of reactive oxygen 
species (Doolan and Colby, 2015; Falsig et al., 2012; Herrmann et al., 2015; Sonati et al., 2013). The 
proposed mechanism of action postulates that the amino-terminal, flexible tail of PrPC mediates the 
toxicity of antiprion antibodies by binding to the globular domain of PrPC (Sonati et al., 2013).  Indeed, 
exposure of primary hippocampal cultures to prion-mimetic antibodies selectivelly increased clustering 
of mGluR5 (but not of AMPA and NMDA receptors) in dendritic spine heads, thus bringing them 
closer to synaptic glutamate. Prion mimetics also increased the level of PrPC in spines, reinforcing the 
notion that mGluR5 and PrPC are part of the same complex whose accumulation at excitatory 
synapses instigates neurotoxicity in prion diseases. Increased cell surface clustering may also slow 
down endocytosis, thereby increasing the amount of functional mGluR5s at the cell surface (Casley et 
al., 2009; Hamilton A. et al., 2014; Um et al., 2013). Indeed, 2h exposure of cerebellar organotypic 
slice cultures to high concentrations of toxic scPOM1 antibodies induced an increase in the cell 
surface expression of mGluR5s. Interestingly, parallel treatment with the specific mGluR5 inhibitor 
MPEP reduced the mGluRs surface expression. These results support our hypothesis that mGluR5 
clustering at synapses may amplify responses to glutamate, thereby inducing Ca2+ influx and spine 
loss, a primary event in prion diseases (Fuhrmann et al., 2007).  
The POM2 antibody (Polymenidou et al., 2008) against the Flexible Tail (FT) of PrP is neuroprotective 
in vivo and in vitro (Reimann et al., 2016; Sonati et al., 2013). If mGluR5 is instrumental to POM1 
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toxicity, its clustering may be relieved by POM2. Indeed, exposure of primary cultures to POM2 
prevented mGluR5 clustering and spine translocation. We observed reduced mGluR5 and PrPC 
enrichment in spines even after exposure to POM2 alone. More importantly, in cell surface 
biotinylation experiments performed in COCS, exposure to scPOM2 did not significantly increase the 
surface expression of mGluR5s in COCS. Also blocking of scPOM1 toxicity with addition of scPOM2 
resulted in significant reduction of the mGluR5s surface expression. Hence prion-mimetic and 
protective antibodies have opposite effects on the mGluR5-PrPC complex, with anti-GD antibodies 
promoting spine translocation and anti-FT antibodies inhibiting it. Since both POM2 and mGluR5 bind 
to the N-terminus of PrPC, binding of mGluR5 to PrPC may facilitate its activation whereas POM2 may 
compete for PrPC binding. The hypothesized mechanism of action is summarized in the figure below 
(Figure 4.1.) 
 
Figure 4.1. Model of the interactions between mGluR5, PrPC, and anti-PrP antibodies (A) In untreated neurons, mGluR5-PrPC complexes are distributed within and outside spines. Upon 
exposure to prion-mimetic antibodies (B), mGluR5 translocates to the spine, where it may enhance 
neurotoxicity by contributing to a Ca2+ overload. (C) Exposure to POM2, in contrast, engages the N-
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terminal “flexible tail” of PrPC, thereby making it unavailable to mGluR5. Consequently, mGluR5-PrPC 
(and possibly also mGluR1-PrPC) complexes do not translocate to spines. As a result, POM2 affords 
functional neuroprotection similarly to mGluR5 antagonists. (D) We speculate that prion infection may 
trigger topological rearrangements similar to those observed after POM1 exposure.  
4.7. Conclusion 
The above data propose that group-I mGluRs interaction is crucial for the propagation of prion-
induced toxicity in the synaptic level. Indeed, we showed that exposure to toxic, prion-mimetic anti-
PrPC antibodies (GD ligands) increases the clustering of mGluR5s on dendritic spines as well as the 
mGluR5s cell surface expression. Conversely, exposure to protective anti-PrPC antibodies (FT 
ligands) reduced clustering of mGluR5s on dendritic spines as well as the mGluR5s cell surface 
expression. Interestingly, we observed the same protection upon exposure of prion-infected models to 
MPEP treatment. We additionally need to identify the intracellular, downstream pathways that are 
activated upon prion-induced toxicity and how MPEP treatment conveys protection. In AD, it has been 
reported that Aβo-mGluR5-PrPC complexes at the neuronal surface mobilize mGluR5 to activating 
cytoplasmic Fyn kinase and trigger eEF2 phosphorylation; increasing intracellular calcium signaling 
and inducing dendritic spine loss (Um et al., 2013). We are currently examining whether a similar 
mechanism is triggered upon formation of stable PrPSc-mGluR5-PrPC complexes on the neuronal 
surface. This work is ongoing. 
Our results further propose that inhibition may improve the phenotypic dysfunctions associated with 
prion diseases, for which there are currently no disease-modifying therapies. MGluR5 antagonists 
have only a moderate effect on survival, mainly due to the fact that they are probably affecting 
downstream pathways of prion toxicity rather than the formation and propagation of PrPSc per se. 
However, the fact that well-tolerated, with high bioavailability and blood-brain-barrier penetration 
(Gasparini et al., 2013; Pop et al., 2014; Schaefer et al., 2015) mGluR5 antagonists exist gives 
promise for their use in enhancing the quality of life of prion patients - a legitimate aim even if the 
overall life expectancy may not be dramatically improved.  
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